6	PROLIA.xml:S1:4:1	O
ADVERSE	PROLIA.xml:S1:6:7	O
REACTIONS	PROLIA.xml:S1:14:9	O

The	PROLIA.xml:S1:27:3	O
following	PROLIA.xml:S1:31:9	O
serious	PROLIA.xml:S1:41:7	O
adverse	PROLIA.xml:S1:49:7	O
reactions	PROLIA.xml:S1:57:9	O
are	PROLIA.xml:S1:67:3	O
discussed	PROLIA.xml:S1:71:9	O
below	PROLIA.xml:S1:81:5	O
and	PROLIA.xml:S1:87:3	O
also	PROLIA.xml:S1:91:4	O
elsewhere	PROLIA.xml:S1:96:9	O
in	PROLIA.xml:S1:106:2	O
the	PROLIA.xml:S1:109:3	O
labeling	PROLIA.xml:S1:113:8	O
:	PROLIA.xml:S1:121:1	O

Hypocalcemia	PROLIA.xml:S1:130:12	B-AdverseReaction
[	PROLIA.xml:S1:143:1	O
see	PROLIA.xml:S1:144:3	O
Warnings	PROLIA.xml:S1:148:8	O
and	PROLIA.xml:S1:157:3	O
Precautions	PROLIA.xml:S1:161:11	O
(	PROLIA.xml:S1:173:1	O
5.3	PROLIA.xml:S1:176:3	O
)]	PROLIA.xml:S1:181:2	O

Serious	PROLIA.xml:S1:190:7	B-Severity
Infections	PROLIA.xml:S1:198:10	B-AdverseReaction
[	PROLIA.xml:S1:209:1	O
see	PROLIA.xml:S1:210:3	O
Warnings	PROLIA.xml:S1:214:8	O
and	PROLIA.xml:S1:223:3	O
Precautions	PROLIA.xml:S1:227:11	O
(	PROLIA.xml:S1:239:1	O
5.6	PROLIA.xml:S1:242:3	O
)]	PROLIA.xml:S1:247:2	O

Dermatologic	PROLIA.xml:S1:256:12	B-AdverseReaction
Adverse	PROLIA.xml:S1:269:7	I-AdverseReaction
Reactions	PROLIA.xml:S1:277:9	I-AdverseReaction
[	PROLIA.xml:S1:287:1	O
see	PROLIA.xml:S1:288:3	O
Warnings	PROLIA.xml:S1:292:8	O
and	PROLIA.xml:S1:301:3	O
Precautions	PROLIA.xml:S1:305:11	O
(	PROLIA.xml:S1:317:1	O
5.7	PROLIA.xml:S1:320:3	O
)]	PROLIA.xml:S1:325:2	O

Osteonecrosis	PROLIA.xml:S1:334:13	B-AdverseReaction
of	PROLIA.xml:S1:348:2	I-AdverseReaction
the	PROLIA.xml:S1:351:3	I-AdverseReaction
Jaw	PROLIA.xml:S1:355:3	I-AdverseReaction
[	PROLIA.xml:S1:359:1	O
see	PROLIA.xml:S1:360:3	O
Warnings	PROLIA.xml:S1:364:8	O
and	PROLIA.xml:S1:373:3	O
Precautions	PROLIA.xml:S1:377:11	O
(	PROLIA.xml:S1:389:1	O
5.4	PROLIA.xml:S1:392:3	O
)]	PROLIA.xml:S1:397:2	O

Atypical	PROLIA.xml:S1:406:8	B-AdverseReaction
Subtrochanteric	PROLIA.xml:S1:415:15	I-AdverseReaction
and	PROLIA.xml:S1:431:3	O
Diaphyseal	PROLIA.xml:S1:435:10	I-AdverseReaction
Femoral	PROLIA.xml:S1:446:7	I-AdverseReaction
Fractures	PROLIA.xml:S1:454:9	I-AdverseReaction
[	PROLIA.xml:S1:464:1	O
see	PROLIA.xml:S1:465:3	O
Warnings	PROLIA.xml:S1:469:8	O
and	PROLIA.xml:S1:478:3	O
Precautions	PROLIA.xml:S1:482:11	O
(	PROLIA.xml:S1:494:1	O
5.5	PROLIA.xml:S1:497:3	O
)]	PROLIA.xml:S1:502:2	O

The	PROLIA.xml:S1:511:3	O
most	PROLIA.xml:S1:515:4	O
common	PROLIA.xml:S1:520:6	O
adverse	PROLIA.xml:S1:527:7	O
reactions	PROLIA.xml:S1:535:9	O
reported	PROLIA.xml:S1:545:8	O
with	PROLIA.xml:S1:554:4	O
Prolia	PROLIA.xml:S1:559:6	O
in	PROLIA.xml:S1:566:2	O
patients	PROLIA.xml:S1:569:8	O
with	PROLIA.xml:S1:578:4	O
postmenopausal	PROLIA.xml:S1:583:14	O
osteoporosis	PROLIA.xml:S1:598:12	O
are	PROLIA.xml:S1:611:3	O
back	PROLIA.xml:S1:615:4	B-AdverseReaction
pain	PROLIA.xml:S1:620:4	I-AdverseReaction
,	PROLIA.xml:S1:624:1	O
pain	PROLIA.xml:S1:626:4	B-AdverseReaction
in	PROLIA.xml:S1:631:2	I-AdverseReaction
extremity	PROLIA.xml:S1:634:9	I-AdverseReaction
,	PROLIA.xml:S1:643:1	O
musculoskeletal	PROLIA.xml:S1:645:15	B-AdverseReaction
pain	PROLIA.xml:S1:661:4	I-AdverseReaction
,	PROLIA.xml:S1:665:1	O
hypercholesterolemia	PROLIA.xml:S1:667:20	B-AdverseReaction
,	PROLIA.xml:S1:687:1	O
and	PROLIA.xml:S1:689:3	O
cystitis	PROLIA.xml:S1:693:8	B-AdverseReaction
.	PROLIA.xml:S1:701:1	O

The	PROLIA.xml:S1:707:3	O

most	PROLIA.xml:S1:711:4	O
common	PROLIA.xml:S1:716:6	O
adverse	PROLIA.xml:S1:723:7	O
reactions	PROLIA.xml:S1:731:9	O
reported	PROLIA.xml:S1:741:8	O
with	PROLIA.xml:S1:750:4	O
Prolia	PROLIA.xml:S1:755:6	O
in	PROLIA.xml:S1:762:2	O
men	PROLIA.xml:S1:765:3	O
with	PROLIA.xml:S1:769:4	O
osteoporosis	PROLIA.xml:S1:774:12	O
are	PROLIA.xml:S1:787:3	O
back	PROLIA.xml:S1:791:4	B-AdverseReaction
pain	PROLIA.xml:S1:796:4	I-AdverseReaction
,	PROLIA.xml:S1:800:1	O
arthralgia	PROLIA.xml:S1:802:10	B-AdverseReaction
,	PROLIA.xml:S1:812:1	O
and	PROLIA.xml:S1:814:3	O
nasopharyngitis	PROLIA.xml:S1:818:15	B-AdverseReaction
.	PROLIA.xml:S1:833:1	O

The	PROLIA.xml:S1:839:3	O
most	PROLIA.xml:S1:843:4	O
common	PROLIA.xml:S1:848:6	O
(	PROLIA.xml:S1:855:1	O
per	PROLIA.xml:S1:856:3	O
patient	PROLIA.xml:S1:860:7	O
incidence	PROLIA.xml:S1:868:9	O
10%	PROLIA.xml:S1:881:3	O
)	PROLIA.xml:S1:884:1	O
adverse	PROLIA.xml:S1:886:7	O
reactions	PROLIA.xml:S1:894:9	O
reported	PROLIA.xml:S1:904:8	O
with	PROLIA.xml:S1:913:4	O
Prolia	PROLIA.xml:S1:918:6	O
in	PROLIA.xml:S1:925:2	O
patients	PROLIA.xml:S1:928:8	O
with	PROLIA.xml:S1:937:4	O
bone	PROLIA.xml:S1:942:4	O
loss	PROLIA.xml:S1:947:4	O
receiving	PROLIA.xml:S1:952:9	O
androgen	PROLIA.xml:S1:962:8	O
deprivation	PROLIA.xml:S1:971:11	O
therapy	PROLIA.xml:S1:983:7	O
for	PROLIA.xml:S1:991:3	O
prostate	PROLIA.xml:S1:995:8	O
cancer	PROLIA.xml:S1:1004:6	O
or	PROLIA.xml:S1:1011:2	O
adjuvant	PROLIA.xml:S1:1014:8	O
aromatase	PROLIA.xml:S1:1023:9	O
inhibitor	PROLIA.xml:S1:1033:9	O
therapy	PROLIA.xml:S1:1043:7	O
for	PROLIA.xml:S1:1051:3	O
breast	PROLIA.xml:S1:1055:6	O
cancer	PROLIA.xml:S1:1062:6	O
are	PROLIA.xml:S1:1069:3	O
arthralgia	PROLIA.xml:S1:1073:10	B-AdverseReaction
and	PROLIA.xml:S1:1084:3	O
back	PROLIA.xml:S1:1088:4	B-AdverseReaction
pain	PROLIA.xml:S1:1093:4	I-AdverseReaction
.	PROLIA.xml:S1:1097:1	O

Pain	PROLIA.xml:S1:1100:4	B-AdverseReaction
in	PROLIA.xml:S1:1105:2	I-AdverseReaction
extremity	PROLIA.xml:S1:1108:9	I-AdverseReaction
and	PROLIA.xml:S1:1118:3	O
musculoskeletal	PROLIA.xml:S1:1122:15	B-AdverseReaction
pain	PROLIA.xml:S1:1138:4	I-AdverseReaction
have	PROLIA.xml:S1:1143:4	O
also	PROLIA.xml:S1:1148:4	O
been	PROLIA.xml:S1:1153:4	O
reported	PROLIA.xml:S1:1158:8	O
in	PROLIA.xml:S1:1167:2	O
clinical	PROLIA.xml:S1:1170:8	O
trials	PROLIA.xml:S1:1179:6	O
.	PROLIA.xml:S1:1185:1	O

The	PROLIA.xml:S1:1192:3	O
most	PROLIA.xml:S1:1196:4	O
common	PROLIA.xml:S1:1201:6	O
adverse	PROLIA.xml:S1:1208:7	O
reactions	PROLIA.xml:S1:1216:9	O
leading	PROLIA.xml:S1:1226:7	O
to	PROLIA.xml:S1:1234:2	O
discontinuation	PROLIA.xml:S1:1237:15	O
of	PROLIA.xml:S1:1253:2	O
Prolia	PROLIA.xml:S1:1256:6	O
in	PROLIA.xml:S1:1263:2	O
patients	PROLIA.xml:S1:1266:8	O
with	PROLIA.xml:S1:1275:4	O
postmenopausal	PROLIA.xml:S1:1280:14	O
osteoporosis	PROLIA.xml:S1:1295:12	O
are	PROLIA.xml:S1:1308:3	O
back	PROLIA.xml:S1:1312:4	B-AdverseReaction
pain	PROLIA.xml:S1:1317:4	I-AdverseReaction
and	PROLIA.xml:S1:1322:3	O
constipation	PROLIA.xml:S1:1326:12	B-AdverseReaction
.	PROLIA.xml:S1:1338:1	O

The	PROLIA.xml:S1:1344:3	O
Prolia	PROLIA.xml:S1:1348:6	O
Postmarketing	PROLIA.xml:S1:1355:13	O
Active	PROLIA.xml:S1:1369:6	O
Safety	PROLIA.xml:S1:1376:6	O
Surveillance	PROLIA.xml:S1:1383:12	O
Program	PROLIA.xml:S1:1396:7	O
is	PROLIA.xml:S1:1404:2	O
available	PROLIA.xml:S1:1407:9	O
to	PROLIA.xml:S1:1417:2	O
collect	PROLIA.xml:S1:1420:7	O
information	PROLIA.xml:S1:1428:11	O
from	PROLIA.xml:S1:1440:4	O
prescribers	PROLIA.xml:S1:1445:11	O
on	PROLIA.xml:S1:1457:2	O
specific	PROLIA.xml:S1:1460:8	O
adverse	PROLIA.xml:S1:1469:7	O
events	PROLIA.xml:S1:1477:6	O
.	PROLIA.xml:S1:1483:1	O

Please	PROLIA.xml:S1:1486:6	O
see	PROLIA.xml:S1:1493:3	O
www	PROLIA.xml:S1:1497:3	O
.	PROLIA.xml:S1:1500:1	O
proliasafety	PROLIA.xml:S1:1501:12	O
.	PROLIA.xml:S1:1513:1	O
com	PROLIA.xml:S1:1514:3	O
or	PROLIA.xml:S1:1518:2	O
call	PROLIA.xml:S1:1521:4	O
1	PROLIA.xml:S1:1526:1	O
-	PROLIA.xml:S1:1527:1	O
800	PROLIA.xml:S1:1528:3	O
-	PROLIA.xml:S1:1531:1	O
772	PROLIA.xml:S1:1532:3	O
-	PROLIA.xml:S1:1535:1	O
6436	PROLIA.xml:S1:1536:4	O
for	PROLIA.xml:S1:1541:3	O
more	PROLIA.xml:S1:1545:4	O
information	PROLIA.xml:S1:1550:11	O
about	PROLIA.xml:S1:1562:5	O
this	PROLIA.xml:S1:1568:4	O
program	PROLIA.xml:S1:1573:7	O
.	PROLIA.xml:S1:1580:1	O

EXCERPT	PROLIA.xml:S1:1590:7	O
:	PROLIA.xml:S1:1597:1	O
Postmenopausal	PROLIA.xml:S1:1605:14	O
osteoporosis	PROLIA.xml:S1:1620:12	O
:	PROLIA.xml:S1:1632:1	O
Most	PROLIA.xml:S1:1634:4	O
common	PROLIA.xml:S1:1639:6	O
adverse	PROLIA.xml:S1:1646:7	O
reactions	PROLIA.xml:S1:1654:9	O
(	PROLIA.xml:S1:1664:1	O
5%	PROLIA.xml:S1:1667:2	O
and	PROLIA.xml:S1:1670:3	O
more	PROLIA.xml:S1:1674:4	O
common	PROLIA.xml:S1:1679:6	O
than	PROLIA.xml:S1:1686:4	O
placebo	PROLIA.xml:S1:1691:7	O
)	PROLIA.xml:S1:1698:1	O
were	PROLIA.xml:S1:1700:4	O
:	PROLIA.xml:S1:1704:1	O
back	PROLIA.xml:S1:1706:4	B-AdverseReaction
pain	PROLIA.xml:S1:1711:4	I-AdverseReaction
,	PROLIA.xml:S1:1715:1	O
pain	PROLIA.xml:S1:1717:4	B-AdverseReaction
in	PROLIA.xml:S1:1722:2	I-AdverseReaction
extremity	PROLIA.xml:S1:1725:9	I-AdverseReaction
,	PROLIA.xml:S1:1734:1	O
hypercholesterolemia	PROLIA.xml:S1:1736:20	B-AdverseReaction
,	PROLIA.xml:S1:1756:1	O
musculoskeletal	PROLIA.xml:S1:1758:15	B-AdverseReaction
pain	PROLIA.xml:S1:1774:4	I-AdverseReaction
,	PROLIA.xml:S1:1778:1	O
and	PROLIA.xml:S1:1780:3	O
cystitis	PROLIA.xml:S1:1784:8	B-AdverseReaction
.	PROLIA.xml:S1:1792:1	O

Pancreatitis	PROLIA.xml:S1:1794:12	B-AdverseReaction
has	PROLIA.xml:S1:1807:3	O
been	PROLIA.xml:S1:1811:4	O
reported	PROLIA.xml:S1:1816:8	O
in	PROLIA.xml:S1:1825:2	O
clinical	PROLIA.xml:S1:1828:8	O
trials	PROLIA.xml:S1:1837:6	O
(	PROLIA.xml:S1:1844:1	O
6.1	PROLIA.xml:S1:1847:3	O
)	PROLIA.xml:S1:1852:1	O

Male	PROLIA.xml:S1:1859:4	O
Osteoporosis	PROLIA.xml:S1:1864:12	O
:	PROLIA.xml:S1:1876:1	O
Most	PROLIA.xml:S1:1878:4	O
common	PROLIA.xml:S1:1883:6	O
adverse	PROLIA.xml:S1:1890:7	O
reactions	PROLIA.xml:S1:1898:9	O
(	PROLIA.xml:S1:1908:1	O
5%	PROLIA.xml:S1:1911:2	O
and	PROLIA.xml:S1:1914:3	O
more	PROLIA.xml:S1:1918:4	O
common	PROLIA.xml:S1:1923:6	O
than	PROLIA.xml:S1:1930:4	O
placebo	PROLIA.xml:S1:1935:7	O
)	PROLIA.xml:S1:1942:1	O
were	PROLIA.xml:S1:1944:4	O
:	PROLIA.xml:S1:1948:1	O
back	PROLIA.xml:S1:1950:4	B-AdverseReaction
pain	PROLIA.xml:S1:1955:4	I-AdverseReaction
,	PROLIA.xml:S1:1959:1	O
arthralgia	PROLIA.xml:S1:1961:10	B-AdverseReaction
,	PROLIA.xml:S1:1971:1	O
and	PROLIA.xml:S1:1973:3	O
nasopharyngitis	PROLIA.xml:S1:1977:15	B-AdverseReaction
(	PROLIA.xml:S1:1993:1	O
6.1	PROLIA.xml:S1:1996:3	O
)	PROLIA.xml:S1:2001:1	O

Bone	PROLIA.xml:S1:2008:4	O
loss	PROLIA.xml:S1:2013:4	O
due	PROLIA.xml:S1:2018:3	O
to	PROLIA.xml:S1:2022:2	O
hormone	PROLIA.xml:S1:2025:7	O
ablation	PROLIA.xml:S1:2033:8	O
for	PROLIA.xml:S1:2042:3	O
cancer	PROLIA.xml:S1:2046:6	O
:	PROLIA.xml:S1:2052:1	O
Most	PROLIA.xml:S1:2054:4	O
common	PROLIA.xml:S1:2059:6	O
adverse	PROLIA.xml:S1:2066:7	O
reactions	PROLIA.xml:S1:2074:9	O
(	PROLIA.xml:S1:2084:1	O
10%	PROLIA.xml:S1:2088:3	O
and	PROLIA.xml:S1:2092:3	O
more	PROLIA.xml:S1:2096:4	O
common	PROLIA.xml:S1:2101:6	O
than	PROLIA.xml:S1:2108:4	O
placebo	PROLIA.xml:S1:2113:7	O
)	PROLIA.xml:S1:2120:1	O
were	PROLIA.xml:S1:2122:4	O
:	PROLIA.xml:S1:2126:1	O
arthralgia	PROLIA.xml:S1:2128:10	B-AdverseReaction
and	PROLIA.xml:S1:2139:3	O
back	PROLIA.xml:S1:2143:4	B-AdverseReaction
pain	PROLIA.xml:S1:2148:4	I-AdverseReaction
.	PROLIA.xml:S1:2152:1	O

Pain	PROLIA.xml:S1:2154:4	B-AdverseReaction
in	PROLIA.xml:S1:2159:2	I-AdverseReaction
extremity	PROLIA.xml:S1:2162:9	I-AdverseReaction
and	PROLIA.xml:S1:2172:3	O
musculoskeletal	PROLIA.xml:S1:2176:15	B-AdverseReaction
pain	PROLIA.xml:S1:2192:4	I-AdverseReaction
have	PROLIA.xml:S1:2197:4	O
also	PROLIA.xml:S1:2202:4	O
been	PROLIA.xml:S1:2207:4	O
reported	PROLIA.xml:S1:2212:8	O
in	PROLIA.xml:S1:2221:2	O
clinical	PROLIA.xml:S1:2224:8	O
trials	PROLIA.xml:S1:2233:6	O
(	PROLIA.xml:S1:2240:1	O
6.1	PROLIA.xml:S1:2243:3	O
)	PROLIA.xml:S1:2248:1	O

To	PROLIA.xml:S1:2257:2	O
report	PROLIA.xml:S1:2260:6	O
SUSPECTED	PROLIA.xml:S1:2267:9	O
ADVERSE	PROLIA.xml:S1:2277:7	O
REACTIONS	PROLIA.xml:S1:2285:9	O
,	PROLIA.xml:S1:2294:1	O
contact	PROLIA.xml:S1:2296:7	O
Amgen	PROLIA.xml:S1:2304:5	O
Inc	PROLIA.xml:S1:2310:3	O
.	PROLIA.xml:S1:2313:1	O

at	PROLIA.xml:S1:2315:2	O
1	PROLIA.xml:S1:2318:1	O
-	PROLIA.xml:S1:2319:1	O
800	PROLIA.xml:S1:2320:3	O
-	PROLIA.xml:S1:2323:1	O
77	PROLIA.xml:S1:2324:2	O
-	PROLIA.xml:S1:2326:1	O
AMGEN	PROLIA.xml:S1:2327:5	O
(	PROLIA.xml:S1:2333:1	O
1	PROLIA.xml:S1:2334:1	O
-	PROLIA.xml:S1:2335:1	O
800	PROLIA.xml:S1:2336:3	O
-	PROLIA.xml:S1:2339:1	O
772	PROLIA.xml:S1:2340:3	O
-	PROLIA.xml:S1:2343:1	O
6436	PROLIA.xml:S1:2344:4	O
)	PROLIA.xml:S1:2348:1	O
or	PROLIA.xml:S1:2350:2	O
FDA	PROLIA.xml:S1:2353:3	O
at	PROLIA.xml:S1:2357:2	O
1	PROLIA.xml:S1:2360:1	O
-	PROLIA.xml:S1:2361:1	O
800	PROLIA.xml:S1:2362:3	O
-	PROLIA.xml:S1:2365:1	O
FDA	PROLIA.xml:S1:2366:3	O
-	PROLIA.xml:S1:2369:1	O
1088	PROLIA.xml:S1:2370:4	O
or	PROLIA.xml:S1:2375:2	O
www	PROLIA.xml:S1:2381:3	O
.	PROLIA.xml:S1:2384:1	O
fda	PROLIA.xml:S1:2385:3	O
.	PROLIA.xml:S1:2388:1	O
gov	PROLIA.xml:S1:2389:3	O
medwatch	PROLIA.xml:S1:2393:8	O
.	PROLIA.xml:S1:2407:1	O

6.1	PROLIA.xml:S1:2423:3	O

Clinical	PROLIA.xml:S1:2427:8	O

Trials	PROLIA.xml:S1:2436:6	O
Experience	PROLIA.xml:S1:2443:10	O

Because	PROLIA.xml:S1:2457:7	O
clinical	PROLIA.xml:S1:2465:8	O
studies	PROLIA.xml:S1:2474:7	O
are	PROLIA.xml:S1:2482:3	O
conducted	PROLIA.xml:S1:2486:9	O
under	PROLIA.xml:S1:2496:5	O
widely	PROLIA.xml:S1:2502:6	O
varying	PROLIA.xml:S1:2509:7	O
conditions	PROLIA.xml:S1:2517:10	O
,	PROLIA.xml:S1:2527:1	O
adverse	PROLIA.xml:S1:2529:7	O
reaction	PROLIA.xml:S1:2537:8	O
rates	PROLIA.xml:S1:2546:5	O
observed	PROLIA.xml:S1:2552:8	O
in	PROLIA.xml:S1:2561:2	O
the	PROLIA.xml:S1:2564:3	O
clinical	PROLIA.xml:S1:2568:8	O
studies	PROLIA.xml:S1:2577:7	O
of	PROLIA.xml:S1:2585:2	O
a	PROLIA.xml:S1:2588:1	O
drug	PROLIA.xml:S1:2590:4	O
cannot	PROLIA.xml:S1:2595:6	O
be	PROLIA.xml:S1:2602:2	O
directly	PROLIA.xml:S1:2605:8	O
compared	PROLIA.xml:S1:2614:8	O
to	PROLIA.xml:S1:2623:2	O
rates	PROLIA.xml:S1:2626:5	O
in	PROLIA.xml:S1:2632:2	O
the	PROLIA.xml:S1:2635:3	O
clinical	PROLIA.xml:S1:2639:8	O
studies	PROLIA.xml:S1:2648:7	O
of	PROLIA.xml:S1:2656:2	O
another	PROLIA.xml:S1:2659:7	O
drug	PROLIA.xml:S1:2667:4	O
and	PROLIA.xml:S1:2672:3	O
may	PROLIA.xml:S1:2676:3	O
not	PROLIA.xml:S1:2680:3	O
reflect	PROLIA.xml:S1:2684:7	O
the	PROLIA.xml:S1:2692:3	O
rates	PROLIA.xml:S1:2696:5	O
observed	PROLIA.xml:S1:2702:8	O
in	PROLIA.xml:S1:2711:2	O
clinical	PROLIA.xml:S1:2714:8	O
practice	PROLIA.xml:S1:2723:8	O
.	PROLIA.xml:S1:2731:1	O

Treatment	PROLIA.xml:S1:2740:9	O
of	PROLIA.xml:S1:2750:2	O
Postmenopausal	PROLIA.xml:S1:2753:14	O
Women	PROLIA.xml:S1:2768:5	O
with	PROLIA.xml:S1:2774:4	O
Osteoporosis	PROLIA.xml:S1:2779:12	O

The	PROLIA.xml:S1:2798:3	O
safety	PROLIA.xml:S1:2802:6	O
of	PROLIA.xml:S1:2809:2	O
Prolia	PROLIA.xml:S1:2812:6	O
in	PROLIA.xml:S1:2819:2	O
the	PROLIA.xml:S1:2822:3	O
treatment	PROLIA.xml:S1:2826:9	O
of	PROLIA.xml:S1:2836:2	O
postmenopausal	PROLIA.xml:S1:2839:14	O
osteoporosis	PROLIA.xml:S1:2854:12	O
was	PROLIA.xml:S1:2867:3	O
assessed	PROLIA.xml:S1:2871:8	O
in	PROLIA.xml:S1:2880:2	O
a	PROLIA.xml:S1:2883:1	O
3	PROLIA.xml:S1:2885:1	O
-	PROLIA.xml:S1:2886:1	O
year	PROLIA.xml:S1:2887:4	O
,	PROLIA.xml:S1:2891:1	O
randomized	PROLIA.xml:S1:2893:10	O
,	PROLIA.xml:S1:2903:1	O
double	PROLIA.xml:S1:2905:6	O
-	PROLIA.xml:S1:2911:1	O
blind	PROLIA.xml:S1:2912:5	O
,	PROLIA.xml:S1:2917:1	O
placebo	PROLIA.xml:S1:2919:7	O
-	PROLIA.xml:S1:2926:1	O
controlled	PROLIA.xml:S1:2927:10	O
,	PROLIA.xml:S1:2937:1	O
multinational	PROLIA.xml:S1:2939:13	O
study	PROLIA.xml:S1:2953:5	O
of	PROLIA.xml:S1:2959:2	O
7808	PROLIA.xml:S1:2962:4	O
postmenopausal	PROLIA.xml:S1:2967:14	O
women	PROLIA.xml:S1:2982:5	O
aged	PROLIA.xml:S1:2988:4	O
60	PROLIA.xml:S1:2993:2	O
to	PROLIA.xml:S1:2996:2	O
91	PROLIA.xml:S1:2999:2	O
years	PROLIA.xml:S1:3002:5	O
.	PROLIA.xml:S1:3007:1	O

A	PROLIA.xml:S1:3009:1	O
total	PROLIA.xml:S1:3011:5	O
of	PROLIA.xml:S1:3017:2	O
3876	PROLIA.xml:S1:3020:4	O
women	PROLIA.xml:S1:3025:5	O
were	PROLIA.xml:S1:3031:4	O
exposed	PROLIA.xml:S1:3036:7	O
to	PROLIA.xml:S1:3044:2	O
placebo	PROLIA.xml:S1:3047:7	O
and	PROLIA.xml:S1:3055:3	O
3886	PROLIA.xml:S1:3059:4	O
women	PROLIA.xml:S1:3064:5	O
were	PROLIA.xml:S1:3070:4	O
exposed	PROLIA.xml:S1:3075:7	O
to	PROLIA.xml:S1:3083:2	O
Prolia	PROLIA.xml:S1:3086:6	O
administered	PROLIA.xml:S1:3093:12	O
subcutaneously	PROLIA.xml:S1:3106:14	O
once	PROLIA.xml:S1:3121:4	O
every	PROLIA.xml:S1:3126:5	O
6	PROLIA.xml:S1:3132:1	O
months	PROLIA.xml:S1:3134:6	O
as	PROLIA.xml:S1:3141:2	O
a	PROLIA.xml:S1:3144:1	O
single	PROLIA.xml:S1:3146:6	O
60	PROLIA.xml:S1:3153:2	O
mg	PROLIA.xml:S1:3156:2	O
dose	PROLIA.xml:S1:3159:4	O
.	PROLIA.xml:S1:3163:1	O

All	PROLIA.xml:S1:3165:3	O
women	PROLIA.xml:S1:3169:5	O
were	PROLIA.xml:S1:3175:4	O
instructed	PROLIA.xml:S1:3180:10	O
to	PROLIA.xml:S1:3191:2	O
take	PROLIA.xml:S1:3194:4	O
at	PROLIA.xml:S1:3199:2	O
least	PROLIA.xml:S1:3202:5	O
1000	PROLIA.xml:S1:3208:4	O
mg	PROLIA.xml:S1:3213:2	O
of	PROLIA.xml:S1:3216:2	O
calcium	PROLIA.xml:S1:3219:7	O
and	PROLIA.xml:S1:3227:3	O
400	PROLIA.xml:S1:3231:3	O
IU	PROLIA.xml:S1:3235:2	O
of	PROLIA.xml:S1:3238:2	O
vitamin	PROLIA.xml:S1:3241:7	O
D	PROLIA.xml:S1:3249:1	O
supplementation	PROLIA.xml:S1:3251:15	O
per	PROLIA.xml:S1:3267:3	O
day	PROLIA.xml:S1:3271:3	O
.	PROLIA.xml:S1:3274:1	O

The	PROLIA.xml:S1:3280:3	O
incidence	PROLIA.xml:S1:3284:9	O
of	PROLIA.xml:S1:3294:2	O
all	PROLIA.xml:S1:3297:3	O
-	PROLIA.xml:S1:3300:1	O
cause	PROLIA.xml:S1:3301:5	O
mortality	PROLIA.xml:S1:3307:9	B-AdverseReaction
was	PROLIA.xml:S1:3317:3	O
2.3%	PROLIA.xml:S1:3321:4	O
(	PROLIA.xml:S1:3326:1	O
n	PROLIA.xml:S1:3327:1	O
90	PROLIA.xml:S1:3331:2	O
)	PROLIA.xml:S1:3333:1	O
in	PROLIA.xml:S1:3335:2	O
the	PROLIA.xml:S1:3338:3	O
placebo	PROLIA.xml:S1:3342:7	O
group	PROLIA.xml:S1:3350:5	O
and	PROLIA.xml:S1:3356:3	O
1.8%	PROLIA.xml:S1:3360:4	O
(	PROLIA.xml:S1:3365:1	O
n	PROLIA.xml:S1:3366:1	O
70	PROLIA.xml:S1:3370:2	O
)	PROLIA.xml:S1:3372:1	O
in	PROLIA.xml:S1:3374:2	O
the	PROLIA.xml:S1:3377:3	O
Prolia	PROLIA.xml:S1:3381:6	O
group	PROLIA.xml:S1:3388:5	O
.	PROLIA.xml:S1:3393:1	O

The	PROLIA.xml:S1:3395:3	O
incidence	PROLIA.xml:S1:3399:9	O
of	PROLIA.xml:S1:3409:2	O
nonfatal	PROLIA.xml:S1:3412:8	O
serious	PROLIA.xml:S1:3421:7	O
adverse	PROLIA.xml:S1:3429:7	O
events	PROLIA.xml:S1:3437:6	O
was	PROLIA.xml:S1:3444:3	O
24.2%	PROLIA.xml:S1:3448:5	O
in	PROLIA.xml:S1:3454:2	O
the	PROLIA.xml:S1:3457:3	O
placebo	PROLIA.xml:S1:3461:7	O
group	PROLIA.xml:S1:3469:5	O
and	PROLIA.xml:S1:3475:3	O
25.0%	PROLIA.xml:S1:3479:5	O
in	PROLIA.xml:S1:3485:2	O
the	PROLIA.xml:S1:3488:3	O
Prolia	PROLIA.xml:S1:3492:6	O
group	PROLIA.xml:S1:3499:5	O
.	PROLIA.xml:S1:3504:1	O

The	PROLIA.xml:S1:3506:3	O
percentage	PROLIA.xml:S1:3510:10	O
of	PROLIA.xml:S1:3521:2	O
patients	PROLIA.xml:S1:3524:8	O
who	PROLIA.xml:S1:3533:3	O
withdrew	PROLIA.xml:S1:3537:8	O
from	PROLIA.xml:S1:3546:4	O
the	PROLIA.xml:S1:3551:3	O
study	PROLIA.xml:S1:3555:5	O
due	PROLIA.xml:S1:3561:3	O
to	PROLIA.xml:S1:3565:2	O
adverse	PROLIA.xml:S1:3568:7	O
events	PROLIA.xml:S1:3576:6	O
was	PROLIA.xml:S1:3583:3	O
2.1%	PROLIA.xml:S1:3587:4	O
and	PROLIA.xml:S1:3592:3	O
2.4%	PROLIA.xml:S1:3596:4	O
for	PROLIA.xml:S1:3601:3	O
the	PROLIA.xml:S1:3605:3	O
placebo	PROLIA.xml:S1:3609:7	O
and	PROLIA.xml:S1:3617:3	O
Prolia	PROLIA.xml:S1:3621:6	O
groups	PROLIA.xml:S1:3628:6	O
,	PROLIA.xml:S1:3634:1	O
respectively	PROLIA.xml:S1:3636:12	O
.	PROLIA.xml:S1:3648:1	O

Adverse	PROLIA.xml:S1:3654:7	O
reactions	PROLIA.xml:S1:3662:9	O
reported	PROLIA.xml:S1:3672:8	O
in	PROLIA.xml:S1:3681:2	O
2%	PROLIA.xml:S1:3687:2	O
of	PROLIA.xml:S1:3690:2	O
postmenopausal	PROLIA.xml:S1:3693:14	O
women	PROLIA.xml:S1:3708:5	O
with	PROLIA.xml:S1:3714:4	O
osteoporosis	PROLIA.xml:S1:3719:12	O
and	PROLIA.xml:S1:3732:3	O
more	PROLIA.xml:S1:3736:4	O
frequently	PROLIA.xml:S1:3741:10	O
in	PROLIA.xml:S1:3752:2	O
the	PROLIA.xml:S1:3755:3	O
Prolia	PROLIA.xml:S1:3759:6	O
-	PROLIA.xml:S1:3765:1	O
treated	PROLIA.xml:S1:3766:7	O
women	PROLIA.xml:S1:3774:5	O
than	PROLIA.xml:S1:3780:4	O
in	PROLIA.xml:S1:3785:2	O
the	PROLIA.xml:S1:3788:3	O
placebo	PROLIA.xml:S1:3792:7	O
-	PROLIA.xml:S1:3799:1	O
treated	PROLIA.xml:S1:3800:7	O
women	PROLIA.xml:S1:3808:5	O
are	PROLIA.xml:S1:3814:3	O
shown	PROLIA.xml:S1:3818:5	O
in	PROLIA.xml:S1:3824:2	O
the	PROLIA.xml:S1:3827:3	O
table	PROLIA.xml:S1:3831:5	O
below	PROLIA.xml:S1:3837:5	O
.	PROLIA.xml:S1:3842:1	O

Table	PROLIA.xml:S1:3848:5	O
1	PROLIA.xml:S1:3854:1	O
.	PROLIA.xml:S1:3855:1	O

Adverse	PROLIA.xml:S1:3857:7	O
Reactions	PROLIA.xml:S1:3865:9	O
Occurring	PROLIA.xml:S1:3875:9	O
in	PROLIA.xml:S1:3885:2	O
2%	PROLIA.xml:S1:3891:2	O
of	PROLIA.xml:S1:3894:2	O
Patients	PROLIA.xml:S1:3897:8	O
with	PROLIA.xml:S1:3906:4	O
Osteoporosis	PROLIA.xml:S1:3911:12	O
and	PROLIA.xml:S1:3924:3	O
More	PROLIA.xml:S1:3928:4	O
Frequently	PROLIA.xml:S1:3933:10	O
than	PROLIA.xml:S1:3944:4	O
in	PROLIA.xml:S1:3949:2	O
Placebo	PROLIA.xml:S1:3952:7	O
-	PROLIA.xml:S1:3959:1	O
treated	PROLIA.xml:S1:3960:7	O
Patients	PROLIA.xml:S1:3968:8	O

SYSTEM	PROLIA.xml:S1:3981:6	O
ORGAN	PROLIA.xml:S1:3988:5	O
CLASS	PROLIA.xml:S1:3994:5	O
Preferred	PROLIA.xml:S1:4002:9	O
Term	PROLIA.xml:S1:4012:4	O
Prolia	PROLIA.xml:S1:4023:6	O
(	PROLIA.xml:S1:4029:1	O
N	PROLIA.xml:S1:4030:1	O
3886	PROLIA.xml:S1:4034:4	O
)	PROLIA.xml:S1:4038:1	O
n	PROLIA.xml:S1:4039:1	O
(	PROLIA.xml:S1:4041:1	O
)	PROLIA.xml:S1:4043:1	O
Placebo	PROLIA.xml:S1:4051:7	O
(	PROLIA.xml:S1:4058:1	O
N	PROLIA.xml:S1:4059:1	O
3876	PROLIA.xml:S1:4063:4	O
)	PROLIA.xml:S1:4067:1	O
n	PROLIA.xml:S1:4068:1	O
(	PROLIA.xml:S1:4070:1	O
)	PROLIA.xml:S1:4072:1	O

BLOOD	PROLIA.xml:S1:4083:5	O
AND	PROLIA.xml:S1:4089:3	O
LYMPHATIC	PROLIA.xml:S1:4093:9	O
SYSTEM	PROLIA.xml:S1:4103:6	O
DISORDERS	PROLIA.xml:S1:4110:9	O

Anemia	PROLIA.xml:S1:4130:6	B-AdverseReaction
129	PROLIA.xml:S1:4139:3	O
(	PROLIA.xml:S1:4143:1	O
3.3	PROLIA.xml:S1:4144:3	O
)	PROLIA.xml:S1:4147:1	O
107	PROLIA.xml:S1:4151:3	O
(	PROLIA.xml:S1:4155:1	O
2.8	PROLIA.xml:S1:4156:3	O
)	PROLIA.xml:S1:4159:1	O

CARDIAC	PROLIA.xml:S1:4168:7	O
DISORDERS	PROLIA.xml:S1:4176:9	O

Angina	PROLIA.xml:S1:4196:6	B-AdverseReaction
pectoris	PROLIA.xml:S1:4203:8	I-AdverseReaction
101	PROLIA.xml:S1:4214:3	O
(	PROLIA.xml:S1:4218:1	O
2.6	PROLIA.xml:S1:4219:3	O
)	PROLIA.xml:S1:4222:1	O
87	PROLIA.xml:S1:4226:2	O
(	PROLIA.xml:S1:4229:1	O
2.2	PROLIA.xml:S1:4230:3	O
)	PROLIA.xml:S1:4233:1	O

Atrial	PROLIA.xml:S1:4243:6	B-AdverseReaction
fibrillation	PROLIA.xml:S1:4250:12	I-AdverseReaction
79	PROLIA.xml:S1:4265:2	O
(	PROLIA.xml:S1:4268:1	O
2.0	PROLIA.xml:S1:4269:3	O
)	PROLIA.xml:S1:4272:1	O
77	PROLIA.xml:S1:4276:2	O
(	PROLIA.xml:S1:4279:1	O
2.0	PROLIA.xml:S1:4280:3	O
)	PROLIA.xml:S1:4283:1	O

EAR	PROLIA.xml:S1:4292:3	O
AND	PROLIA.xml:S1:4296:3	O
LABYRINTH	PROLIA.xml:S1:4300:9	O
DISORDERS	PROLIA.xml:S1:4310:9	O

Vertigo	PROLIA.xml:S1:4330:7	B-AdverseReaction
195	PROLIA.xml:S1:4340:3	O
(	PROLIA.xml:S1:4344:1	O
5.0	PROLIA.xml:S1:4345:3	O
)	PROLIA.xml:S1:4348:1	O
187	PROLIA.xml:S1:4352:3	O
(	PROLIA.xml:S1:4356:1	O
4.8	PROLIA.xml:S1:4357:3	O
)	PROLIA.xml:S1:4360:1	O

GASTROINTESTINAL	PROLIA.xml:S1:4369:16	O
DISORDERS	PROLIA.xml:S1:4386:9	O

Abdominal	PROLIA.xml:S1:4406:9	B-AdverseReaction
pain	PROLIA.xml:S1:4416:4	I-AdverseReaction
upper	PROLIA.xml:S1:4421:5	I-AdverseReaction
129	PROLIA.xml:S1:4429:3	O
(	PROLIA.xml:S1:4433:1	O
3.3	PROLIA.xml:S1:4434:3	O
)	PROLIA.xml:S1:4437:1	O
111	PROLIA.xml:S1:4441:3	O
(	PROLIA.xml:S1:4445:1	O
2.9	PROLIA.xml:S1:4446:3	O
)	PROLIA.xml:S1:4449:1	O

Flatulence	PROLIA.xml:S1:4459:10	B-AdverseReaction
84	PROLIA.xml:S1:4472:2	O
(	PROLIA.xml:S1:4475:1	O
2.2	PROLIA.xml:S1:4476:3	O
)	PROLIA.xml:S1:4479:1	O
53	PROLIA.xml:S1:4483:2	O
(	PROLIA.xml:S1:4486:1	O
1.4	PROLIA.xml:S1:4487:3	O
)	PROLIA.xml:S1:4490:1	O

Gastroesophageal	PROLIA.xml:S1:4500:16	B-AdverseReaction
reflux	PROLIA.xml:S1:4517:6	I-AdverseReaction
disease	PROLIA.xml:S1:4524:7	I-AdverseReaction
80	PROLIA.xml:S1:4534:2	O
(	PROLIA.xml:S1:4537:1	O
2.1	PROLIA.xml:S1:4538:3	O
)	PROLIA.xml:S1:4541:1	O
66	PROLIA.xml:S1:4545:2	O
(	PROLIA.xml:S1:4548:1	O
1.7	PROLIA.xml:S1:4549:3	O
)	PROLIA.xml:S1:4552:1	O

GENERAL	PROLIA.xml:S1:4561:7	O
DISORDERS	PROLIA.xml:S1:4569:9	O
AND	PROLIA.xml:S1:4579:3	O
ADMINISTRATION	PROLIA.xml:S1:4583:14	O
SITE	PROLIA.xml:S1:4598:4	O
CONDITIONS	PROLIA.xml:S1:4603:10	O

Edema	PROLIA.xml:S1:4624:5	B-AdverseReaction
peripheral	PROLIA.xml:S1:4630:10	I-AdverseReaction
189	PROLIA.xml:S1:4643:3	O
(	PROLIA.xml:S1:4647:1	O
4.9	PROLIA.xml:S1:4648:3	O
)	PROLIA.xml:S1:4651:1	O
155	PROLIA.xml:S1:4655:3	O
(	PROLIA.xml:S1:4659:1	O
4.0	PROLIA.xml:S1:4660:3	O
)	PROLIA.xml:S1:4663:1	O

Asthenia	PROLIA.xml:S1:4673:8	B-AdverseReaction
90	PROLIA.xml:S1:4684:2	O
(	PROLIA.xml:S1:4687:1	O
2.3	PROLIA.xml:S1:4688:3	O
)	PROLIA.xml:S1:4691:1	O
73	PROLIA.xml:S1:4695:2	O
(	PROLIA.xml:S1:4698:1	O
1.9	PROLIA.xml:S1:4699:3	O
)	PROLIA.xml:S1:4702:1	O

INFECTIONS	PROLIA.xml:S1:4711:10	O
AND	PROLIA.xml:S1:4722:3	O
INFESTATIONS	PROLIA.xml:S1:4726:12	O

Cystitis	PROLIA.xml:S1:4749:8	B-AdverseReaction
228	PROLIA.xml:S1:4760:3	O
(	PROLIA.xml:S1:4764:1	O
5.9	PROLIA.xml:S1:4765:3	O
)	PROLIA.xml:S1:4768:1	O
225	PROLIA.xml:S1:4772:3	O
(	PROLIA.xml:S1:4776:1	O
5.8	PROLIA.xml:S1:4777:3	O
)	PROLIA.xml:S1:4780:1	O

Upper	PROLIA.xml:S1:4790:5	B-AdverseReaction
respiratory	PROLIA.xml:S1:4796:11	I-AdverseReaction
tract	PROLIA.xml:S1:4808:5	I-AdverseReaction
infection	PROLIA.xml:S1:4814:9	I-AdverseReaction
190	PROLIA.xml:S1:4826:3	O
(	PROLIA.xml:S1:4830:1	O
4.9	PROLIA.xml:S1:4831:3	O
)	PROLIA.xml:S1:4834:1	O
167	PROLIA.xml:S1:4838:3	O
(	PROLIA.xml:S1:4842:1	O
4.3	PROLIA.xml:S1:4843:3	O
)	PROLIA.xml:S1:4846:1	O

Pneumonia	PROLIA.xml:S1:4856:9	B-AdverseReaction
152	PROLIA.xml:S1:4868:3	O
(	PROLIA.xml:S1:4872:1	O
3.9	PROLIA.xml:S1:4873:3	O
)	PROLIA.xml:S1:4876:1	O
150	PROLIA.xml:S1:4880:3	O
(	PROLIA.xml:S1:4884:1	O
3.9	PROLIA.xml:S1:4885:3	O
)	PROLIA.xml:S1:4888:1	O

Pharyngitis	PROLIA.xml:S1:4898:11	B-AdverseReaction
91	PROLIA.xml:S1:4912:2	O
(	PROLIA.xml:S1:4915:1	O
2.3	PROLIA.xml:S1:4916:3	O
)	PROLIA.xml:S1:4919:1	O
78	PROLIA.xml:S1:4923:2	O
(	PROLIA.xml:S1:4926:1	O
2.0	PROLIA.xml:S1:4927:3	O
)	PROLIA.xml:S1:4930:1	O

Herpes	PROLIA.xml:S1:4940:6	B-AdverseReaction
zoster	PROLIA.xml:S1:4947:6	I-AdverseReaction
79	PROLIA.xml:S1:4956:2	O
(	PROLIA.xml:S1:4959:1	O
2.0	PROLIA.xml:S1:4960:3	O
)	PROLIA.xml:S1:4963:1	O
72	PROLIA.xml:S1:4967:2	O
(	PROLIA.xml:S1:4970:1	O
1.9	PROLIA.xml:S1:4971:3	O
)	PROLIA.xml:S1:4974:1	O

METABOLISM	PROLIA.xml:S1:4983:10	O
AND	PROLIA.xml:S1:4994:3	O
NUTRITION	PROLIA.xml:S1:4998:9	O
DISORDERS	PROLIA.xml:S1:5008:9	O

Hypercholesterolemia	PROLIA.xml:S1:5028:20	B-AdverseReaction
280	PROLIA.xml:S1:5051:3	O
(	PROLIA.xml:S1:5055:1	O
7.2	PROLIA.xml:S1:5056:3	O
)	PROLIA.xml:S1:5059:1	O
236	PROLIA.xml:S1:5063:3	O
(	PROLIA.xml:S1:5067:1	O
6.1	PROLIA.xml:S1:5068:3	O
)	PROLIA.xml:S1:5071:1	O

MUSCULOSKELETAL	PROLIA.xml:S1:5080:15	O
AND	PROLIA.xml:S1:5096:3	O
CONNECTIVE	PROLIA.xml:S1:5100:10	O
TISSUE	PROLIA.xml:S1:5111:6	O
DISORDERS	PROLIA.xml:S1:5118:9	O

Back	PROLIA.xml:S1:5138:4	B-AdverseReaction
pain	PROLIA.xml:S1:5143:4	I-AdverseReaction
1347	PROLIA.xml:S1:5150:4	O
(	PROLIA.xml:S1:5155:1	O
34.7	PROLIA.xml:S1:5156:4	O
)	PROLIA.xml:S1:5160:1	O
1340	PROLIA.xml:S1:5164:4	O
(	PROLIA.xml:S1:5169:1	O
34.6	PROLIA.xml:S1:5170:4	O
)	PROLIA.xml:S1:5174:1	O

Pain	PROLIA.xml:S1:5184:4	B-AdverseReaction
in	PROLIA.xml:S1:5189:2	I-AdverseReaction
extremity	PROLIA.xml:S1:5192:9	I-AdverseReaction
453	PROLIA.xml:S1:5204:3	O
(	PROLIA.xml:S1:5208:1	O
11.7	PROLIA.xml:S1:5209:4	O
)	PROLIA.xml:S1:5213:1	O
430	PROLIA.xml:S1:5217:3	O
(	PROLIA.xml:S1:5221:1	O
11.1	PROLIA.xml:S1:5222:4	O
)	PROLIA.xml:S1:5226:1	O

Musculoskeletal	PROLIA.xml:S1:5236:15	B-AdverseReaction
pain	PROLIA.xml:S1:5252:4	I-AdverseReaction
297	PROLIA.xml:S1:5259:3	O
(	PROLIA.xml:S1:5263:1	O
7.6	PROLIA.xml:S1:5264:3	O
)	PROLIA.xml:S1:5267:1	O
291	PROLIA.xml:S1:5271:3	O
(	PROLIA.xml:S1:5275:1	O
7.5	PROLIA.xml:S1:5276:3	O
)	PROLIA.xml:S1:5279:1	O

Bone	PROLIA.xml:S1:5289:4	B-AdverseReaction
pain	PROLIA.xml:S1:5294:4	I-AdverseReaction
142	PROLIA.xml:S1:5301:3	O
(	PROLIA.xml:S1:5305:1	O
3.7	PROLIA.xml:S1:5306:3	O
)	PROLIA.xml:S1:5309:1	O
117	PROLIA.xml:S1:5313:3	O
(	PROLIA.xml:S1:5317:1	O
3.0	PROLIA.xml:S1:5318:3	O
)	PROLIA.xml:S1:5321:1	O

Myalgia	PROLIA.xml:S1:5331:7	B-AdverseReaction
114	PROLIA.xml:S1:5341:3	O
(	PROLIA.xml:S1:5345:1	O
2.9	PROLIA.xml:S1:5346:3	O
)	PROLIA.xml:S1:5349:1	O
94	PROLIA.xml:S1:5353:2	O
(	PROLIA.xml:S1:5356:1	O
2.4	PROLIA.xml:S1:5357:3	O
)	PROLIA.xml:S1:5360:1	O

Spinal	PROLIA.xml:S1:5370:6	B-AdverseReaction
osteoarthritis	PROLIA.xml:S1:5377:14	I-AdverseReaction
82	PROLIA.xml:S1:5394:2	O
(	PROLIA.xml:S1:5397:1	O
2.1	PROLIA.xml:S1:5398:3	O
)	PROLIA.xml:S1:5401:1	O
64	PROLIA.xml:S1:5405:2	O
(	PROLIA.xml:S1:5408:1	O
1.7	PROLIA.xml:S1:5409:3	O
)	PROLIA.xml:S1:5412:1	O

NERVOUS	PROLIA.xml:S1:5421:7	O
SYSTEM	PROLIA.xml:S1:5429:6	O
DISORDERS	PROLIA.xml:S1:5436:9	O

Sciatica	PROLIA.xml:S1:5456:8	B-AdverseReaction
178	PROLIA.xml:S1:5467:3	O
(	PROLIA.xml:S1:5471:1	O
4.6	PROLIA.xml:S1:5472:3	O
)	PROLIA.xml:S1:5475:1	O
149	PROLIA.xml:S1:5479:3	O
(	PROLIA.xml:S1:5483:1	O
3.8	PROLIA.xml:S1:5484:3	O
)	PROLIA.xml:S1:5487:1	O

PSYCHIATRIC	PROLIA.xml:S1:5496:11	O
DISORDERS	PROLIA.xml:S1:5508:9	O

Insomnia	PROLIA.xml:S1:5528:8	B-AdverseReaction
126	PROLIA.xml:S1:5539:3	O
(	PROLIA.xml:S1:5543:1	O
3.2	PROLIA.xml:S1:5544:3	O
)	PROLIA.xml:S1:5547:1	O
122	PROLIA.xml:S1:5551:3	O
(	PROLIA.xml:S1:5555:1	O
3.1	PROLIA.xml:S1:5556:3	O
)	PROLIA.xml:S1:5559:1	O

SKIN	PROLIA.xml:S1:5568:4	O
AND	PROLIA.xml:S1:5573:3	O
SUBCUTANEOUS	PROLIA.xml:S1:5577:12	O
TISSUE	PROLIA.xml:S1:5590:6	O
DISORDERS	PROLIA.xml:S1:5597:9	O

Rash	PROLIA.xml:S1:5617:4	B-AdverseReaction
96	PROLIA.xml:S1:5624:2	O
(	PROLIA.xml:S1:5627:1	O
2.5	PROLIA.xml:S1:5628:3	O
)	PROLIA.xml:S1:5631:1	O
79	PROLIA.xml:S1:5635:2	O
(	PROLIA.xml:S1:5638:1	O
2.0	PROLIA.xml:S1:5639:3	O
)	PROLIA.xml:S1:5642:1	O

Pruritus	PROLIA.xml:S1:5652:8	B-AdverseReaction
87	PROLIA.xml:S1:5663:2	O
(	PROLIA.xml:S1:5666:1	O
2.2	PROLIA.xml:S1:5667:3	O
)	PROLIA.xml:S1:5670:1	O
82	PROLIA.xml:S1:5674:2	O
(	PROLIA.xml:S1:5677:1	O
2.1	PROLIA.xml:S1:5678:3	O
)	PROLIA.xml:S1:5681:1	O

Hypocalcemia	PROLIA.xml:S1:5697:12	B-AdverseReaction
Decreases	PROLIA.xml:S1:5711:9	B-AdverseReaction
in	PROLIA.xml:S1:5721:2	I-AdverseReaction
serum	PROLIA.xml:S1:5724:5	I-AdverseReaction
calcium	PROLIA.xml:S1:5730:7	I-AdverseReaction
levels	PROLIA.xml:S1:5738:6	I-AdverseReaction
to	PROLIA.xml:S1:5745:2	O
less	PROLIA.xml:S1:5748:4	O
than	PROLIA.xml:S1:5753:4	O
8.5	PROLIA.xml:S1:5758:3	O
mg	PROLIA.xml:S1:5762:2	O
dL	PROLIA.xml:S1:5765:2	O
at	PROLIA.xml:S1:5768:2	O
any	PROLIA.xml:S1:5771:3	O
visit	PROLIA.xml:S1:5775:5	O
were	PROLIA.xml:S1:5781:4	O
reported	PROLIA.xml:S1:5786:8	O
in	PROLIA.xml:S1:5795:2	O
0.4%	PROLIA.xml:S1:5798:4	O
women	PROLIA.xml:S1:5803:5	O
in	PROLIA.xml:S1:5809:2	O
the	PROLIA.xml:S1:5812:3	O
placebo	PROLIA.xml:S1:5816:7	O
group	PROLIA.xml:S1:5824:5	O
and	PROLIA.xml:S1:5830:3	O
1.7%	PROLIA.xml:S1:5834:4	O
women	PROLIA.xml:S1:5839:5	O
in	PROLIA.xml:S1:5845:2	O
the	PROLIA.xml:S1:5848:3	O
Prolia	PROLIA.xml:S1:5852:6	O
group	PROLIA.xml:S1:5859:5	O
.	PROLIA.xml:S1:5864:1	O

The	PROLIA.xml:S1:5866:3	O
nadir	PROLIA.xml:S1:5870:5	O
in	PROLIA.xml:S1:5876:2	O
serum	PROLIA.xml:S1:5879:5	O
calcium	PROLIA.xml:S1:5885:7	O
level	PROLIA.xml:S1:5893:5	O
occurs	PROLIA.xml:S1:5899:6	O
at	PROLIA.xml:S1:5906:2	O
approximately	PROLIA.xml:S1:5909:13	O
day	PROLIA.xml:S1:5923:3	O
10	PROLIA.xml:S1:5927:2	O
after	PROLIA.xml:S1:5930:5	O
Prolia	PROLIA.xml:S1:5936:6	O
dosing	PROLIA.xml:S1:5943:6	O
in	PROLIA.xml:S1:5950:2	O
subjects	PROLIA.xml:S1:5953:8	O
with	PROLIA.xml:S1:5962:4	O
normal	PROLIA.xml:S1:5967:6	O
renal	PROLIA.xml:S1:5974:5	O
function	PROLIA.xml:S1:5980:8	O
.	PROLIA.xml:S1:5988:1	O

In	PROLIA.xml:S1:5994:2	O

clinical	PROLIA.xml:S1:5997:8	O
studies	PROLIA.xml:S1:6006:7	O
,	PROLIA.xml:S1:6013:1	O
subjects	PROLIA.xml:S1:6015:8	O
with	PROLIA.xml:S1:6024:4	O
impaired	PROLIA.xml:S1:6029:8	O
renal	PROLIA.xml:S1:6038:5	O
function	PROLIA.xml:S1:6044:8	O
were	PROLIA.xml:S1:6053:4	O
more	PROLIA.xml:S1:6058:4	O
likely	PROLIA.xml:S1:6063:6	O
to	PROLIA.xml:S1:6070:2	O
have	PROLIA.xml:S1:6073:4	O
greater	PROLIA.xml:S1:6078:7	O
reductions	PROLIA.xml:S1:6086:10	O
in	PROLIA.xml:S1:6097:2	O
serum	PROLIA.xml:S1:6100:5	O
calcium	PROLIA.xml:S1:6106:7	O
levels	PROLIA.xml:S1:6114:6	O
compared	PROLIA.xml:S1:6121:8	O
to	PROLIA.xml:S1:6130:2	O
subjects	PROLIA.xml:S1:6133:8	O
with	PROLIA.xml:S1:6142:4	O
normal	PROLIA.xml:S1:6147:6	O
renal	PROLIA.xml:S1:6154:5	O
function	PROLIA.xml:S1:6160:8	O
.	PROLIA.xml:S1:6168:1	O

In	PROLIA.xml:S1:6170:2	O
a	PROLIA.xml:S1:6173:1	O
study	PROLIA.xml:S1:6175:5	O
of	PROLIA.xml:S1:6181:2	O
55	PROLIA.xml:S1:6184:2	O
subjects	PROLIA.xml:S1:6187:8	O
with	PROLIA.xml:S1:6196:4	O
varying	PROLIA.xml:S1:6201:7	O
degrees	PROLIA.xml:S1:6209:7	O
of	PROLIA.xml:S1:6217:2	O
renal	PROLIA.xml:S1:6220:5	O
function	PROLIA.xml:S1:6226:8	O
,	PROLIA.xml:S1:6234:1	O
serum	PROLIA.xml:S1:6236:5	O
calcium	PROLIA.xml:S1:6242:7	O
levels	PROLIA.xml:S1:6250:6	O
7.5	PROLIA.xml:S1:6259:3	O
mg	PROLIA.xml:S1:6263:2	O
dL	PROLIA.xml:S1:6266:2	O
or	PROLIA.xml:S1:6269:2	O
symptomatic	PROLIA.xml:S1:6272:11	B-AdverseReaction
hypocalcemia	PROLIA.xml:S1:6284:12	I-AdverseReaction
were	PROLIA.xml:S1:6297:4	O
observed	PROLIA.xml:S1:6302:8	O
in	PROLIA.xml:S1:6311:2	O
5	PROLIA.xml:S1:6314:1	O
subjects	PROLIA.xml:S1:6316:8	O
.	PROLIA.xml:S1:6324:1	O

These	PROLIA.xml:S1:6326:5	O
included	PROLIA.xml:S1:6332:8	O
no	PROLIA.xml:S1:6341:2	O
subjects	PROLIA.xml:S1:6344:8	O
in	PROLIA.xml:S1:6353:2	O
the	PROLIA.xml:S1:6356:3	O
normal	PROLIA.xml:S1:6360:6	O
renal	PROLIA.xml:S1:6367:5	O
function	PROLIA.xml:S1:6373:8	O
group	PROLIA.xml:S1:6382:5	O
,	PROLIA.xml:S1:6387:1	O
10%	PROLIA.xml:S1:6389:3	O
of	PROLIA.xml:S1:6393:2	O
subjects	PROLIA.xml:S1:6396:8	O
in	PROLIA.xml:S1:6405:2	O
the	PROLIA.xml:S1:6408:3	O
creatinine	PROLIA.xml:S1:6412:10	O
clearance	PROLIA.xml:S1:6423:9	O
50	PROLIA.xml:S1:6433:2	O
to	PROLIA.xml:S1:6436:2	O
80	PROLIA.xml:S1:6439:2	O
mL	PROLIA.xml:S1:6442:2	O
min	PROLIA.xml:S1:6445:3	O
group	PROLIA.xml:S1:6449:5	O
,	PROLIA.xml:S1:6454:1	O
29%	PROLIA.xml:S1:6456:3	O
of	PROLIA.xml:S1:6460:2	O
subjects	PROLIA.xml:S1:6463:8	O
in	PROLIA.xml:S1:6472:2	O
the	PROLIA.xml:S1:6475:3	O
creatinine	PROLIA.xml:S1:6479:10	O
clearance	PROLIA.xml:S1:6490:9	O
30	PROLIA.xml:S1:6502:2	O
mL	PROLIA.xml:S1:6505:2	O
min	PROLIA.xml:S1:6508:3	O
group	PROLIA.xml:S1:6512:5	O
,	PROLIA.xml:S1:6517:1	O
and	PROLIA.xml:S1:6519:3	O
29%	PROLIA.xml:S1:6523:3	O
of	PROLIA.xml:S1:6527:2	O
subjects	PROLIA.xml:S1:6530:8	O
in	PROLIA.xml:S1:6539:2	O
the	PROLIA.xml:S1:6542:3	O
hemodialysis	PROLIA.xml:S1:6546:12	O
group	PROLIA.xml:S1:6559:5	O
.	PROLIA.xml:S1:6564:1	O

These	PROLIA.xml:S1:6566:5	O
subjects	PROLIA.xml:S1:6572:8	O
did	PROLIA.xml:S1:6581:3	O
not	PROLIA.xml:S1:6585:3	O
receive	PROLIA.xml:S1:6589:7	O
calcium	PROLIA.xml:S1:6597:7	O
and	PROLIA.xml:S1:6605:3	O
vitamin	PROLIA.xml:S1:6609:7	O
D	PROLIA.xml:S1:6617:1	O
supplementation	PROLIA.xml:S1:6619:15	O
.	PROLIA.xml:S1:6634:1	O

In	PROLIA.xml:S1:6636:2	O
a	PROLIA.xml:S1:6639:1	O
study	PROLIA.xml:S1:6641:5	O
of	PROLIA.xml:S1:6647:2	O
4550	PROLIA.xml:S1:6650:4	O
postmenopausal	PROLIA.xml:S1:6655:14	O
women	PROLIA.xml:S1:6670:5	O
with	PROLIA.xml:S1:6676:4	O
osteoporosis	PROLIA.xml:S1:6681:12	O
,	PROLIA.xml:S1:6693:1	O
the	PROLIA.xml:S1:6695:3	O
mean	PROLIA.xml:S1:6699:4	O
change	PROLIA.xml:S1:6704:6	O
from	PROLIA.xml:S1:6711:4	O
baseline	PROLIA.xml:S1:6716:8	O
in	PROLIA.xml:S1:6725:2	O
serum	PROLIA.xml:S1:6728:5	O
calcium	PROLIA.xml:S1:6734:7	O
level	PROLIA.xml:S1:6742:5	O
10	PROLIA.xml:S1:6748:2	O
days	PROLIA.xml:S1:6751:4	O
after	PROLIA.xml:S1:6756:5	O
Prolia	PROLIA.xml:S1:6762:6	O
dosing	PROLIA.xml:S1:6769:6	O
was	PROLIA.xml:S1:6776:3	O
-	PROLIA.xml:S1:6780:1	O
5.5%	PROLIA.xml:S1:6781:4	O
in	PROLIA.xml:S1:6786:2	O
subjects	PROLIA.xml:S1:6789:8	O
with	PROLIA.xml:S1:6798:4	O
creatinine	PROLIA.xml:S1:6803:10	O
clearance	PROLIA.xml:S1:6814:9	O
30	PROLIA.xml:S1:6826:2	O
mL	PROLIA.xml:S1:6829:2	O
min	PROLIA.xml:S1:6832:3	O
vs	PROLIA.xml:S1:6836:2	O
.	PROLIA.xml:S1:6838:1	O

-	PROLIA.xml:S1:6840:1	O
3.1%	PROLIA.xml:S1:6841:4	O
in	PROLIA.xml:S1:6846:2	O
subjects	PROLIA.xml:S1:6849:8	O
with	PROLIA.xml:S1:6858:4	O
creatinine	PROLIA.xml:S1:6863:10	O
clearance	PROLIA.xml:S1:6874:9	O
30	PROLIA.xml:S1:6887:2	O
mL	PROLIA.xml:S1:6890:2	O
min	PROLIA.xml:S1:6893:3	O
.	PROLIA.xml:S1:6896:1	O

Serious	PROLIA.xml:S1:6905:7	O
Infections	PROLIA.xml:S1:6913:10	O
Receptor	PROLIA.xml:S1:6925:8	O
activator	PROLIA.xml:S1:6934:9	O
of	PROLIA.xml:S1:6944:2	O
nuclear	PROLIA.xml:S1:6947:7	O
factor	PROLIA.xml:S1:6955:6	O
kappa	PROLIA.xml:S1:6962:5	O
-	PROLIA.xml:S1:6967:1	O
B	PROLIA.xml:S1:6968:1	O
ligand	PROLIA.xml:S1:6970:6	O
(	PROLIA.xml:S1:6977:1	O
RANKL	PROLIA.xml:S1:6978:5	O
)	PROLIA.xml:S1:6983:1	O
is	PROLIA.xml:S1:6985:2	O
expressed	PROLIA.xml:S1:6988:9	O
on	PROLIA.xml:S1:6998:2	O
activated	PROLIA.xml:S1:7001:9	O
T	PROLIA.xml:S1:7011:1	O
and	PROLIA.xml:S1:7013:3	O
B	PROLIA.xml:S1:7017:1	O
lymphocytes	PROLIA.xml:S1:7019:11	O
and	PROLIA.xml:S1:7031:3	O
in	PROLIA.xml:S1:7035:2	O
lymph	PROLIA.xml:S1:7038:5	O
nodes	PROLIA.xml:S1:7044:5	O
.	PROLIA.xml:S1:7049:1	O

Therefore	PROLIA.xml:S1:7051:9	O
,	PROLIA.xml:S1:7060:1	O
a	PROLIA.xml:S1:7062:1	O
RANKL	PROLIA.xml:S1:7064:5	O
inhibitor	PROLIA.xml:S1:7070:9	O
such	PROLIA.xml:S1:7080:4	O
as	PROLIA.xml:S1:7085:2	O
Prolia	PROLIA.xml:S1:7088:6	O
may	PROLIA.xml:S1:7095:3	O
increase	PROLIA.xml:S1:7099:8	O
the	PROLIA.xml:S1:7108:3	O
risk	PROLIA.xml:S1:7112:4	B-Factor
of	PROLIA.xml:S1:7117:2	O
infection	PROLIA.xml:S1:7120:9	B-AdverseReaction
.	PROLIA.xml:S1:7129:1	O

In	PROLIA.xml:S1:7137:2	O
the	PROLIA.xml:S1:7140:3	O
clinical	PROLIA.xml:S1:7144:8	O
study	PROLIA.xml:S1:7153:5	O
of	PROLIA.xml:S1:7159:2	O
7808	PROLIA.xml:S1:7162:4	O
postmenopausal	PROLIA.xml:S1:7167:14	O
women	PROLIA.xml:S1:7182:5	O
with	PROLIA.xml:S1:7188:4	O
osteoporosis	PROLIA.xml:S1:7193:12	O
,	PROLIA.xml:S1:7205:1	O
the	PROLIA.xml:S1:7207:3	O
incidence	PROLIA.xml:S1:7211:9	O
of	PROLIA.xml:S1:7221:2	O
infections	PROLIA.xml:S1:7224:10	B-AdverseReaction
resulting	PROLIA.xml:S1:7235:9	O
in	PROLIA.xml:S1:7245:2	O
death	PROLIA.xml:S1:7248:5	B-AdverseReaction
was	PROLIA.xml:S1:7254:3	O
0.2%	PROLIA.xml:S1:7258:4	O
in	PROLIA.xml:S1:7263:2	O
both	PROLIA.xml:S1:7266:4	O
placebo	PROLIA.xml:S1:7271:7	O
and	PROLIA.xml:S1:7279:3	O
Prolia	PROLIA.xml:S1:7283:6	O
treatment	PROLIA.xml:S1:7290:9	O
groups	PROLIA.xml:S1:7300:6	O
.	PROLIA.xml:S1:7306:1	O

However	PROLIA.xml:S1:7308:7	O
,	PROLIA.xml:S1:7315:1	O
the	PROLIA.xml:S1:7317:3	O
incidence	PROLIA.xml:S1:7321:9	O
of	PROLIA.xml:S1:7331:2	O
nonfatal	PROLIA.xml:S1:7334:8	O
serious	PROLIA.xml:S1:7343:7	B-Severity
infections	PROLIA.xml:S1:7351:10	B-AdverseReaction
was	PROLIA.xml:S1:7362:3	O
3.3%	PROLIA.xml:S1:7366:4	O
in	PROLIA.xml:S1:7371:2	O
the	PROLIA.xml:S1:7374:3	O
placebo	PROLIA.xml:S1:7378:7	O
and	PROLIA.xml:S1:7386:3	O
4.0%	PROLIA.xml:S1:7390:4	O
in	PROLIA.xml:S1:7395:2	O
the	PROLIA.xml:S1:7398:3	O
Prolia	PROLIA.xml:S1:7402:6	O
groups	PROLIA.xml:S1:7409:6	O
.	PROLIA.xml:S1:7415:1	O

Hospitalizations	PROLIA.xml:S1:7417:16	O
due	PROLIA.xml:S1:7434:3	O
to	PROLIA.xml:S1:7438:2	O
serious	PROLIA.xml:S1:7441:7	B-Severity
infections	PROLIA.xml:S1:7449:10	B-AdverseReaction
in	PROLIA.xml:S1:7460:2	I-AdverseReaction
the	PROLIA.xml:S1:7463:3	I-AdverseReaction
abdomen	PROLIA.xml:S1:7467:7	I-AdverseReaction
(	PROLIA.xml:S1:7475:1	O
0.7%	PROLIA.xml:S1:7476:4	O
placebo	PROLIA.xml:S1:7481:7	O
vs	PROLIA.xml:S1:7489:2	O
.	PROLIA.xml:S1:7491:1	O

0.9%	PROLIA.xml:S1:7493:4	O
Prolia	PROLIA.xml:S1:7498:6	O
)	PROLIA.xml:S1:7504:1	O
,	PROLIA.xml:S1:7505:1	O
urinary	PROLIA.xml:S1:7507:7	I-AdverseReaction
tract	PROLIA.xml:S1:7515:5	I-AdverseReaction
(	PROLIA.xml:S1:7521:1	O
0.5%	PROLIA.xml:S1:7522:4	O
placebo	PROLIA.xml:S1:7527:7	O
vs	PROLIA.xml:S1:7535:2	O
.	PROLIA.xml:S1:7537:1	O

0.7%	PROLIA.xml:S1:7539:4	O
Prolia	PROLIA.xml:S1:7544:6	O
)	PROLIA.xml:S1:7550:1	O
,	PROLIA.xml:S1:7551:1	O
and	PROLIA.xml:S1:7553:3	O
ear	PROLIA.xml:S1:7557:3	I-AdverseReaction
(	PROLIA.xml:S1:7561:1	O
0.0%	PROLIA.xml:S1:7562:4	O
placebo	PROLIA.xml:S1:7567:7	O
vs	PROLIA.xml:S1:7575:2	O
.	PROLIA.xml:S1:7577:1	O

0.1%	PROLIA.xml:S1:7579:4	O
Prolia	PROLIA.xml:S1:7584:6	O
)	PROLIA.xml:S1:7590:1	O
were	PROLIA.xml:S1:7592:4	O
reported	PROLIA.xml:S1:7597:8	O
.	PROLIA.xml:S1:7605:1	O

Endocarditis	PROLIA.xml:S1:7607:12	B-AdverseReaction
was	PROLIA.xml:S1:7620:3	O
reported	PROLIA.xml:S1:7624:8	O
in	PROLIA.xml:S1:7633:2	O
no	PROLIA.xml:S1:7636:2	O
placebo	PROLIA.xml:S1:7639:7	O
patients	PROLIA.xml:S1:7647:8	O
and	PROLIA.xml:S1:7656:3	O
3	PROLIA.xml:S1:7660:1	O
patients	PROLIA.xml:S1:7662:8	O
receiving	PROLIA.xml:S1:7671:9	O
Prolia	PROLIA.xml:S1:7681:6	O
.	PROLIA.xml:S1:7687:1	O

Skin	PROLIA.xml:S1:7693:4	B-AdverseReaction
infections	PROLIA.xml:S1:7698:10	I-AdverseReaction
,	PROLIA.xml:S1:7708:1	O
including	PROLIA.xml:S1:7710:9	O
erysipelas	PROLIA.xml:S1:7720:10	B-AdverseReaction
and	PROLIA.xml:S1:7731:3	O
cellulitis	PROLIA.xml:S1:7735:10	B-AdverseReaction
,	PROLIA.xml:S1:7745:1	O
leading	PROLIA.xml:S1:7747:7	O
to	PROLIA.xml:S1:7755:2	O
hospitalization	PROLIA.xml:S1:7758:15	O
were	PROLIA.xml:S1:7774:4	O
reported	PROLIA.xml:S1:7779:8	O
more	PROLIA.xml:S1:7788:4	O
frequently	PROLIA.xml:S1:7793:10	O
in	PROLIA.xml:S1:7804:2	O
patients	PROLIA.xml:S1:7807:8	O
treated	PROLIA.xml:S1:7816:7	O
with	PROLIA.xml:S1:7824:4	O
Prolia	PROLIA.xml:S1:7829:6	O
(	PROLIA.xml:S1:7836:1	O
0.1%	PROLIA.xml:S1:7839:4	O
placebo	PROLIA.xml:S1:7844:7	O
vs	PROLIA.xml:S1:7852:2	O
.	PROLIA.xml:S1:7854:1	O

0.4%	PROLIA.xml:S1:7856:4	O
Prolia	PROLIA.xml:S1:7861:6	O
)	PROLIA.xml:S1:7867:1	O
.	PROLIA.xml:S1:7868:1	O

The	PROLIA.xml:S1:7874:3	O
incidence	PROLIA.xml:S1:7878:9	O
of	PROLIA.xml:S1:7888:2	O
opportunistic	PROLIA.xml:S1:7891:13	B-AdverseReaction
infections	PROLIA.xml:S1:7905:10	I-AdverseReaction
was	PROLIA.xml:S1:7916:3	O
similar	PROLIA.xml:S1:7920:7	O
to	PROLIA.xml:S1:7928:2	O
that	PROLIA.xml:S1:7931:4	O
reported	PROLIA.xml:S1:7936:8	O
with	PROLIA.xml:S1:7945:4	O
placebo	PROLIA.xml:S1:7950:7	O
.	PROLIA.xml:S1:7957:1	O

Dermatologic	PROLIA.xml:S1:7965:12	O
Reactions	PROLIA.xml:S1:7978:9	O
A	PROLIA.xml:S1:7989:1	O
significantly	PROLIA.xml:S1:7991:13	O
higher	PROLIA.xml:S1:8005:6	O
number	PROLIA.xml:S1:8012:6	O
of	PROLIA.xml:S1:8019:2	O
patients	PROLIA.xml:S1:8022:8	O
treated	PROLIA.xml:S1:8031:7	O
with	PROLIA.xml:S1:8039:4	O
Prolia	PROLIA.xml:S1:8044:6	O
developed	PROLIA.xml:S1:8051:9	O
epidermal	PROLIA.xml:S1:8061:9	B-AdverseReaction
and	PROLIA.xml:S1:8071:3	O
dermal	PROLIA.xml:S1:8075:6	B-AdverseReaction
adverse	PROLIA.xml:S1:8082:7	I-AdverseReaction
events	PROLIA.xml:S1:8090:6	I-AdverseReaction
(	PROLIA.xml:S1:8097:1	O
such	PROLIA.xml:S1:8098:4	O
as	PROLIA.xml:S1:8103:2	O
dermatitis	PROLIA.xml:S1:8106:10	B-AdverseReaction
,	PROLIA.xml:S1:8116:1	O
eczema	PROLIA.xml:S1:8118:6	B-AdverseReaction
,	PROLIA.xml:S1:8124:1	O
and	PROLIA.xml:S1:8126:3	O
rashes	PROLIA.xml:S1:8130:6	B-AdverseReaction
)	PROLIA.xml:S1:8136:1	O
,	PROLIA.xml:S1:8137:1	O
with	PROLIA.xml:S1:8139:4	O
these	PROLIA.xml:S1:8144:5	O
events	PROLIA.xml:S1:8150:6	O
reported	PROLIA.xml:S1:8157:8	O
in	PROLIA.xml:S1:8166:2	O
8.2%	PROLIA.xml:S1:8169:4	O
of	PROLIA.xml:S1:8174:2	O
the	PROLIA.xml:S1:8177:3	O
placebo	PROLIA.xml:S1:8181:7	O
and	PROLIA.xml:S1:8189:3	O
10.8%	PROLIA.xml:S1:8193:5	O
of	PROLIA.xml:S1:8199:2	O
the	PROLIA.xml:S1:8202:3	O
Prolia	PROLIA.xml:S1:8206:6	O
groups	PROLIA.xml:S1:8213:6	O
(	PROLIA.xml:S1:8220:1	O
p	PROLIA.xml:S1:8221:1	O
0.0001	PROLIA.xml:S1:8225:6	O
)	PROLIA.xml:S1:8231:1	O
.	PROLIA.xml:S1:8232:1	O

Most	PROLIA.xml:S1:8234:4	O
of	PROLIA.xml:S1:8239:2	O
these	PROLIA.xml:S1:8242:5	O
events	PROLIA.xml:S1:8248:6	O
were	PROLIA.xml:S1:8255:4	O
not	PROLIA.xml:S1:8260:3	O
specific	PROLIA.xml:S1:8264:8	O
to	PROLIA.xml:S1:8273:2	O
the	PROLIA.xml:S1:8276:3	O
injection	PROLIA.xml:S1:8280:9	O
site	PROLIA.xml:S1:8290:4	O
[	PROLIA.xml:S1:8296:1	O
see	PROLIA.xml:S1:8297:3	O
Warnings	PROLIA.xml:S1:8301:8	O
and	PROLIA.xml:S1:8310:3	O
Precautions	PROLIA.xml:S1:8314:11	O
(	PROLIA.xml:S1:8326:1	O
5.7	PROLIA.xml:S1:8329:3	O
)]	PROLIA.xml:S1:8334:2	O
.	PROLIA.xml:S1:8336:1	O

Osteonecrosis	PROLIA.xml:S1:8346:13	B-AdverseReaction
of	PROLIA.xml:S1:8360:2	I-AdverseReaction
the	PROLIA.xml:S1:8363:3	I-AdverseReaction
Jaw	PROLIA.xml:S1:8367:3	I-AdverseReaction
ONJ	PROLIA.xml:S1:8372:3	B-AdverseReaction
has	PROLIA.xml:S1:8376:3	O
been	PROLIA.xml:S1:8380:4	O
reported	PROLIA.xml:S1:8385:8	O
in	PROLIA.xml:S1:8394:2	O
the	PROLIA.xml:S1:8397:3	O
osteoporosis	PROLIA.xml:S1:8401:12	O
clinical	PROLIA.xml:S1:8414:8	O
trial	PROLIA.xml:S1:8423:5	O
program	PROLIA.xml:S1:8429:7	O
in	PROLIA.xml:S1:8437:2	O
patients	PROLIA.xml:S1:8440:8	O
treated	PROLIA.xml:S1:8449:7	O
with	PROLIA.xml:S1:8457:4	O
Prolia	PROLIA.xml:S1:8462:6	O
[	PROLIA.xml:S1:8470:1	O
see	PROLIA.xml:S1:8471:3	O
Warnings	PROLIA.xml:S1:8475:8	O
and	PROLIA.xml:S1:8484:3	O
Precautions	PROLIA.xml:S1:8488:11	O
(	PROLIA.xml:S1:8500:1	O
5.4	PROLIA.xml:S1:8503:3	O
)]	PROLIA.xml:S1:8508:2	O
.	PROLIA.xml:S1:8510:1	O

Atypical	PROLIA.xml:S1:8520:8	O
Subtrochanteric	PROLIA.xml:S1:8529:15	O
and	PROLIA.xml:S1:8545:3	O
Diaphyseal	PROLIA.xml:S1:8549:10	O
Fractures	PROLIA.xml:S1:8560:9	O
In	PROLIA.xml:S1:8571:2	O
the	PROLIA.xml:S1:8574:3	O
osteoporosis	PROLIA.xml:S1:8578:12	O
clinical	PROLIA.xml:S1:8591:8	O
trial	PROLIA.xml:S1:8600:5	O
program	PROLIA.xml:S1:8606:7	O
,	PROLIA.xml:S1:8613:1	O
atypical	PROLIA.xml:S1:8615:8	B-AdverseReaction
femoral	PROLIA.xml:S1:8624:7	I-AdverseReaction
fractures	PROLIA.xml:S1:8632:9	I-AdverseReaction
were	PROLIA.xml:S1:8642:4	O
reported	PROLIA.xml:S1:8647:8	O
in	PROLIA.xml:S1:8656:2	O
patients	PROLIA.xml:S1:8659:8	O
treated	PROLIA.xml:S1:8668:7	O
with	PROLIA.xml:S1:8676:4	O
Prolia	PROLIA.xml:S1:8681:6	O
.	PROLIA.xml:S1:8687:1	O

The	PROLIA.xml:S1:8689:3	O
duration	PROLIA.xml:S1:8693:8	O
of	PROLIA.xml:S1:8702:2	O
Prolia	PROLIA.xml:S1:8705:6	O
exposure	PROLIA.xml:S1:8712:8	O
to	PROLIA.xml:S1:8721:2	O
time	PROLIA.xml:S1:8724:4	O
of	PROLIA.xml:S1:8729:2	O
atypical	PROLIA.xml:S1:8732:8	B-AdverseReaction
femoral	PROLIA.xml:S1:8741:7	I-AdverseReaction
fracture	PROLIA.xml:S1:8749:8	I-AdverseReaction
diagnosis	PROLIA.xml:S1:8758:9	O
was	PROLIA.xml:S1:8768:3	O
as	PROLIA.xml:S1:8772:2	O
early	PROLIA.xml:S1:8775:5	O
as	PROLIA.xml:S1:8781:2	O
21	PROLIA.xml:S1:8784:2	O
2	PROLIA.xml:S1:8787:1	O
years	PROLIA.xml:S1:8789:5	O
[	PROLIA.xml:S1:8796:1	O
see	PROLIA.xml:S1:8797:3	O
Warnings	PROLIA.xml:S1:8801:8	O
and	PROLIA.xml:S1:8810:3	O
Precautions	PROLIA.xml:S1:8814:11	O
(	PROLIA.xml:S1:8826:1	O
5.5	PROLIA.xml:S1:8829:3	O
)]	PROLIA.xml:S1:8834:2	O
.	PROLIA.xml:S1:8838:1	O

Pancreatitis	PROLIA.xml:S1:8846:12	O
Pancreatitis	PROLIA.xml:S1:8860:12	B-AdverseReaction
was	PROLIA.xml:S1:8873:3	O
reported	PROLIA.xml:S1:8877:8	O
in	PROLIA.xml:S1:8886:2	O
4	PROLIA.xml:S1:8889:1	O
patients	PROLIA.xml:S1:8891:8	O
(	PROLIA.xml:S1:8900:1	O
0.1%	PROLIA.xml:S1:8901:4	O
)	PROLIA.xml:S1:8905:1	O
in	PROLIA.xml:S1:8907:2	O
the	PROLIA.xml:S1:8910:3	O
placebo	PROLIA.xml:S1:8914:7	O
and	PROLIA.xml:S1:8922:3	O
8	PROLIA.xml:S1:8926:1	O
patients	PROLIA.xml:S1:8928:8	O
(	PROLIA.xml:S1:8937:1	O
0.2%	PROLIA.xml:S1:8938:4	O
)	PROLIA.xml:S1:8942:1	O
in	PROLIA.xml:S1:8944:2	O
the	PROLIA.xml:S1:8947:3	O
Prolia	PROLIA.xml:S1:8951:6	O
groups	PROLIA.xml:S1:8958:6	O
.	PROLIA.xml:S1:8964:1	O

Of	PROLIA.xml:S1:8966:2	O
these	PROLIA.xml:S1:8969:5	O
reports	PROLIA.xml:S1:8975:7	O
,	PROLIA.xml:S1:8982:1	O
1	PROLIA.xml:S1:8984:1	O
patient	PROLIA.xml:S1:8986:7	O
in	PROLIA.xml:S1:8994:2	O
the	PROLIA.xml:S1:8997:3	O
placebo	PROLIA.xml:S1:9001:7	O
group	PROLIA.xml:S1:9009:5	O
and	PROLIA.xml:S1:9015:3	O
all	PROLIA.xml:S1:9019:3	O
8	PROLIA.xml:S1:9023:1	O
patients	PROLIA.xml:S1:9025:8	O
in	PROLIA.xml:S1:9034:2	O
the	PROLIA.xml:S1:9037:3	O
Prolia	PROLIA.xml:S1:9041:6	O
group	PROLIA.xml:S1:9048:5	O
had	PROLIA.xml:S1:9054:3	O
serious	PROLIA.xml:S1:9058:7	O
events	PROLIA.xml:S1:9066:6	O
,	PROLIA.xml:S1:9072:1	O
including	PROLIA.xml:S1:9074:9	O
one	PROLIA.xml:S1:9084:3	O
death	PROLIA.xml:S1:9088:5	B-AdverseReaction
in	PROLIA.xml:S1:9094:2	O
the	PROLIA.xml:S1:9097:3	O
Prolia	PROLIA.xml:S1:9101:6	O
group	PROLIA.xml:S1:9108:5	O
.	PROLIA.xml:S1:9113:1	O

Several	PROLIA.xml:S1:9115:7	O
patients	PROLIA.xml:S1:9123:8	O
had	PROLIA.xml:S1:9132:3	O
a	PROLIA.xml:S1:9136:1	O
prior	PROLIA.xml:S1:9138:5	O
history	PROLIA.xml:S1:9144:7	O
of	PROLIA.xml:S1:9152:2	O
pancreatitis	PROLIA.xml:S1:9155:12	O
.	PROLIA.xml:S1:9167:1	O

The	PROLIA.xml:S1:9169:3	O
time	PROLIA.xml:S1:9173:4	O
from	PROLIA.xml:S1:9178:4	O
product	PROLIA.xml:S1:9183:7	O
administration	PROLIA.xml:S1:9191:14	O
to	PROLIA.xml:S1:9206:2	O
event	PROLIA.xml:S1:9209:5	O
occurrence	PROLIA.xml:S1:9215:10	O
was	PROLIA.xml:S1:9226:3	O
variable	PROLIA.xml:S1:9230:8	O
.	PROLIA.xml:S1:9238:1	O

New	PROLIA.xml:S1:9246:3	O
Malignancies	PROLIA.xml:S1:9250:12	O
The	PROLIA.xml:S1:9264:3	O
overall	PROLIA.xml:S1:9268:7	O
incidence	PROLIA.xml:S1:9276:9	O
of	PROLIA.xml:S1:9286:2	O
new	PROLIA.xml:S1:9289:3	O
malignancies	PROLIA.xml:S1:9293:12	B-AdverseReaction
was	PROLIA.xml:S1:9306:3	O
4.3%	PROLIA.xml:S1:9310:4	O
in	PROLIA.xml:S1:9315:2	O
the	PROLIA.xml:S1:9318:3	O
placebo	PROLIA.xml:S1:9322:7	O
and	PROLIA.xml:S1:9330:3	O
4.8%	PROLIA.xml:S1:9334:4	O
in	PROLIA.xml:S1:9339:2	O
the	PROLIA.xml:S1:9342:3	O
Prolia	PROLIA.xml:S1:9346:6	O
groups	PROLIA.xml:S1:9353:6	O
.	PROLIA.xml:S1:9359:1	O

New	PROLIA.xml:S1:9361:3	O
malignancies	PROLIA.xml:S1:9365:12	B-AdverseReaction
related	PROLIA.xml:S1:9378:7	O
to	PROLIA.xml:S1:9386:2	I-AdverseReaction
the	PROLIA.xml:S1:9389:3	I-AdverseReaction
breast	PROLIA.xml:S1:9393:6	I-AdverseReaction
(	PROLIA.xml:S1:9400:1	O
0.7%	PROLIA.xml:S1:9401:4	O
placebo	PROLIA.xml:S1:9406:7	O
vs	PROLIA.xml:S1:9414:2	O
.	PROLIA.xml:S1:9416:1	O

0.9%	PROLIA.xml:S1:9418:4	O
Prolia	PROLIA.xml:S1:9423:6	O
)	PROLIA.xml:S1:9429:1	O
,	PROLIA.xml:S1:9430:1	O
reproductive	PROLIA.xml:S1:9432:12	I-AdverseReaction
system	PROLIA.xml:S1:9445:6	I-AdverseReaction
(	PROLIA.xml:S1:9452:1	O
0.2%	PROLIA.xml:S1:9453:4	O
placebo	PROLIA.xml:S1:9458:7	O
vs	PROLIA.xml:S1:9466:2	O
.	PROLIA.xml:S1:9468:1	O

0.5%	PROLIA.xml:S1:9470:4	O
Prolia	PROLIA.xml:S1:9475:6	O
)	PROLIA.xml:S1:9481:1	O
,	PROLIA.xml:S1:9482:1	O
and	PROLIA.xml:S1:9484:3	O
gastrointestinal	PROLIA.xml:S1:9488:16	I-AdverseReaction
system	PROLIA.xml:S1:9505:6	I-AdverseReaction
(	PROLIA.xml:S1:9512:1	O
0.6%	PROLIA.xml:S1:9513:4	O
placebo	PROLIA.xml:S1:9518:7	O
vs	PROLIA.xml:S1:9526:2	O
.	PROLIA.xml:S1:9528:1	O

0.9%	PROLIA.xml:S1:9530:4	O
Prolia	PROLIA.xml:S1:9535:6	O
)	PROLIA.xml:S1:9541:1	O
were	PROLIA.xml:S1:9543:4	O
reported	PROLIA.xml:S1:9548:8	O
.	PROLIA.xml:S1:9556:1	O

A	PROLIA.xml:S1:9558:1	O
causal	PROLIA.xml:S1:9560:6	O
relationship	PROLIA.xml:S1:9567:12	O
to	PROLIA.xml:S1:9580:2	O
drug	PROLIA.xml:S1:9583:4	O
exposure	PROLIA.xml:S1:9588:8	O
has	PROLIA.xml:S1:9597:3	O
not	PROLIA.xml:S1:9601:3	O
been	PROLIA.xml:S1:9605:4	O
established	PROLIA.xml:S1:9610:11	O
.	PROLIA.xml:S1:9621:1	O

Treatment	PROLIA.xml:S1:9629:9	O
to	PROLIA.xml:S1:9639:2	O
Increase	PROLIA.xml:S1:9642:8	O
Bone	PROLIA.xml:S1:9651:4	O
Mass	PROLIA.xml:S1:9656:4	O
in	PROLIA.xml:S1:9661:2	O
Men	PROLIA.xml:S1:9667:3	O
with	PROLIA.xml:S1:9671:4	O
Osteoporosis	PROLIA.xml:S1:9676:12	O

The	PROLIA.xml:S1:9695:3	O
safety	PROLIA.xml:S1:9699:6	O
of	PROLIA.xml:S1:9706:2	O
Prolia	PROLIA.xml:S1:9709:6	O
in	PROLIA.xml:S1:9716:2	O
the	PROLIA.xml:S1:9719:3	O
treatment	PROLIA.xml:S1:9723:9	O
of	PROLIA.xml:S1:9733:2	O
men	PROLIA.xml:S1:9736:3	O
with	PROLIA.xml:S1:9740:4	O
osteoporosis	PROLIA.xml:S1:9745:12	O
was	PROLIA.xml:S1:9758:3	O
assessed	PROLIA.xml:S1:9762:8	O
in	PROLIA.xml:S1:9771:2	O
a	PROLIA.xml:S1:9774:1	O
1	PROLIA.xml:S1:9776:1	O
-	PROLIA.xml:S1:9777:1	O
year	PROLIA.xml:S1:9778:4	O
randomized	PROLIA.xml:S1:9783:10	O
,	PROLIA.xml:S1:9793:1	O
double	PROLIA.xml:S1:9795:6	O
-	PROLIA.xml:S1:9801:1	O
blind	PROLIA.xml:S1:9802:5	O
,	PROLIA.xml:S1:9807:1	O
placebo	PROLIA.xml:S1:9809:7	O
-	PROLIA.xml:S1:9816:1	O
controlled	PROLIA.xml:S1:9817:10	O
study	PROLIA.xml:S1:9828:5	O
.	PROLIA.xml:S1:9833:1	O

A	PROLIA.xml:S1:9835:1	O
total	PROLIA.xml:S1:9837:5	O
of	PROLIA.xml:S1:9843:2	O
120	PROLIA.xml:S1:9846:3	O
men	PROLIA.xml:S1:9850:3	O
were	PROLIA.xml:S1:9854:4	O
exposed	PROLIA.xml:S1:9859:7	O
to	PROLIA.xml:S1:9867:2	O
placebo	PROLIA.xml:S1:9870:7	O
and	PROLIA.xml:S1:9878:3	O
120	PROLIA.xml:S1:9882:3	O
men	PROLIA.xml:S1:9886:3	O
were	PROLIA.xml:S1:9890:4	O
exposed	PROLIA.xml:S1:9895:7	O
to	PROLIA.xml:S1:9903:2	O
Prolia	PROLIA.xml:S1:9906:6	O
administered	PROLIA.xml:S1:9913:12	O
subcutaneously	PROLIA.xml:S1:9926:14	O
once	PROLIA.xml:S1:9941:4	O
every	PROLIA.xml:S1:9946:5	O
6	PROLIA.xml:S1:9952:1	O
months	PROLIA.xml:S1:9954:6	O
as	PROLIA.xml:S1:9961:2	O
a	PROLIA.xml:S1:9964:1	O
single	PROLIA.xml:S1:9966:6	O
60	PROLIA.xml:S1:9973:2	O
mg	PROLIA.xml:S1:9976:2	O
dose	PROLIA.xml:S1:9979:4	O
.	PROLIA.xml:S1:9983:1	O

All	PROLIA.xml:S1:9985:3	O
men	PROLIA.xml:S1:9989:3	O
were	PROLIA.xml:S1:9993:4	O
instructed	PROLIA.xml:S1:9998:10	O
to	PROLIA.xml:S1:10009:2	O
take	PROLIA.xml:S1:10012:4	O
at	PROLIA.xml:S1:10017:2	O
least	PROLIA.xml:S1:10020:5	O
1000	PROLIA.xml:S1:10026:4	O
mg	PROLIA.xml:S1:10031:2	O
of	PROLIA.xml:S1:10034:2	O
calcium	PROLIA.xml:S1:10037:7	O
and	PROLIA.xml:S1:10045:3	O
800	PROLIA.xml:S1:10049:3	O
IU	PROLIA.xml:S1:10053:2	O
of	PROLIA.xml:S1:10056:2	O
vitamin	PROLIA.xml:S1:10059:7	O
D	PROLIA.xml:S1:10067:1	O
supplementation	PROLIA.xml:S1:10069:15	O
per	PROLIA.xml:S1:10085:3	O
day	PROLIA.xml:S1:10089:3	O
.	PROLIA.xml:S1:10092:1	O

The	PROLIA.xml:S1:10098:3	O
incidence	PROLIA.xml:S1:10102:9	O
of	PROLIA.xml:S1:10112:2	O
all	PROLIA.xml:S1:10115:3	O
-	PROLIA.xml:S1:10118:1	O
cause	PROLIA.xml:S1:10119:5	O
mortality	PROLIA.xml:S1:10125:9	B-AdverseReaction
was	PROLIA.xml:S1:10135:3	O
0.8%	PROLIA.xml:S1:10139:4	O
(	PROLIA.xml:S1:10144:1	O
n	PROLIA.xml:S1:10145:1	O
1	PROLIA.xml:S1:10149:1	O
)	PROLIA.xml:S1:10150:1	O
in	PROLIA.xml:S1:10152:2	O
the	PROLIA.xml:S1:10155:3	O
placebo	PROLIA.xml:S1:10159:7	O
group	PROLIA.xml:S1:10167:5	O
and	PROLIA.xml:S1:10173:3	O
0.8%	PROLIA.xml:S1:10177:4	O
(	PROLIA.xml:S1:10182:1	O
n	PROLIA.xml:S1:10183:1	O
1	PROLIA.xml:S1:10187:1	O
)	PROLIA.xml:S1:10188:1	O
in	PROLIA.xml:S1:10190:2	O
the	PROLIA.xml:S1:10193:3	O
Prolia	PROLIA.xml:S1:10197:6	O
group	PROLIA.xml:S1:10204:5	O
.	PROLIA.xml:S1:10209:1	O

The	PROLIA.xml:S1:10211:3	O
incidence	PROLIA.xml:S1:10215:9	O
of	PROLIA.xml:S1:10225:2	O
nonfatal	PROLIA.xml:S1:10228:8	O
serious	PROLIA.xml:S1:10237:7	O
adverse	PROLIA.xml:S1:10245:7	O
events	PROLIA.xml:S1:10253:6	O
was	PROLIA.xml:S1:10260:3	O
7.5%	PROLIA.xml:S1:10264:4	O
in	PROLIA.xml:S1:10269:2	O
the	PROLIA.xml:S1:10272:3	O
placebo	PROLIA.xml:S1:10276:7	O
group	PROLIA.xml:S1:10284:5	O
and	PROLIA.xml:S1:10290:3	O
8.3%	PROLIA.xml:S1:10294:4	O
in	PROLIA.xml:S1:10299:2	O
the	PROLIA.xml:S1:10302:3	O
Prolia	PROLIA.xml:S1:10306:6	O
group	PROLIA.xml:S1:10313:5	O
.	PROLIA.xml:S1:10318:1	O

The	PROLIA.xml:S1:10320:3	O
percentage	PROLIA.xml:S1:10324:10	O
of	PROLIA.xml:S1:10335:2	O
patients	PROLIA.xml:S1:10338:8	O
who	PROLIA.xml:S1:10347:3	O
withdrew	PROLIA.xml:S1:10351:8	O
from	PROLIA.xml:S1:10360:4	O
the	PROLIA.xml:S1:10365:3	O
study	PROLIA.xml:S1:10369:5	O
due	PROLIA.xml:S1:10375:3	O
to	PROLIA.xml:S1:10379:2	O
adverse	PROLIA.xml:S1:10382:7	O
events	PROLIA.xml:S1:10390:6	O
was	PROLIA.xml:S1:10397:3	O
0%	PROLIA.xml:S1:10401:2	O
and	PROLIA.xml:S1:10404:3	O
2.5%	PROLIA.xml:S1:10408:4	O
for	PROLIA.xml:S1:10413:3	O
the	PROLIA.xml:S1:10417:3	O
placebo	PROLIA.xml:S1:10421:7	O
and	PROLIA.xml:S1:10429:3	O
Prolia	PROLIA.xml:S1:10433:6	O
groups	PROLIA.xml:S1:10440:6	O
,	PROLIA.xml:S1:10446:1	O
respectively	PROLIA.xml:S1:10448:12	O
.	PROLIA.xml:S1:10460:1	O

Adverse	PROLIA.xml:S1:10466:7	O
reactions	PROLIA.xml:S1:10474:9	O
reported	PROLIA.xml:S1:10484:8	O
in	PROLIA.xml:S1:10493:2	O
5%	PROLIA.xml:S1:10499:2	O
of	PROLIA.xml:S1:10502:2	O
men	PROLIA.xml:S1:10505:3	O
with	PROLIA.xml:S1:10509:4	O
osteoporosis	PROLIA.xml:S1:10514:12	O
and	PROLIA.xml:S1:10527:3	O
more	PROLIA.xml:S1:10531:4	O
frequently	PROLIA.xml:S1:10536:10	O
with	PROLIA.xml:S1:10547:4	O
Prolia	PROLIA.xml:S1:10552:6	O
than	PROLIA.xml:S1:10559:4	O
in	PROLIA.xml:S1:10564:2	O
the	PROLIA.xml:S1:10567:3	O
placebo	PROLIA.xml:S1:10571:7	O
-	PROLIA.xml:S1:10578:1	O
treated	PROLIA.xml:S1:10579:7	O
patients	PROLIA.xml:S1:10587:8	O
were	PROLIA.xml:S1:10596:4	O
:	PROLIA.xml:S1:10600:1	O
back	PROLIA.xml:S1:10602:4	B-AdverseReaction
pain	PROLIA.xml:S1:10607:4	I-AdverseReaction
(	PROLIA.xml:S1:10612:1	O
6.7%	PROLIA.xml:S1:10613:4	O
placebo	PROLIA.xml:S1:10618:7	O
vs	PROLIA.xml:S1:10626:2	O
.	PROLIA.xml:S1:10628:1	O

8.3%	PROLIA.xml:S1:10630:4	O
Prolia	PROLIA.xml:S1:10635:6	O
)	PROLIA.xml:S1:10641:1	O
,	PROLIA.xml:S1:10642:1	O
arthralgia	PROLIA.xml:S1:10644:10	B-AdverseReaction
(	PROLIA.xml:S1:10655:1	O
5.8%	PROLIA.xml:S1:10656:4	O
placebo	PROLIA.xml:S1:10661:7	O
vs	PROLIA.xml:S1:10669:2	O
.	PROLIA.xml:S1:10671:1	O

6.7%	PROLIA.xml:S1:10673:4	O
Prolia	PROLIA.xml:S1:10678:6	O
)	PROLIA.xml:S1:10684:1	O
,	PROLIA.xml:S1:10685:1	O
and	PROLIA.xml:S1:10687:3	O
nasopharyngitis	PROLIA.xml:S1:10691:15	B-AdverseReaction
(	PROLIA.xml:S1:10707:1	O
5.8%	PROLIA.xml:S1:10708:4	O
placebo	PROLIA.xml:S1:10713:7	O
vs	PROLIA.xml:S1:10721:2	O
.	PROLIA.xml:S1:10723:1	O

6.7%	PROLIA.xml:S1:10725:4	O
Prolia	PROLIA.xml:S1:10730:6	O
)	PROLIA.xml:S1:10736:1	O
.	PROLIA.xml:S1:10737:1	O

Serious	PROLIA.xml:S1:10745:7	O
Infections	PROLIA.xml:S1:10753:10	O
S	PROLIA.xml:S1:10767:1	B-Severity
erious	PROLIA.xml:S1:10770:6	I-Severity
infection	PROLIA.xml:S1:10777:9	B-AdverseReaction
was	PROLIA.xml:S1:10787:3	O
reported	PROLIA.xml:S1:10791:8	O
in	PROLIA.xml:S1:10800:2	O
1	PROLIA.xml:S1:10803:1	O
patient	PROLIA.xml:S1:10805:7	O
(	PROLIA.xml:S1:10813:1	O
0.8%	PROLIA.xml:S1:10814:4	O
)	PROLIA.xml:S1:10818:1	O
in	PROLIA.xml:S1:10820:2	O
the	PROLIA.xml:S1:10823:3	O
placebo	PROLIA.xml:S1:10827:7	O
group	PROLIA.xml:S1:10835:5	O
and	PROLIA.xml:S1:10841:3	O
no	PROLIA.xml:S1:10845:2	B-Negation
patients	PROLIA.xml:S1:10848:8	O
in	PROLIA.xml:S1:10857:2	O
the	PROLIA.xml:S1:10860:3	O
Prolia	PROLIA.xml:S1:10864:6	O
group	PROLIA.xml:S1:10871:5	O
.	PROLIA.xml:S1:10876:1	O

Dermatologic	PROLIA.xml:S1:10884:12	O
Reactions	PROLIA.xml:S1:10897:9	O
Epidermal	PROLIA.xml:S1:10908:9	B-AdverseReaction
and	PROLIA.xml:S1:10918:3	O
dermal	PROLIA.xml:S1:10922:6	B-AdverseReaction
adverse	PROLIA.xml:S1:10929:7	I-AdverseReaction
events	PROLIA.xml:S1:10937:6	I-AdverseReaction
(	PROLIA.xml:S1:10944:1	O
such	PROLIA.xml:S1:10945:4	O
as	PROLIA.xml:S1:10950:2	O
dermatitis	PROLIA.xml:S1:10953:10	B-AdverseReaction
,	PROLIA.xml:S1:10963:1	O
eczema	PROLIA.xml:S1:10965:6	B-AdverseReaction
,	PROLIA.xml:S1:10971:1	O
and	PROLIA.xml:S1:10973:3	O
rashes	PROLIA.xml:S1:10977:6	B-AdverseReaction
)	PROLIA.xml:S1:10983:1	O
were	PROLIA.xml:S1:10985:4	O
reported	PROLIA.xml:S1:10990:8	O
in	PROLIA.xml:S1:10999:2	O
4	PROLIA.xml:S1:11002:1	O
patients	PROLIA.xml:S1:11004:8	O
(	PROLIA.xml:S1:11013:1	O
3.3%	PROLIA.xml:S1:11014:4	O
)	PROLIA.xml:S1:11018:1	O
in	PROLIA.xml:S1:11020:2	O
the	PROLIA.xml:S1:11023:3	O
placebo	PROLIA.xml:S1:11027:7	O
group	PROLIA.xml:S1:11035:5	O
and	PROLIA.xml:S1:11041:3	O
5	PROLIA.xml:S1:11045:1	O
patients	PROLIA.xml:S1:11047:8	O
(	PROLIA.xml:S1:11056:1	O
4.2%	PROLIA.xml:S1:11057:4	O
)	PROLIA.xml:S1:11061:1	O
in	PROLIA.xml:S1:11063:2	O
the	PROLIA.xml:S1:11066:3	O
Prolia	PROLIA.xml:S1:11070:6	O
group	PROLIA.xml:S1:11077:5	O
.	PROLIA.xml:S1:11082:1	O

Osteonecrosis	PROLIA.xml:S1:11090:13	O
of	PROLIA.xml:S1:11104:2	O
the	PROLIA.xml:S1:11107:3	O
Jaw	PROLIA.xml:S1:11111:3	O
No	PROLIA.xml:S1:11116:2	B-Negation
cases	PROLIA.xml:S1:11119:5	O
of	PROLIA.xml:S1:11125:2	O
ONJ	PROLIA.xml:S1:11128:3	B-AdverseReaction
were	PROLIA.xml:S1:11132:4	O
reported	PROLIA.xml:S1:11137:8	O
.	PROLIA.xml:S1:11145:1	O

Pancreatitis	PROLIA.xml:S1:11153:12	O
Pancreatitis	PROLIA.xml:S1:11167:12	B-AdverseReaction
was	PROLIA.xml:S1:11180:3	O
reported	PROLIA.xml:S1:11184:8	O
in	PROLIA.xml:S1:11193:2	O
1	PROLIA.xml:S1:11196:1	O
patient	PROLIA.xml:S1:11198:7	O
(	PROLIA.xml:S1:11206:1	O
0.8%	PROLIA.xml:S1:11207:4	O
)	PROLIA.xml:S1:11211:1	O
in	PROLIA.xml:S1:11213:2	O
the	PROLIA.xml:S1:11216:3	O
placebo	PROLIA.xml:S1:11220:7	O
group	PROLIA.xml:S1:11228:5	O
and	PROLIA.xml:S1:11234:3	O
1	PROLIA.xml:S1:11238:1	O
patient	PROLIA.xml:S1:11240:7	O
(	PROLIA.xml:S1:11248:1	O
0.8%	PROLIA.xml:S1:11249:4	O
)	PROLIA.xml:S1:11253:1	O
in	PROLIA.xml:S1:11255:2	O
the	PROLIA.xml:S1:11258:3	O
Prolia	PROLIA.xml:S1:11262:6	O
group	PROLIA.xml:S1:11269:5	O
.	PROLIA.xml:S1:11274:1	O

New	PROLIA.xml:S1:11283:3	O
Malignancies	PROLIA.xml:S1:11287:12	O
New	PROLIA.xml:S1:11301:3	O
malignancies	PROLIA.xml:S1:11305:12	B-AdverseReaction
were	PROLIA.xml:S1:11318:4	O
reported	PROLIA.xml:S1:11323:8	O
in	PROLIA.xml:S1:11332:2	O
no	PROLIA.xml:S1:11335:2	O
patients	PROLIA.xml:S1:11338:8	O
in	PROLIA.xml:S1:11347:2	O
the	PROLIA.xml:S1:11350:3	O
placebo	PROLIA.xml:S1:11354:7	O
group	PROLIA.xml:S1:11362:5	O
and	PROLIA.xml:S1:11368:3	O
4	PROLIA.xml:S1:11372:1	O
(	PROLIA.xml:S1:11374:1	O
3.3%	PROLIA.xml:S1:11375:4	O
)	PROLIA.xml:S1:11379:1	O
patients	PROLIA.xml:S1:11381:8	O
(	PROLIA.xml:S1:11390:1	O
3	PROLIA.xml:S1:11391:1	O
prostate	PROLIA.xml:S1:11393:8	B-AdverseReaction
cancers	PROLIA.xml:S1:11402:7	I-AdverseReaction
,	PROLIA.xml:S1:11409:1	O
1	PROLIA.xml:S1:11411:1	O
basal	PROLIA.xml:S1:11413:5	B-AdverseReaction
cell	PROLIA.xml:S1:11419:4	I-AdverseReaction
carcinoma	PROLIA.xml:S1:11424:9	I-AdverseReaction
)	PROLIA.xml:S1:11433:1	O
in	PROLIA.xml:S1:11435:2	O
the	PROLIA.xml:S1:11438:3	O
Prolia	PROLIA.xml:S1:11442:6	O
group	PROLIA.xml:S1:11449:5	O
.	PROLIA.xml:S1:11454:1	O

Treatment	PROLIA.xml:S1:11462:9	O
of	PROLIA.xml:S1:11472:2	O
Bone	PROLIA.xml:S1:11475:4	O
Loss	PROLIA.xml:S1:11480:4	O
in	PROLIA.xml:S1:11485:2	O
Patients	PROLIA.xml:S1:11488:8	O
Receiving	PROLIA.xml:S1:11497:9	O
Androgen	PROLIA.xml:S1:11507:8	O
Deprivation	PROLIA.xml:S1:11516:11	O
Therapy	PROLIA.xml:S1:11528:7	O
for	PROLIA.xml:S1:11536:3	O
Prostate	PROLIA.xml:S1:11540:8	O
Cancer	PROLIA.xml:S1:11549:6	O
or	PROLIA.xml:S1:11556:2	O
Adjuvant	PROLIA.xml:S1:11559:8	O
Aromatase	PROLIA.xml:S1:11568:9	O
Inhibitor	PROLIA.xml:S1:11578:9	O
Therapy	PROLIA.xml:S1:11588:7	O
for	PROLIA.xml:S1:11596:3	O
Breast	PROLIA.xml:S1:11600:6	O
Cancer	PROLIA.xml:S1:11607:6	O

The	PROLIA.xml:S1:11620:3	O
safety	PROLIA.xml:S1:11624:6	O
of	PROLIA.xml:S1:11631:2	O
Prolia	PROLIA.xml:S1:11634:6	O
in	PROLIA.xml:S1:11641:2	O
the	PROLIA.xml:S1:11644:3	O
treatment	PROLIA.xml:S1:11648:9	O
of	PROLIA.xml:S1:11658:2	O
bone	PROLIA.xml:S1:11661:4	O
loss	PROLIA.xml:S1:11666:4	O
in	PROLIA.xml:S1:11671:2	O
men	PROLIA.xml:S1:11674:3	O
with	PROLIA.xml:S1:11678:4	O
nonmetastatic	PROLIA.xml:S1:11683:13	O
prostate	PROLIA.xml:S1:11697:8	O
cancer	PROLIA.xml:S1:11706:6	O
receiving	PROLIA.xml:S1:11713:9	O
androgen	PROLIA.xml:S1:11723:8	O
deprivation	PROLIA.xml:S1:11732:11	O
therapy	PROLIA.xml:S1:11744:7	O
(	PROLIA.xml:S1:11752:1	O
ADT	PROLIA.xml:S1:11753:3	O
)	PROLIA.xml:S1:11756:1	O
was	PROLIA.xml:S1:11758:3	O
assessed	PROLIA.xml:S1:11762:8	O
in	PROLIA.xml:S1:11771:2	O
a	PROLIA.xml:S1:11774:1	O
3	PROLIA.xml:S1:11776:1	O
-	PROLIA.xml:S1:11777:1	O
year	PROLIA.xml:S1:11778:4	O
,	PROLIA.xml:S1:11782:1	O
randomized	PROLIA.xml:S1:11784:10	O
,	PROLIA.xml:S1:11794:1	O
double	PROLIA.xml:S1:11796:6	O
-	PROLIA.xml:S1:11802:1	O
blind	PROLIA.xml:S1:11803:5	O
,	PROLIA.xml:S1:11808:1	O
placebo	PROLIA.xml:S1:11810:7	O
-	PROLIA.xml:S1:11817:1	O
controlled	PROLIA.xml:S1:11818:10	O
,	PROLIA.xml:S1:11828:1	O
multinational	PROLIA.xml:S1:11830:13	O
study	PROLIA.xml:S1:11844:5	O
of	PROLIA.xml:S1:11850:2	O
1468	PROLIA.xml:S1:11853:4	O
men	PROLIA.xml:S1:11858:3	O
aged	PROLIA.xml:S1:11862:4	O
48	PROLIA.xml:S1:11867:2	O
to	PROLIA.xml:S1:11870:2	O
97	PROLIA.xml:S1:11873:2	O
years	PROLIA.xml:S1:11876:5	O
.	PROLIA.xml:S1:11881:1	O

A	PROLIA.xml:S1:11883:1	O
total	PROLIA.xml:S1:11885:5	O
of	PROLIA.xml:S1:11891:2	O
725	PROLIA.xml:S1:11894:3	O
men	PROLIA.xml:S1:11898:3	O
were	PROLIA.xml:S1:11902:4	O
exposed	PROLIA.xml:S1:11907:7	O
to	PROLIA.xml:S1:11915:2	O
placebo	PROLIA.xml:S1:11918:7	O
and	PROLIA.xml:S1:11926:3	O
731	PROLIA.xml:S1:11930:3	O
men	PROLIA.xml:S1:11934:3	O
were	PROLIA.xml:S1:11938:4	O
exposed	PROLIA.xml:S1:11943:7	O
to	PROLIA.xml:S1:11951:2	O
Prolia	PROLIA.xml:S1:11954:6	O
administered	PROLIA.xml:S1:11961:12	O
once	PROLIA.xml:S1:11974:4	O
every	PROLIA.xml:S1:11979:5	O
6	PROLIA.xml:S1:11985:1	O
months	PROLIA.xml:S1:11987:6	O
as	PROLIA.xml:S1:11994:2	O
a	PROLIA.xml:S1:11997:1	O
single	PROLIA.xml:S1:11999:6	O
60	PROLIA.xml:S1:12006:2	O
mg	PROLIA.xml:S1:12009:2	O
subcutaneous	PROLIA.xml:S1:12012:12	O
dose	PROLIA.xml:S1:12025:4	O
.	PROLIA.xml:S1:12029:1	O

All	PROLIA.xml:S1:12031:3	O
men	PROLIA.xml:S1:12035:3	O
were	PROLIA.xml:S1:12039:4	O
instructed	PROLIA.xml:S1:12044:10	O
to	PROLIA.xml:S1:12055:2	O
take	PROLIA.xml:S1:12058:4	O
at	PROLIA.xml:S1:12063:2	O
least	PROLIA.xml:S1:12066:5	O
1000	PROLIA.xml:S1:12072:4	O
mg	PROLIA.xml:S1:12077:2	O
of	PROLIA.xml:S1:12080:2	O
calcium	PROLIA.xml:S1:12083:7	O
and	PROLIA.xml:S1:12091:3	O
400	PROLIA.xml:S1:12095:3	O
IU	PROLIA.xml:S1:12099:2	O
of	PROLIA.xml:S1:12102:2	O
vitamin	PROLIA.xml:S1:12105:7	O
D	PROLIA.xml:S1:12113:1	O
supplementation	PROLIA.xml:S1:12115:15	O
per	PROLIA.xml:S1:12131:3	O
day	PROLIA.xml:S1:12135:3	O
.	PROLIA.xml:S1:12138:1	O

The	PROLIA.xml:S1:12144:3	O
incidence	PROLIA.xml:S1:12148:9	O
of	PROLIA.xml:S1:12158:2	O
serious	PROLIA.xml:S1:12161:7	O
adverse	PROLIA.xml:S1:12169:7	O
events	PROLIA.xml:S1:12177:6	O
was	PROLIA.xml:S1:12184:3	O
30.6%	PROLIA.xml:S1:12188:5	O
in	PROLIA.xml:S1:12194:2	O
the	PROLIA.xml:S1:12197:3	O
placebo	PROLIA.xml:S1:12201:7	O
group	PROLIA.xml:S1:12209:5	O
and	PROLIA.xml:S1:12215:3	O
34.6%	PROLIA.xml:S1:12219:5	O
in	PROLIA.xml:S1:12225:2	O
the	PROLIA.xml:S1:12228:3	O
Prolia	PROLIA.xml:S1:12232:6	O
group	PROLIA.xml:S1:12239:5	O
.	PROLIA.xml:S1:12244:1	O

The	PROLIA.xml:S1:12246:3	O
percentage	PROLIA.xml:S1:12250:10	O
of	PROLIA.xml:S1:12261:2	O
patients	PROLIA.xml:S1:12264:8	O
who	PROLIA.xml:S1:12273:3	O
withdrew	PROLIA.xml:S1:12277:8	O
from	PROLIA.xml:S1:12286:4	O
the	PROLIA.xml:S1:12291:3	O
study	PROLIA.xml:S1:12295:5	O
due	PROLIA.xml:S1:12301:3	O
to	PROLIA.xml:S1:12305:2	O
adverse	PROLIA.xml:S1:12308:7	O
events	PROLIA.xml:S1:12316:6	O
was	PROLIA.xml:S1:12323:3	O
6.1%	PROLIA.xml:S1:12327:4	O
and	PROLIA.xml:S1:12332:3	O
7.0%	PROLIA.xml:S1:12336:4	O
for	PROLIA.xml:S1:12341:3	O
the	PROLIA.xml:S1:12345:3	O
placebo	PROLIA.xml:S1:12349:7	O
and	PROLIA.xml:S1:12357:3	O
Prolia	PROLIA.xml:S1:12361:6	O
groups	PROLIA.xml:S1:12368:6	O
,	PROLIA.xml:S1:12374:1	O
respectively	PROLIA.xml:S1:12376:12	O
.	PROLIA.xml:S1:12388:1	O

The	PROLIA.xml:S1:12394:3	O
safety	PROLIA.xml:S1:12398:6	O
of	PROLIA.xml:S1:12405:2	O
Prolia	PROLIA.xml:S1:12408:6	O
in	PROLIA.xml:S1:12415:2	O
the	PROLIA.xml:S1:12418:3	O
treatment	PROLIA.xml:S1:12422:9	O
of	PROLIA.xml:S1:12432:2	O
bone	PROLIA.xml:S1:12435:4	O
loss	PROLIA.xml:S1:12440:4	O
in	PROLIA.xml:S1:12445:2	O
women	PROLIA.xml:S1:12448:5	O
with	PROLIA.xml:S1:12454:4	O
nonmetastatic	PROLIA.xml:S1:12459:13	O
breast	PROLIA.xml:S1:12473:6	O
cancer	PROLIA.xml:S1:12480:6	O
receiving	PROLIA.xml:S1:12487:9	O
aromatase	PROLIA.xml:S1:12497:9	O
inhibitor	PROLIA.xml:S1:12507:9	O
(	PROLIA.xml:S1:12517:1	O
AI	PROLIA.xml:S1:12518:2	O
)	PROLIA.xml:S1:12520:1	O
therapy	PROLIA.xml:S1:12523:7	O
was	PROLIA.xml:S1:12531:3	O
assessed	PROLIA.xml:S1:12535:8	O
in	PROLIA.xml:S1:12544:2	O
a	PROLIA.xml:S1:12547:1	O
2	PROLIA.xml:S1:12549:1	O
-	PROLIA.xml:S1:12550:1	O
year	PROLIA.xml:S1:12551:4	O
,	PROLIA.xml:S1:12555:1	O
randomized	PROLIA.xml:S1:12557:10	O
,	PROLIA.xml:S1:12567:1	O
double	PROLIA.xml:S1:12569:6	O
-	PROLIA.xml:S1:12575:1	O
blind	PROLIA.xml:S1:12576:5	O
,	PROLIA.xml:S1:12581:1	O
placebo	PROLIA.xml:S1:12583:7	O
-	PROLIA.xml:S1:12590:1	O
controlled	PROLIA.xml:S1:12591:10	O
,	PROLIA.xml:S1:12601:1	O
multinational	PROLIA.xml:S1:12603:13	O
study	PROLIA.xml:S1:12617:5	O
of	PROLIA.xml:S1:12623:2	O
252	PROLIA.xml:S1:12626:3	O
postmenopausal	PROLIA.xml:S1:12630:14	O
women	PROLIA.xml:S1:12645:5	O
aged	PROLIA.xml:S1:12651:4	O
35	PROLIA.xml:S1:12656:2	O
to	PROLIA.xml:S1:12659:2	O
84	PROLIA.xml:S1:12662:2	O
years	PROLIA.xml:S1:12665:5	O
.	PROLIA.xml:S1:12670:1	O

A	PROLIA.xml:S1:12672:1	O
total	PROLIA.xml:S1:12674:5	O
of	PROLIA.xml:S1:12680:2	O
120	PROLIA.xml:S1:12683:3	O
women	PROLIA.xml:S1:12687:5	O
were	PROLIA.xml:S1:12693:4	O
exposed	PROLIA.xml:S1:12698:7	O
to	PROLIA.xml:S1:12706:2	O
placebo	PROLIA.xml:S1:12709:7	O
and	PROLIA.xml:S1:12717:3	O
129	PROLIA.xml:S1:12721:3	O
women	PROLIA.xml:S1:12725:5	O
were	PROLIA.xml:S1:12731:4	O
exposed	PROLIA.xml:S1:12736:7	O
to	PROLIA.xml:S1:12744:2	O
Prolia	PROLIA.xml:S1:12747:6	O
administered	PROLIA.xml:S1:12754:12	O
once	PROLIA.xml:S1:12767:4	O
every	PROLIA.xml:S1:12772:5	O
6	PROLIA.xml:S1:12778:1	O
months	PROLIA.xml:S1:12780:6	O
as	PROLIA.xml:S1:12787:2	O
a	PROLIA.xml:S1:12790:1	O
single	PROLIA.xml:S1:12792:6	O
60	PROLIA.xml:S1:12799:2	O
mg	PROLIA.xml:S1:12802:2	O
subcutaneous	PROLIA.xml:S1:12805:12	O
dose	PROLIA.xml:S1:12818:4	O
.	PROLIA.xml:S1:12822:1	O

All	PROLIA.xml:S1:12824:3	O
women	PROLIA.xml:S1:12828:5	O
were	PROLIA.xml:S1:12834:4	O
instructed	PROLIA.xml:S1:12839:10	O
to	PROLIA.xml:S1:12850:2	O
take	PROLIA.xml:S1:12853:4	O
at	PROLIA.xml:S1:12858:2	O
least	PROLIA.xml:S1:12861:5	O
1000	PROLIA.xml:S1:12867:4	O
mg	PROLIA.xml:S1:12872:2	O
of	PROLIA.xml:S1:12875:2	O
calcium	PROLIA.xml:S1:12878:7	O
and	PROLIA.xml:S1:12886:3	O
400	PROLIA.xml:S1:12890:3	O
IU	PROLIA.xml:S1:12894:2	O
of	PROLIA.xml:S1:12897:2	O
vitamin	PROLIA.xml:S1:12900:7	O
D	PROLIA.xml:S1:12908:1	O
supplementation	PROLIA.xml:S1:12910:15	O
per	PROLIA.xml:S1:12926:3	O
day	PROLIA.xml:S1:12930:3	O
.	PROLIA.xml:S1:12933:1	O

The	PROLIA.xml:S1:12939:3	O
incidence	PROLIA.xml:S1:12943:9	O
of	PROLIA.xml:S1:12953:2	O
serious	PROLIA.xml:S1:12956:7	O
adverse	PROLIA.xml:S1:12964:7	O
events	PROLIA.xml:S1:12972:6	O
was	PROLIA.xml:S1:12979:3	O
9.2%	PROLIA.xml:S1:12983:4	O
in	PROLIA.xml:S1:12988:2	O
the	PROLIA.xml:S1:12991:3	O
placebo	PROLIA.xml:S1:12995:7	O
group	PROLIA.xml:S1:13003:5	O
and	PROLIA.xml:S1:13009:3	O
14.7%	PROLIA.xml:S1:13013:5	O
in	PROLIA.xml:S1:13019:2	O
the	PROLIA.xml:S1:13022:3	O
Prolia	PROLIA.xml:S1:13026:6	O
group	PROLIA.xml:S1:13033:5	O
.	PROLIA.xml:S1:13038:1	O

The	PROLIA.xml:S1:13040:3	O
percentage	PROLIA.xml:S1:13044:10	O
of	PROLIA.xml:S1:13055:2	O
patients	PROLIA.xml:S1:13058:8	O
who	PROLIA.xml:S1:13067:3	O
withdrew	PROLIA.xml:S1:13071:8	O
from	PROLIA.xml:S1:13080:4	O
the	PROLIA.xml:S1:13085:3	O
study	PROLIA.xml:S1:13089:5	O
due	PROLIA.xml:S1:13095:3	O
to	PROLIA.xml:S1:13099:2	O
adverse	PROLIA.xml:S1:13102:7	O
events	PROLIA.xml:S1:13110:6	O
was	PROLIA.xml:S1:13117:3	O
4.2%	PROLIA.xml:S1:13121:4	O
and	PROLIA.xml:S1:13126:3	O
0.8%	PROLIA.xml:S1:13130:4	O
for	PROLIA.xml:S1:13135:3	O
the	PROLIA.xml:S1:13139:3	O
placebo	PROLIA.xml:S1:13143:7	O
and	PROLIA.xml:S1:13151:3	O
Prolia	PROLIA.xml:S1:13155:6	O
groups	PROLIA.xml:S1:13162:6	O
,	PROLIA.xml:S1:13168:1	O
respectively	PROLIA.xml:S1:13170:12	O
.	PROLIA.xml:S1:13182:1	O

Adverse	PROLIA.xml:S1:13188:7	O
reactions	PROLIA.xml:S1:13196:9	O
reported	PROLIA.xml:S1:13206:8	O
in	PROLIA.xml:S1:13215:2	O
10%	PROLIA.xml:S1:13221:3	O
of	PROLIA.xml:S1:13225:2	O
Prolia	PROLIA.xml:S1:13228:6	O
-	PROLIA.xml:S1:13234:1	O
treated	PROLIA.xml:S1:13235:7	O
patients	PROLIA.xml:S1:13243:8	O
receiving	PROLIA.xml:S1:13252:9	O
ADT	PROLIA.xml:S1:13262:3	O
for	PROLIA.xml:S1:13266:3	O
prostate	PROLIA.xml:S1:13270:8	O
cancer	PROLIA.xml:S1:13279:6	O
or	PROLIA.xml:S1:13286:2	O
adjuvant	PROLIA.xml:S1:13289:8	O
AI	PROLIA.xml:S1:13298:2	O
therapy	PROLIA.xml:S1:13301:7	O
for	PROLIA.xml:S1:13309:3	O
breast	PROLIA.xml:S1:13313:6	O
cancer	PROLIA.xml:S1:13320:6	O
,	PROLIA.xml:S1:13326:1	O
and	PROLIA.xml:S1:13328:3	O
more	PROLIA.xml:S1:13332:4	O
frequently	PROLIA.xml:S1:13337:10	O
than	PROLIA.xml:S1:13348:4	O
in	PROLIA.xml:S1:13353:2	O
the	PROLIA.xml:S1:13356:3	O
placebo	PROLIA.xml:S1:13360:7	O
-	PROLIA.xml:S1:13367:1	O
treated	PROLIA.xml:S1:13368:7	O
patients	PROLIA.xml:S1:13376:8	O
were	PROLIA.xml:S1:13385:4	O
:	PROLIA.xml:S1:13389:1	O
arthralgia	PROLIA.xml:S1:13391:10	B-AdverseReaction
(	PROLIA.xml:S1:13402:1	O
13.0%	PROLIA.xml:S1:13403:5	O
placebo	PROLIA.xml:S1:13409:7	O
vs	PROLIA.xml:S1:13417:2	O
.	PROLIA.xml:S1:13419:1	O

14.3%	PROLIA.xml:S1:13421:5	O
Prolia	PROLIA.xml:S1:13427:6	O
)	PROLIA.xml:S1:13433:1	O
and	PROLIA.xml:S1:13435:3	O
back	PROLIA.xml:S1:13439:4	B-AdverseReaction
pain	PROLIA.xml:S1:13444:4	I-AdverseReaction
(	PROLIA.xml:S1:13449:1	O
10.5%	PROLIA.xml:S1:13450:5	O
placebo	PROLIA.xml:S1:13456:7	O
vs	PROLIA.xml:S1:13464:2	O
.	PROLIA.xml:S1:13466:1	O

11.5%	PROLIA.xml:S1:13468:5	O
Prolia	PROLIA.xml:S1:13474:6	O
)	PROLIA.xml:S1:13480:1	O
.	PROLIA.xml:S1:13481:1	O

Pain	PROLIA.xml:S1:13483:4	B-AdverseReaction
in	PROLIA.xml:S1:13488:2	I-AdverseReaction
extremity	PROLIA.xml:S1:13491:9	I-AdverseReaction
(	PROLIA.xml:S1:13501:1	O
7.7%	PROLIA.xml:S1:13502:4	O
placebo	PROLIA.xml:S1:13507:7	O
vs	PROLIA.xml:S1:13515:2	O
.	PROLIA.xml:S1:13517:1	O

9.9%	PROLIA.xml:S1:13519:4	O
Prolia	PROLIA.xml:S1:13524:6	O
)	PROLIA.xml:S1:13530:1	O
and	PROLIA.xml:S1:13532:3	O
musculoskeletal	PROLIA.xml:S1:13536:15	B-AdverseReaction
pain	PROLIA.xml:S1:13552:4	I-AdverseReaction
(	PROLIA.xml:S1:13557:1	O
3.8%	PROLIA.xml:S1:13558:4	O
placebo	PROLIA.xml:S1:13563:7	O
vs	PROLIA.xml:S1:13571:2	O
.	PROLIA.xml:S1:13573:1	O

6.0%	PROLIA.xml:S1:13575:4	O
Prolia	PROLIA.xml:S1:13580:6	O
)	PROLIA.xml:S1:13586:1	O
have	PROLIA.xml:S1:13588:4	O
also	PROLIA.xml:S1:13593:4	O
been	PROLIA.xml:S1:13598:4	O
reported	PROLIA.xml:S1:13603:8	O
in	PROLIA.xml:S1:13612:2	O
clinical	PROLIA.xml:S1:13615:8	O
trials	PROLIA.xml:S1:13624:6	O
.	PROLIA.xml:S1:13630:1	O

Additionally	PROLIA.xml:S1:13632:12	O
in	PROLIA.xml:S1:13645:2	O
Prolia	PROLIA.xml:S1:13648:6	O
-	PROLIA.xml:S1:13654:1	O
treated	PROLIA.xml:S1:13655:7	O
men	PROLIA.xml:S1:13663:3	O
with	PROLIA.xml:S1:13667:4	O
nonmetastatic	PROLIA.xml:S1:13672:13	O
prostate	PROLIA.xml:S1:13686:8	O
cancer	PROLIA.xml:S1:13695:6	O
receiving	PROLIA.xml:S1:13702:9	O
ADT	PROLIA.xml:S1:13712:3	O
,	PROLIA.xml:S1:13715:1	O
a	PROLIA.xml:S1:13717:1	O
greater	PROLIA.xml:S1:13719:7	O
incidence	PROLIA.xml:S1:13727:9	O
of	PROLIA.xml:S1:13737:2	O
cataracts	PROLIA.xml:S1:13740:9	B-AdverseReaction
was	PROLIA.xml:S1:13750:3	O
observed	PROLIA.xml:S1:13754:8	O
(	PROLIA.xml:S1:13763:1	O
1.2%	PROLIA.xml:S1:13764:4	O
placebo	PROLIA.xml:S1:13769:7	O
vs	PROLIA.xml:S1:13777:2	O
.	PROLIA.xml:S1:13779:1	O

4.7%	PROLIA.xml:S1:13781:4	O
Prolia	PROLIA.xml:S1:13786:6	O
)	PROLIA.xml:S1:13792:1	O
.	PROLIA.xml:S1:13793:1	O

Hypocalcemia	PROLIA.xml:S1:13795:12	B-AdverseReaction
(	PROLIA.xml:S1:13808:1	O
serum	PROLIA.xml:S1:13809:5	O
calcium	PROLIA.xml:S1:13815:7	O
8.4	PROLIA.xml:S1:13825:3	O
mg	PROLIA.xml:S1:13829:2	O
dL	PROLIA.xml:S1:13832:2	O
)	PROLIA.xml:S1:13834:1	O
was	PROLIA.xml:S1:13836:3	O
reported	PROLIA.xml:S1:13840:8	O
only	PROLIA.xml:S1:13849:4	O
in	PROLIA.xml:S1:13854:2	O
Prolia	PROLIA.xml:S1:13857:6	O
-	PROLIA.xml:S1:13863:1	O
treated	PROLIA.xml:S1:13864:7	O
patients	PROLIA.xml:S1:13872:8	O
(	PROLIA.xml:S1:13881:1	O
2.4%	PROLIA.xml:S1:13882:4	O
vs	PROLIA.xml:S1:13887:2	O
.	PROLIA.xml:S1:13889:1	O

0%	PROLIA.xml:S1:13891:2	O
)	PROLIA.xml:S1:13893:1	O
at	PROLIA.xml:S1:13895:2	O
the	PROLIA.xml:S1:13898:3	O
month	PROLIA.xml:S1:13902:5	O
1	PROLIA.xml:S1:13908:1	O
visit	PROLIA.xml:S1:13910:5	O
.	PROLIA.xml:S1:13915:1	O

6.2	PROLIA.xml:S1:13923:3	O
Postmarketing	PROLIA.xml:S1:13927:13	O
Experience	PROLIA.xml:S1:13941:10	O

Because	PROLIA.xml:S1:13955:7	O
postmarketing	PROLIA.xml:S1:13963:13	O
reactions	PROLIA.xml:S1:13977:9	O
are	PROLIA.xml:S1:13987:3	O
reported	PROLIA.xml:S1:13991:8	O
voluntarily	PROLIA.xml:S1:14000:11	O
from	PROLIA.xml:S1:14012:4	O
a	PROLIA.xml:S1:14017:1	O
population	PROLIA.xml:S1:14019:10	O
of	PROLIA.xml:S1:14030:2	O
uncertain	PROLIA.xml:S1:14033:9	O
size	PROLIA.xml:S1:14043:4	O
,	PROLIA.xml:S1:14047:1	O
it	PROLIA.xml:S1:14049:2	O
is	PROLIA.xml:S1:14052:2	O
not	PROLIA.xml:S1:14055:3	O
always	PROLIA.xml:S1:14059:6	O
possible	PROLIA.xml:S1:14066:8	O
to	PROLIA.xml:S1:14075:2	O
reliably	PROLIA.xml:S1:14078:8	O
estimate	PROLIA.xml:S1:14087:8	O
their	PROLIA.xml:S1:14096:5	O
frequency	PROLIA.xml:S1:14102:9	O
or	PROLIA.xml:S1:14112:2	O
establish	PROLIA.xml:S1:14115:9	O
a	PROLIA.xml:S1:14125:1	O
causal	PROLIA.xml:S1:14127:6	O
relationship	PROLIA.xml:S1:14134:12	O
to	PROLIA.xml:S1:14147:2	O
drug	PROLIA.xml:S1:14150:4	O
exposure	PROLIA.xml:S1:14155:8	O
.	PROLIA.xml:S1:14163:1	O

The	PROLIA.xml:S1:14169:3	O
following	PROLIA.xml:S1:14173:9	O
adverse	PROLIA.xml:S1:14183:7	O
reactions	PROLIA.xml:S1:14191:9	O
have	PROLIA.xml:S1:14201:4	O
been	PROLIA.xml:S1:14206:4	O
identified	PROLIA.xml:S1:14211:10	O
during	PROLIA.xml:S1:14222:6	O
post	PROLIA.xml:S1:14229:4	O
approval	PROLIA.xml:S1:14234:8	O
use	PROLIA.xml:S1:14243:3	O
of	PROLIA.xml:S1:14247:2	O
Prolia	PROLIA.xml:S1:14250:6	O
:	PROLIA.xml:S1:14256:1	O

Drug	PROLIA.xml:S1:14265:4	O
-	PROLIA.xml:S1:14269:1	O
related	PROLIA.xml:S1:14270:7	O
hypersensitivity	PROLIA.xml:S1:14278:16	B-AdverseReaction
reactions	PROLIA.xml:S1:14295:9	I-AdverseReaction
:	PROLIA.xml:S1:14304:1	O
anaphylaxis	PROLIA.xml:S1:14306:11	B-AdverseReaction
,	PROLIA.xml:S1:14317:1	O
rash	PROLIA.xml:S1:14319:4	B-AdverseReaction
,	PROLIA.xml:S1:14323:1	O
urticaria	PROLIA.xml:S1:14325:9	B-AdverseReaction
,	PROLIA.xml:S1:14334:1	O
facial	PROLIA.xml:S1:14336:6	B-AdverseReaction
swelling	PROLIA.xml:S1:14343:8	I-AdverseReaction
,	PROLIA.xml:S1:14351:1	O
and	PROLIA.xml:S1:14353:3	O
erythema	PROLIA.xml:S1:14357:8	B-AdverseReaction

Hypocalcemia	PROLIA.xml:S1:14373:12	B-AdverseReaction
:	PROLIA.xml:S1:14385:1	O
severe	PROLIA.xml:S1:14387:6	B-Severity
symptomatic	PROLIA.xml:S1:14394:11	B-AdverseReaction
hypocalcemia	PROLIA.xml:S1:14406:12	I-AdverseReaction

Musculoskeletal	PROLIA.xml:S1:14424:15	B-AdverseReaction
pain	PROLIA.xml:S1:14440:4	I-AdverseReaction
,	PROLIA.xml:S1:14444:1	O
including	PROLIA.xml:S1:14446:9	O
severe	PROLIA.xml:S1:14456:6	B-Severity
cases	PROLIA.xml:S1:14463:5	O

Parathyroid	PROLIA.xml:S1:14474:11	O
Hormone	PROLIA.xml:S1:14486:7	O
(	PROLIA.xml:S1:14494:1	O
PTH	PROLIA.xml:S1:14495:3	O
)	PROLIA.xml:S1:14498:1	O
:	PROLIA.xml:S1:14499:1	O
Marked	PROLIA.xml:S1:14501:6	B-Severity
elevation	PROLIA.xml:S1:14508:9	B-AdverseReaction
in	PROLIA.xml:S1:14518:2	I-AdverseReaction
serum	PROLIA.xml:S1:14521:5	I-AdverseReaction
PTH	PROLIA.xml:S1:14527:3	I-AdverseReaction
in	PROLIA.xml:S1:14531:2	O
patients	PROLIA.xml:S1:14534:8	O
with	PROLIA.xml:S1:14543:4	O
severe	PROLIA.xml:S1:14548:6	O
renal	PROLIA.xml:S1:14555:5	O
impairment	PROLIA.xml:S1:14561:10	O
(	PROLIA.xml:S1:14572:1	O
creatinine	PROLIA.xml:S1:14573:10	O
clearance	PROLIA.xml:S1:14584:9	O
30	PROLIA.xml:S1:14596:2	O
mL	PROLIA.xml:S1:14599:2	O
min	PROLIA.xml:S1:14602:3	O
)	PROLIA.xml:S1:14605:1	O
or	PROLIA.xml:S1:14607:2	O
receiving	PROLIA.xml:S1:14610:9	O
dialysis	PROLIA.xml:S1:14620:8	O
.	PROLIA.xml:S1:14628:1	O

6.3	PROLIA.xml:S1:14637:3	O
Immunogenicity	PROLIA.xml:S1:14641:14	O

Denosumab	PROLIA.xml:S1:14659:9	O
is	PROLIA.xml:S1:14669:2	O
a	PROLIA.xml:S1:14672:1	O
human	PROLIA.xml:S1:14674:5	O
monoclonal	PROLIA.xml:S1:14680:10	O
antibody	PROLIA.xml:S1:14691:8	O
.	PROLIA.xml:S1:14699:1	O

As	PROLIA.xml:S1:14701:2	O
with	PROLIA.xml:S1:14704:4	O
all	PROLIA.xml:S1:14709:3	O
therapeutic	PROLIA.xml:S1:14713:11	O
proteins	PROLIA.xml:S1:14725:8	O
,	PROLIA.xml:S1:14733:1	O
there	PROLIA.xml:S1:14735:5	O
is	PROLIA.xml:S1:14741:2	O
potential	PROLIA.xml:S1:14744:9	O
for	PROLIA.xml:S1:14754:3	O
immunogenicity	PROLIA.xml:S1:14758:14	O
.	PROLIA.xml:S1:14772:1	O

Using	PROLIA.xml:S1:14774:5	O
an	PROLIA.xml:S1:14780:2	O
electrochemiluminescent	PROLIA.xml:S1:14783:23	O
bridging	PROLIA.xml:S1:14807:8	O
immunoassay	PROLIA.xml:S1:14816:11	O
,	PROLIA.xml:S1:14827:1	O
less	PROLIA.xml:S1:14829:4	O
than	PROLIA.xml:S1:14834:4	O
1%	PROLIA.xml:S1:14839:2	O
(	PROLIA.xml:S1:14842:1	O
55	PROLIA.xml:S1:14843:2	O
out	PROLIA.xml:S1:14846:3	O
of	PROLIA.xml:S1:14850:2	O
8113	PROLIA.xml:S1:14853:4	O
)	PROLIA.xml:S1:14857:1	O
of	PROLIA.xml:S1:14859:2	O
patients	PROLIA.xml:S1:14862:8	O
treated	PROLIA.xml:S1:14871:7	O
with	PROLIA.xml:S1:14879:4	O
Prolia	PROLIA.xml:S1:14884:6	O
for	PROLIA.xml:S1:14891:3	O
up	PROLIA.xml:S1:14895:2	O
to	PROLIA.xml:S1:14898:2	O
5	PROLIA.xml:S1:14901:1	O
years	PROLIA.xml:S1:14903:5	O
tested	PROLIA.xml:S1:14909:6	O
positive	PROLIA.xml:S1:14916:8	O
for	PROLIA.xml:S1:14925:3	O
binding	PROLIA.xml:S1:14929:7	O
antibodies	PROLIA.xml:S1:14937:10	O
(	PROLIA.xml:S1:14948:1	O
including	PROLIA.xml:S1:14949:9	O
pre	PROLIA.xml:S1:14959:3	O
-	PROLIA.xml:S1:14962:1	O
existing	PROLIA.xml:S1:14963:8	O
,	PROLIA.xml:S1:14971:1	O
transient	PROLIA.xml:S1:14973:9	O
,	PROLIA.xml:S1:14982:1	O
and	PROLIA.xml:S1:14984:3	O
developing	PROLIA.xml:S1:14988:10	O
antibodies	PROLIA.xml:S1:14999:10	O
)	PROLIA.xml:S1:15009:1	O
.	PROLIA.xml:S1:15010:1	O

None	PROLIA.xml:S1:15012:4	O
of	PROLIA.xml:S1:15017:2	O
the	PROLIA.xml:S1:15020:3	O
patients	PROLIA.xml:S1:15024:8	O
tested	PROLIA.xml:S1:15033:6	O
positive	PROLIA.xml:S1:15040:8	O
for	PROLIA.xml:S1:15049:3	O
neutralizing	PROLIA.xml:S1:15053:12	O
antibodies	PROLIA.xml:S1:15066:10	O
,	PROLIA.xml:S1:15076:1	O
as	PROLIA.xml:S1:15078:2	O
was	PROLIA.xml:S1:15081:3	O
assessed	PROLIA.xml:S1:15085:8	O
using	PROLIA.xml:S1:15094:5	O
a	PROLIA.xml:S1:15100:1	O
chemiluminescent	PROLIA.xml:S1:15102:16	O
cell	PROLIA.xml:S1:15119:4	O
-	PROLIA.xml:S1:15123:1	O
based	PROLIA.xml:S1:15124:5	O
in	PROLIA.xml:S1:15130:2	O
vitro	PROLIA.xml:S1:15133:5	O
biological	PROLIA.xml:S1:15139:10	O
assay	PROLIA.xml:S1:15150:5	O
.	PROLIA.xml:S1:15155:1	O

No	PROLIA.xml:S1:15157:2	B-Negation
evidence	PROLIA.xml:S1:15160:8	O
of	PROLIA.xml:S1:15169:2	O
altered	PROLIA.xml:S1:15172:7	O
pharmacokinetic	PROLIA.xml:S1:15180:15	O
profile	PROLIA.xml:S1:15196:7	O
,	PROLIA.xml:S1:15203:1	O
toxicity	PROLIA.xml:S1:15205:8	B-AdverseReaction
profile	PROLIA.xml:S1:15214:7	O
,	PROLIA.xml:S1:15221:1	O
or	PROLIA.xml:S1:15223:2	O
clinical	PROLIA.xml:S1:15226:8	O
response	PROLIA.xml:S1:15235:8	O
was	PROLIA.xml:S1:15244:3	O
associated	PROLIA.xml:S1:15248:10	O
with	PROLIA.xml:S1:15259:4	O
binding	PROLIA.xml:S1:15264:7	O
antibody	PROLIA.xml:S1:15272:8	O
development	PROLIA.xml:S1:15281:11	O
.	PROLIA.xml:S1:15292:1	O

The	PROLIA.xml:S1:15298:3	O
incidence	PROLIA.xml:S1:15302:9	O
of	PROLIA.xml:S1:15312:2	O
antibody	PROLIA.xml:S1:15315:8	O
formation	PROLIA.xml:S1:15324:9	O
is	PROLIA.xml:S1:15334:2	O
highly	PROLIA.xml:S1:15337:6	O
dependent	PROLIA.xml:S1:15344:9	O
on	PROLIA.xml:S1:15354:2	O
the	PROLIA.xml:S1:15357:3	O
sensitivity	PROLIA.xml:S1:15361:11	O
and	PROLIA.xml:S1:15373:3	O
specificity	PROLIA.xml:S1:15377:11	O
of	PROLIA.xml:S1:15389:2	O
the	PROLIA.xml:S1:15392:3	O
assay	PROLIA.xml:S1:15396:5	O
.	PROLIA.xml:S1:15401:1	O

Additionally	PROLIA.xml:S1:15403:12	O
,	PROLIA.xml:S1:15415:1	O
the	PROLIA.xml:S1:15417:3	O
observed	PROLIA.xml:S1:15421:8	O
incidence	PROLIA.xml:S1:15430:9	O
of	PROLIA.xml:S1:15440:2	O
a	PROLIA.xml:S1:15443:1	O
positive	PROLIA.xml:S1:15445:8	O
antibody	PROLIA.xml:S1:15454:8	O
(	PROLIA.xml:S1:15463:1	O
including	PROLIA.xml:S1:15464:9	O
neutralizing	PROLIA.xml:S1:15474:12	O
antibody	PROLIA.xml:S1:15487:8	O
)	PROLIA.xml:S1:15495:1	O
test	PROLIA.xml:S1:15497:4	O
result	PROLIA.xml:S1:15502:6	O
may	PROLIA.xml:S1:15509:3	O
be	PROLIA.xml:S1:15513:2	O
influenced	PROLIA.xml:S1:15516:10	O
by	PROLIA.xml:S1:15527:2	O
several	PROLIA.xml:S1:15530:7	O
factors	PROLIA.xml:S1:15538:7	O
,	PROLIA.xml:S1:15545:1	O
including	PROLIA.xml:S1:15547:9	O
assay	PROLIA.xml:S1:15557:5	O
methodology	PROLIA.xml:S1:15563:11	O
,	PROLIA.xml:S1:15574:1	O
sample	PROLIA.xml:S1:15576:6	O
handling	PROLIA.xml:S1:15583:8	O
,	PROLIA.xml:S1:15591:1	O
timing	PROLIA.xml:S1:15593:6	O
of	PROLIA.xml:S1:15600:2	O
sample	PROLIA.xml:S1:15603:6	O
collection	PROLIA.xml:S1:15610:10	O
,	PROLIA.xml:S1:15620:1	O
concomitant	PROLIA.xml:S1:15622:11	O
medications	PROLIA.xml:S1:15634:11	O
,	PROLIA.xml:S1:15645:1	O
and	PROLIA.xml:S1:15647:3	O
underlying	PROLIA.xml:S1:15651:10	O
disease	PROLIA.xml:S1:15662:7	O
.	PROLIA.xml:S1:15669:1	O

For	PROLIA.xml:S1:15671:3	O
these	PROLIA.xml:S1:15675:5	O
reasons	PROLIA.xml:S1:15681:7	O
,	PROLIA.xml:S1:15688:1	O
comparison	PROLIA.xml:S1:15690:10	O
of	PROLIA.xml:S1:15701:2	O
antibodies	PROLIA.xml:S1:15704:10	O
to	PROLIA.xml:S1:15715:2	O
denosumab	PROLIA.xml:S1:15718:9	O
with	PROLIA.xml:S1:15728:4	O
the	PROLIA.xml:S1:15733:3	O
incidence	PROLIA.xml:S1:15737:9	O
of	PROLIA.xml:S1:15747:2	O
antibodies	PROLIA.xml:S1:15750:10	O
to	PROLIA.xml:S1:15761:2	O
other	PROLIA.xml:S1:15764:5	O
products	PROLIA.xml:S1:15770:8	O
may	PROLIA.xml:S1:15779:3	O
be	PROLIA.xml:S1:15783:2	O
misleading	PROLIA.xml:S1:15786:10	O
.	PROLIA.xml:S1:15796:1	O
5	PROLIA.xml:S2:4:1	O
WARNINGS	PROLIA.xml:S2:6:8	O
AND	PROLIA.xml:S2:15:3	O
PRECAUTIONS	PROLIA.xml:S2:19:11	O

EXCERPT	PROLIA.xml:S2:37:7	O
:	PROLIA.xml:S2:44:1	O
Same	PROLIA.xml:S2:52:4	O
Active	PROLIA.xml:S2:57:6	O
Ingredient	PROLIA.xml:S2:64:10	O
:	PROLIA.xml:S2:74:1	O
Patients	PROLIA.xml:S2:76:8	O
receiving	PROLIA.xml:S2:85:9	O
Prolia	PROLIA.xml:S2:95:6	O
should	PROLIA.xml:S2:102:6	O
not	PROLIA.xml:S2:109:3	O
receive	PROLIA.xml:S2:113:7	O
XGEVA	PROLIA.xml:S2:121:5	O
(	PROLIA.xml:S2:128:1	O
r	PROLIA.xml:S2:129:1	O
)	PROLIA.xml:S2:130:1	O
(	PROLIA.xml:S2:133:1	O
5.1	PROLIA.xml:S2:136:3	O
)	PROLIA.xml:S2:141:1	O

Hypersensitivity	PROLIA.xml:S2:148:16	B-AdverseReaction
including	PROLIA.xml:S2:165:9	O
anaphylactic	PROLIA.xml:S2:175:12	B-AdverseReaction
reactions	PROLIA.xml:S2:188:9	I-AdverseReaction
may	PROLIA.xml:S2:198:3	O
occur	PROLIA.xml:S2:202:5	O
.	PROLIA.xml:S2:207:1	O

Discontinue	PROLIA.xml:S2:209:11	O
permanently	PROLIA.xml:S2:221:11	O
if	PROLIA.xml:S2:233:2	O
a	PROLIA.xml:S2:236:1	O
clinically	PROLIA.xml:S2:238:10	O
significant	PROLIA.xml:S2:249:11	O
reaction	PROLIA.xml:S2:261:8	O
occurs	PROLIA.xml:S2:270:6	O
(	PROLIA.xml:S2:277:1	O
5.2	PROLIA.xml:S2:280:3	O
)	PROLIA.xml:S2:285:1	O

Hypocalcemia	PROLIA.xml:S2:292:12	B-AdverseReaction
:	PROLIA.xml:S2:304:1	O
Must	PROLIA.xml:S2:306:4	O
be	PROLIA.xml:S2:311:2	O
corrected	PROLIA.xml:S2:314:9	O
before	PROLIA.xml:S2:324:6	O
initiating	PROLIA.xml:S2:331:10	O
Prolia	PROLIA.xml:S2:342:6	O
.	PROLIA.xml:S2:348:1	O

May	PROLIA.xml:S2:350:3	O
worsen	PROLIA.xml:S2:354:6	O
,	PROLIA.xml:S2:360:1	O
especially	PROLIA.xml:S2:362:10	O
in	PROLIA.xml:S2:373:2	O
patients	PROLIA.xml:S2:376:8	O
with	PROLIA.xml:S2:385:4	O
renal	PROLIA.xml:S2:390:5	O
impairment	PROLIA.xml:S2:396:10	O
.	PROLIA.xml:S2:406:1	O

Adequately	PROLIA.xml:S2:408:10	O
supplement	PROLIA.xml:S2:419:10	O
patients	PROLIA.xml:S2:430:8	O
with	PROLIA.xml:S2:439:4	O
calcium	PROLIA.xml:S2:444:7	O
and	PROLIA.xml:S2:452:3	O
vitamin	PROLIA.xml:S2:456:7	O
D	PROLIA.xml:S2:464:1	O
(	PROLIA.xml:S2:466:1	O
5.3	PROLIA.xml:S2:469:3	O
)	PROLIA.xml:S2:474:1	O

Osteonecrosis	PROLIA.xml:S2:481:13	B-AdverseReaction
of	PROLIA.xml:S2:495:2	I-AdverseReaction
the	PROLIA.xml:S2:498:3	I-AdverseReaction
jaw	PROLIA.xml:S2:502:3	I-AdverseReaction
:	PROLIA.xml:S2:505:1	O
Has	PROLIA.xml:S2:507:3	O
been	PROLIA.xml:S2:511:4	O
reported	PROLIA.xml:S2:516:8	O
with	PROLIA.xml:S2:525:4	O
Prolia	PROLIA.xml:S2:530:6	O
.	PROLIA.xml:S2:536:1	O

Monitor	PROLIA.xml:S2:538:7	O
for	PROLIA.xml:S2:546:3	O
symptoms	PROLIA.xml:S2:550:8	O
(	PROLIA.xml:S2:559:1	O
5.4	PROLIA.xml:S2:562:3	O
)	PROLIA.xml:S2:567:1	O

Atypical	PROLIA.xml:S2:574:8	B-AdverseReaction
femoral	PROLIA.xml:S2:583:7	I-AdverseReaction
fractures	PROLIA.xml:S2:591:9	I-AdverseReaction
:	PROLIA.xml:S2:600:1	O
Have	PROLIA.xml:S2:602:4	O
been	PROLIA.xml:S2:607:4	O
reported	PROLIA.xml:S2:612:8	O
.	PROLIA.xml:S2:620:1	O

Evaluate	PROLIA.xml:S2:622:8	O
patients	PROLIA.xml:S2:631:8	O
with	PROLIA.xml:S2:640:4	O
thigh	PROLIA.xml:S2:645:5	O
or	PROLIA.xml:S2:651:2	O
groin	PROLIA.xml:S2:654:5	O
pain	PROLIA.xml:S2:660:4	O
to	PROLIA.xml:S2:665:2	O
rule	PROLIA.xml:S2:668:4	O
out	PROLIA.xml:S2:673:3	O
a	PROLIA.xml:S2:677:1	O
femoral	PROLIA.xml:S2:679:7	O
fracture	PROLIA.xml:S2:687:8	O
(	PROLIA.xml:S2:696:1	O
5.5	PROLIA.xml:S2:699:3	O
)	PROLIA.xml:S2:704:1	O

Serious	PROLIA.xml:S2:711:7	B-Severity
infections	PROLIA.xml:S2:719:10	B-AdverseReaction
including	PROLIA.xml:S2:730:9	O
skin	PROLIA.xml:S2:740:4	B-AdverseReaction
infections	PROLIA.xml:S2:745:10	I-AdverseReaction
:	PROLIA.xml:S2:755:1	O
May	PROLIA.xml:S2:757:3	O
occur	PROLIA.xml:S2:761:5	O
,	PROLIA.xml:S2:766:1	O
including	PROLIA.xml:S2:768:9	O
those	PROLIA.xml:S2:778:5	O
leading	PROLIA.xml:S2:784:7	O
to	PROLIA.xml:S2:792:2	O
hospitalization	PROLIA.xml:S2:795:15	O
.	PROLIA.xml:S2:810:1	O

Advise	PROLIA.xml:S2:812:6	O
patients	PROLIA.xml:S2:819:8	O
to	PROLIA.xml:S2:828:2	O
seek	PROLIA.xml:S2:831:4	O
prompt	PROLIA.xml:S2:836:6	O
medical	PROLIA.xml:S2:843:7	O
attention	PROLIA.xml:S2:851:9	O
if	PROLIA.xml:S2:861:2	O
they	PROLIA.xml:S2:864:4	O
develop	PROLIA.xml:S2:869:7	O
signs	PROLIA.xml:S2:877:5	O
or	PROLIA.xml:S2:883:2	O
symptoms	PROLIA.xml:S2:886:8	O
of	PROLIA.xml:S2:895:2	O
infection	PROLIA.xml:S2:898:9	O
,	PROLIA.xml:S2:907:1	O
including	PROLIA.xml:S2:909:9	O
cellulitis	PROLIA.xml:S2:919:10	O
(	PROLIA.xml:S2:930:1	O
5.6	PROLIA.xml:S2:933:3	O
)	PROLIA.xml:S2:938:1	O

Dermatologic	PROLIA.xml:S2:945:12	B-AdverseReaction
reactions	PROLIA.xml:S2:958:9	I-AdverseReaction
:	PROLIA.xml:S2:967:1	O
Dermatitis	PROLIA.xml:S2:969:10	B-AdverseReaction
,	PROLIA.xml:S2:979:1	O
rashes	PROLIA.xml:S2:981:6	B-AdverseReaction
,	PROLIA.xml:S2:987:1	O
and	PROLIA.xml:S2:989:3	O
eczema	PROLIA.xml:S2:993:6	B-AdverseReaction
have	PROLIA.xml:S2:1000:4	O
been	PROLIA.xml:S2:1005:4	O
reported	PROLIA.xml:S2:1010:8	O
.	PROLIA.xml:S2:1018:1	O

Consider	PROLIA.xml:S2:1020:8	O
discontinuing	PROLIA.xml:S2:1029:13	O
Prolia	PROLIA.xml:S2:1043:6	O
if	PROLIA.xml:S2:1050:2	O
severe	PROLIA.xml:S2:1053:6	O
symptoms	PROLIA.xml:S2:1060:8	O
develop	PROLIA.xml:S2:1069:7	O
(	PROLIA.xml:S2:1077:1	O
5.7	PROLIA.xml:S2:1080:3	O
)	PROLIA.xml:S2:1085:1	O

Severe	PROLIA.xml:S2:1092:6	B-Severity
Bone	PROLIA.xml:S2:1099:4	B-AdverseReaction
,	PROLIA.xml:S2:1103:1	O
Joint	PROLIA.xml:S2:1105:5	B-AdverseReaction
,	PROLIA.xml:S2:1110:1	O
Muscle	PROLIA.xml:S2:1112:6	B-AdverseReaction
Pain	PROLIA.xml:S2:1119:4	I-AdverseReaction
may	PROLIA.xml:S2:1124:3	O
occur	PROLIA.xml:S2:1128:5	O
.	PROLIA.xml:S2:1133:1	O

Discontinue	PROLIA.xml:S2:1135:11	O
use	PROLIA.xml:S2:1147:3	O
if	PROLIA.xml:S2:1151:2	O
severe	PROLIA.xml:S2:1154:6	O
symptoms	PROLIA.xml:S2:1161:8	O
develop	PROLIA.xml:S2:1170:7	O
(	PROLIA.xml:S2:1178:1	O
5.8	PROLIA.xml:S2:1181:3	O
)	PROLIA.xml:S2:1186:1	O

Suppression	PROLIA.xml:S2:1193:11	B-AdverseReaction
of	PROLIA.xml:S2:1205:2	I-AdverseReaction
bone	PROLIA.xml:S2:1208:4	I-AdverseReaction
turnover	PROLIA.xml:S2:1213:8	I-AdverseReaction
:	PROLIA.xml:S2:1221:1	O
Significant	PROLIA.xml:S2:1223:11	O
suppression	PROLIA.xml:S2:1235:11	O
has	PROLIA.xml:S2:1247:3	O
been	PROLIA.xml:S2:1251:4	O
demonstrated	PROLIA.xml:S2:1256:12	O
.	PROLIA.xml:S2:1268:1	O

Monitor	PROLIA.xml:S2:1270:7	O
for	PROLIA.xml:S2:1278:3	O
consequences	PROLIA.xml:S2:1282:12	O
of	PROLIA.xml:S2:1295:2	O
bone	PROLIA.xml:S2:1298:4	O
oversuppression	PROLIA.xml:S2:1303:15	O
(	PROLIA.xml:S2:1319:1	O
5.9	PROLIA.xml:S2:1322:3	O
)	PROLIA.xml:S2:1327:1	O

5.1	PROLIA.xml:S2:1341:3	O

Drug	PROLIA.xml:S2:1345:4	O

Products	PROLIA.xml:S2:1350:8	O
with	PROLIA.xml:S2:1359:4	O
Same	PROLIA.xml:S2:1364:4	O
Active	PROLIA.xml:S2:1369:6	O
Ingredient	PROLIA.xml:S2:1376:10	O

Prolia	PROLIA.xml:S2:1392:6	O
contains	PROLIA.xml:S2:1399:8	O
the	PROLIA.xml:S2:1408:3	O
same	PROLIA.xml:S2:1412:4	O
active	PROLIA.xml:S2:1417:6	O
ingredient	PROLIA.xml:S2:1424:10	O
(	PROLIA.xml:S2:1435:1	O
denosumab	PROLIA.xml:S2:1436:9	O
)	PROLIA.xml:S2:1445:1	O
found	PROLIA.xml:S2:1447:5	O
in	PROLIA.xml:S2:1453:2	O
Xgeva	PROLIA.xml:S2:1456:5	O
.	PROLIA.xml:S2:1461:1	O

Patients	PROLIA.xml:S2:1463:8	O
receiving	PROLIA.xml:S2:1472:9	O
Prolia	PROLIA.xml:S2:1482:6	O
should	PROLIA.xml:S2:1489:6	O
not	PROLIA.xml:S2:1496:3	O
receive	PROLIA.xml:S2:1500:7	O
Xgeva	PROLIA.xml:S2:1508:5	O
.	PROLIA.xml:S2:1513:1	O

5.2	PROLIA.xml:S2:1522:3	O
Hypersensitivity	PROLIA.xml:S2:1526:16	O

Clinically	PROLIA.xml:S2:1548:10	O
significant	PROLIA.xml:S2:1559:11	O
hypersensitivity	PROLIA.xml:S2:1571:16	B-AdverseReaction
including	PROLIA.xml:S2:1588:9	O
anaphylaxis	PROLIA.xml:S2:1598:11	B-AdverseReaction
has	PROLIA.xml:S2:1610:3	O
been	PROLIA.xml:S2:1614:4	O
reported	PROLIA.xml:S2:1619:8	O
with	PROLIA.xml:S2:1628:4	O
Prolia	PROLIA.xml:S2:1633:6	O
.	PROLIA.xml:S2:1639:1	O

Symptoms	PROLIA.xml:S2:1641:8	O
have	PROLIA.xml:S2:1650:4	O
included	PROLIA.xml:S2:1655:8	O
hypotension	PROLIA.xml:S2:1664:11	B-AdverseReaction
,	PROLIA.xml:S2:1675:1	O
dyspnea	PROLIA.xml:S2:1677:7	B-AdverseReaction
,	PROLIA.xml:S2:1684:1	O
throat	PROLIA.xml:S2:1686:6	B-AdverseReaction
tightness	PROLIA.xml:S2:1693:9	I-AdverseReaction
,	PROLIA.xml:S2:1702:1	O
facial	PROLIA.xml:S2:1704:6	B-AdverseReaction
and	PROLIA.xml:S2:1711:3	O
upper	PROLIA.xml:S2:1715:5	B-AdverseReaction
airway	PROLIA.xml:S2:1721:6	I-AdverseReaction
edema	PROLIA.xml:S2:1728:5	I-AdverseReaction
,	PROLIA.xml:S2:1733:1	O
pruritus	PROLIA.xml:S2:1735:8	B-AdverseReaction
,	PROLIA.xml:S2:1743:1	O
and	PROLIA.xml:S2:1745:3	O
urticaria	PROLIA.xml:S2:1749:9	B-AdverseReaction
.	PROLIA.xml:S2:1758:1	O

If	PROLIA.xml:S2:1760:2	O
an	PROLIA.xml:S2:1763:2	O
anaphylactic	PROLIA.xml:S2:1766:12	O
or	PROLIA.xml:S2:1779:2	O
other	PROLIA.xml:S2:1782:5	O
clinically	PROLIA.xml:S2:1788:10	O
significant	PROLIA.xml:S2:1799:11	O
allergic	PROLIA.xml:S2:1811:8	O
reaction	PROLIA.xml:S2:1820:8	O
occurs	PROLIA.xml:S2:1829:6	O
,	PROLIA.xml:S2:1835:1	O
initiate	PROLIA.xml:S2:1837:8	O
appropriate	PROLIA.xml:S2:1846:11	O
therapy	PROLIA.xml:S2:1858:7	O
and	PROLIA.xml:S2:1866:3	O
discontinue	PROLIA.xml:S2:1870:11	O
further	PROLIA.xml:S2:1882:7	O
use	PROLIA.xml:S2:1890:3	O
of	PROLIA.xml:S2:1894:2	O
Prolia	PROLIA.xml:S2:1897:6	O
[	PROLIA.xml:S2:1904:1	O
see	PROLIA.xml:S2:1905:3	O
Contraindications	PROLIA.xml:S2:1909:17	O
(	PROLIA.xml:S2:1927:1	O
4.3	PROLIA.xml:S2:1930:3	O
)	PROLIA.xml:S2:1935:1	O
,	PROLIA.xml:S2:1936:1	O
Adverse	PROLIA.xml:S2:1938:7	O
Reactions	PROLIA.xml:S2:1946:9	O
(	PROLIA.xml:S2:1956:1	O
6.2	PROLIA.xml:S2:1959:3	O
)]	PROLIA.xml:S2:1964:2	O
.	PROLIA.xml:S2:1968:1	O

5.3	PROLIA.xml:S2:1977:3	O
Hypocalcemia	PROLIA.xml:S2:1981:12	O
and	PROLIA.xml:S2:1994:3	O
Mineral	PROLIA.xml:S2:1998:7	O
Metabolism	PROLIA.xml:S2:2006:10	O

Hypocalcemia	PROLIA.xml:S2:2023:12	B-AdverseReaction
may	PROLIA.xml:S2:2036:3	B-Factor
be	PROLIA.xml:S2:2040:2	O
exacerbated	PROLIA.xml:S2:2043:11	I-AdverseReaction
by	PROLIA.xml:S2:2055:2	O
the	PROLIA.xml:S2:2058:3	O
use	PROLIA.xml:S2:2062:3	O
of	PROLIA.xml:S2:2066:2	O
Prolia	PROLIA.xml:S2:2069:6	O
.	PROLIA.xml:S2:2075:1	O

Pre	PROLIA.xml:S2:2077:3	O
-	PROLIA.xml:S2:2080:1	O
existing	PROLIA.xml:S2:2081:8	O
hypocalcemia	PROLIA.xml:S2:2090:12	O
must	PROLIA.xml:S2:2103:4	O
be	PROLIA.xml:S2:2108:2	O
corrected	PROLIA.xml:S2:2111:9	O
prior	PROLIA.xml:S2:2121:5	O
to	PROLIA.xml:S2:2127:2	O
initiating	PROLIA.xml:S2:2130:10	O
therapy	PROLIA.xml:S2:2141:7	O
with	PROLIA.xml:S2:2149:4	O
Prolia	PROLIA.xml:S2:2154:6	O
.	PROLIA.xml:S2:2160:1	O

In	PROLIA.xml:S2:2162:2	O
patients	PROLIA.xml:S2:2165:8	O
predisposed	PROLIA.xml:S2:2174:11	O
to	PROLIA.xml:S2:2186:2	O
hypocalcemia	PROLIA.xml:S2:2189:12	O
and	PROLIA.xml:S2:2202:3	O
disturbances	PROLIA.xml:S2:2206:12	O
of	PROLIA.xml:S2:2219:2	O
mineral	PROLIA.xml:S2:2222:7	O
metabolism	PROLIA.xml:S2:2230:10	O
(	PROLIA.xml:S2:2241:1	O
e	PROLIA.xml:S2:2242:1	O
.	PROLIA.xml:S2:2243:1	O
g	PROLIA.xml:S2:2244:1	O
.	PROLIA.xml:S2:2245:1	O

history	PROLIA.xml:S2:2247:7	O
of	PROLIA.xml:S2:2255:2	O
hypoparathyroidism	PROLIA.xml:S2:2258:18	O
,	PROLIA.xml:S2:2276:1	O
thyroid	PROLIA.xml:S2:2278:7	O
surgery	PROLIA.xml:S2:2286:7	O
,	PROLIA.xml:S2:2293:1	O
parathyroid	PROLIA.xml:S2:2295:11	O
surgery	PROLIA.xml:S2:2307:7	O
,	PROLIA.xml:S2:2314:1	O
malabsorption	PROLIA.xml:S2:2316:13	O
syndromes	PROLIA.xml:S2:2330:9	O
,	PROLIA.xml:S2:2339:1	O
excision	PROLIA.xml:S2:2341:8	O
of	PROLIA.xml:S2:2350:2	O
small	PROLIA.xml:S2:2353:5	O
intestine	PROLIA.xml:S2:2359:9	O
,	PROLIA.xml:S2:2368:1	O
severe	PROLIA.xml:S2:2370:6	O
renal	PROLIA.xml:S2:2377:5	O
impairment	PROLIA.xml:S2:2383:10	O
[	PROLIA.xml:S2:2394:1	O
creatinine	PROLIA.xml:S2:2395:10	O
clearance	PROLIA.xml:S2:2406:9	O
30	PROLIA.xml:S2:2418:2	O
mL	PROLIA.xml:S2:2421:2	O
min	PROLIA.xml:S2:2424:3	O
]	PROLIA.xml:S2:2427:1	O
or	PROLIA.xml:S2:2429:2	O
receiving	PROLIA.xml:S2:2432:9	O
dialysis	PROLIA.xml:S2:2442:8	O
)	PROLIA.xml:S2:2450:1	O
,	PROLIA.xml:S2:2451:1	O
clinical	PROLIA.xml:S2:2453:8	O
monitoring	PROLIA.xml:S2:2462:10	O
of	PROLIA.xml:S2:2473:2	O
calcium	PROLIA.xml:S2:2476:7	O
and	PROLIA.xml:S2:2484:3	O
mineral	PROLIA.xml:S2:2488:7	O
levels	PROLIA.xml:S2:2496:6	O
(	PROLIA.xml:S2:2503:1	O
phosphorus	PROLIA.xml:S2:2504:10	O
and	PROLIA.xml:S2:2515:3	O
magnesium	PROLIA.xml:S2:2519:9	O
)	PROLIA.xml:S2:2528:1	O
is	PROLIA.xml:S2:2530:2	O
highly	PROLIA.xml:S2:2533:6	O
recommended	PROLIA.xml:S2:2540:11	O
within	PROLIA.xml:S2:2552:6	O
14	PROLIA.xml:S2:2559:2	O
days	PROLIA.xml:S2:2562:4	O
of	PROLIA.xml:S2:2567:2	O
Prolia	PROLIA.xml:S2:2570:6	O
injection	PROLIA.xml:S2:2577:9	O
.	PROLIA.xml:S2:2586:1	O

In	PROLIA.xml:S2:2588:2	O
some	PROLIA.xml:S2:2591:4	O
postmarketing	PROLIA.xml:S2:2596:13	O
cases	PROLIA.xml:S2:2610:5	O
,	PROLIA.xml:S2:2615:1	O
hypocalcemia	PROLIA.xml:S2:2617:12	B-AdverseReaction
persisted	PROLIA.xml:S2:2630:9	O
for	PROLIA.xml:S2:2640:3	O
weeks	PROLIA.xml:S2:2644:5	O
or	PROLIA.xml:S2:2650:2	O
months	PROLIA.xml:S2:2653:6	O
and	PROLIA.xml:S2:2660:3	O
required	PROLIA.xml:S2:2664:8	O
frequent	PROLIA.xml:S2:2673:8	O
monitoring	PROLIA.xml:S2:2682:10	O
and	PROLIA.xml:S2:2693:3	O
intravenous	PROLIA.xml:S2:2697:11	O
and	PROLIA.xml:S2:2709:3	O
or	PROLIA.xml:S2:2713:2	O
oral	PROLIA.xml:S2:2716:4	O
calcium	PROLIA.xml:S2:2721:7	O
replacement	PROLIA.xml:S2:2729:11	O
,	PROLIA.xml:S2:2740:1	O
with	PROLIA.xml:S2:2742:4	O
or	PROLIA.xml:S2:2747:2	O
without	PROLIA.xml:S2:2750:7	O
vitamin	PROLIA.xml:S2:2758:7	O
D.	PROLIA.xml:S2:2766:2	O

Hypocalcemia	PROLIA.xml:S2:2775:12	B-AdverseReaction
following	PROLIA.xml:S2:2788:9	O
Prolia	PROLIA.xml:S2:2798:6	O
administration	PROLIA.xml:S2:2805:14	O
is	PROLIA.xml:S2:2820:2	O
a	PROLIA.xml:S2:2823:1	O
significant	PROLIA.xml:S2:2825:11	O
risk	PROLIA.xml:S2:2837:4	O
in	PROLIA.xml:S2:2842:2	O
patients	PROLIA.xml:S2:2845:8	O
with	PROLIA.xml:S2:2854:4	O
severe	PROLIA.xml:S2:2859:6	O
renal	PROLIA.xml:S2:2866:5	O
impairment	PROLIA.xml:S2:2872:10	O
[	PROLIA.xml:S2:2883:1	O
creatinine	PROLIA.xml:S2:2884:10	O
clearance	PROLIA.xml:S2:2895:9	O
30	PROLIA.xml:S2:2907:2	O
mL	PROLIA.xml:S2:2910:2	O
min	PROLIA.xml:S2:2913:3	O
]	PROLIA.xml:S2:2916:1	O
or	PROLIA.xml:S2:2918:2	O
receiving	PROLIA.xml:S2:2921:9	O
dialysis	PROLIA.xml:S2:2931:8	O
.	PROLIA.xml:S2:2939:1	O

These	PROLIA.xml:S2:2941:5	O
patients	PROLIA.xml:S2:2947:8	O
may	PROLIA.xml:S2:2956:3	B-Factor
also	PROLIA.xml:S2:2960:4	O
develop	PROLIA.xml:S2:2965:7	O
marked	PROLIA.xml:S2:2973:6	B-Severity
elevations	PROLIA.xml:S2:2980:10	B-AdverseReaction
of	PROLIA.xml:S2:2991:2	I-AdverseReaction
serum	PROLIA.xml:S2:2994:5	I-AdverseReaction
parathyroid	PROLIA.xml:S2:3000:11	I-AdverseReaction
hormone	PROLIA.xml:S2:3012:7	I-AdverseReaction
(	PROLIA.xml:S2:3020:1	O
PTH	PROLIA.xml:S2:3021:3	O
)	PROLIA.xml:S2:3024:1	O
.	PROLIA.xml:S2:3025:1	O

Instruct	PROLIA.xml:S2:3029:8	O
all	PROLIA.xml:S2:3038:3	O
patients	PROLIA.xml:S2:3042:8	O
with	PROLIA.xml:S2:3051:4	O
severe	PROLIA.xml:S2:3056:6	O
renal	PROLIA.xml:S2:3063:5	O
impairment	PROLIA.xml:S2:3069:10	O
,	PROLIA.xml:S2:3079:1	O
including	PROLIA.xml:S2:3081:9	O
those	PROLIA.xml:S2:3091:5	O
receiving	PROLIA.xml:S2:3097:9	O
dialysis	PROLIA.xml:S2:3107:8	O
,	PROLIA.xml:S2:3115:1	O
about	PROLIA.xml:S2:3117:5	O
the	PROLIA.xml:S2:3123:3	O
symptoms	PROLIA.xml:S2:3127:8	O
of	PROLIA.xml:S2:3136:2	O
hypocalcemia	PROLIA.xml:S2:3139:12	O
and	PROLIA.xml:S2:3152:3	O
the	PROLIA.xml:S2:3156:3	O
importance	PROLIA.xml:S2:3160:10	O
of	PROLIA.xml:S2:3171:2	O
maintaining	PROLIA.xml:S2:3174:11	O
calcium	PROLIA.xml:S2:3186:7	O
levels	PROLIA.xml:S2:3194:6	O
with	PROLIA.xml:S2:3201:4	O
adequate	PROLIA.xml:S2:3206:8	O
calcium	PROLIA.xml:S2:3215:7	O
and	PROLIA.xml:S2:3223:3	O
vitamin	PROLIA.xml:S2:3227:7	O
D	PROLIA.xml:S2:3235:1	O
supplementation	PROLIA.xml:S2:3237:15	O
.	PROLIA.xml:S2:3252:1	O

Adequately	PROLIA.xml:S2:3258:10	O
supplement	PROLIA.xml:S2:3269:10	O
all	PROLIA.xml:S2:3280:3	O
patients	PROLIA.xml:S2:3284:8	O
with	PROLIA.xml:S2:3293:4	O
calcium	PROLIA.xml:S2:3298:7	O
and	PROLIA.xml:S2:3306:3	O
vitamin	PROLIA.xml:S2:3310:7	O
D	PROLIA.xml:S2:3318:1	O
[	PROLIA.xml:S2:3320:1	O
see	PROLIA.xml:S2:3321:3	O
Dosage	PROLIA.xml:S2:3325:6	O
and	PROLIA.xml:S2:3332:3	O
Administration	PROLIA.xml:S2:3336:14	O
(	PROLIA.xml:S2:3351:1	O
2.1	PROLIA.xml:S2:3354:3	O
)	PROLIA.xml:S2:3359:1	O
,	PROLIA.xml:S2:3360:1	O
Contraindications	PROLIA.xml:S2:3362:17	O
(	PROLIA.xml:S2:3380:1	O
4.1	PROLIA.xml:S2:3383:3	O
)	PROLIA.xml:S2:3388:1	O
,	PROLIA.xml:S2:3389:1	O
Adverse	PROLIA.xml:S2:3391:7	O
Reactions	PROLIA.xml:S2:3399:9	O
(	PROLIA.xml:S2:3409:1	O
6.1	PROLIA.xml:S2:3412:3	O
)	PROLIA.xml:S2:3417:1	O
,	PROLIA.xml:S2:3418:1	O
and	PROLIA.xml:S2:3420:3	O
Patient	PROLIA.xml:S2:3424:7	O
Counseling	PROLIA.xml:S2:3432:10	O
Information	PROLIA.xml:S2:3443:11	O
(	PROLIA.xml:S2:3455:1	O
17.3	PROLIA.xml:S2:3458:4	O
)]	PROLIA.xml:S2:3464:2	O
.	PROLIA.xml:S2:3468:1	O

5.4	PROLIA.xml:S2:3477:3	O
Osteonecrosis	PROLIA.xml:S2:3481:13	O
of	PROLIA.xml:S2:3495:2	O
the	PROLIA.xml:S2:3498:3	O
Jaw	PROLIA.xml:S2:3502:3	O

Osteonecrosis	PROLIA.xml:S2:3512:13	O
of	PROLIA.xml:S2:3526:2	O
the	PROLIA.xml:S2:3529:3	O
jaw	PROLIA.xml:S2:3533:3	O
(	PROLIA.xml:S2:3537:1	O
ONJ	PROLIA.xml:S2:3538:3	O
)	PROLIA.xml:S2:3541:1	O
,	PROLIA.xml:S2:3542:1	O
which	PROLIA.xml:S2:3544:5	O
can	PROLIA.xml:S2:3550:3	O
occur	PROLIA.xml:S2:3554:5	O
spontaneously	PROLIA.xml:S2:3560:13	O
,	PROLIA.xml:S2:3573:1	O
is	PROLIA.xml:S2:3575:2	O
generally	PROLIA.xml:S2:3578:9	O
associated	PROLIA.xml:S2:3588:10	O
with	PROLIA.xml:S2:3599:4	O
tooth	PROLIA.xml:S2:3604:5	O
extraction	PROLIA.xml:S2:3610:10	O
and	PROLIA.xml:S2:3621:3	O
or	PROLIA.xml:S2:3625:2	O
local	PROLIA.xml:S2:3628:5	O
infection	PROLIA.xml:S2:3634:9	O
with	PROLIA.xml:S2:3644:4	O
delayed	PROLIA.xml:S2:3649:7	O
healing	PROLIA.xml:S2:3657:7	O
.	PROLIA.xml:S2:3664:1	O

ONJ	PROLIA.xml:S2:3666:3	B-AdverseReaction
has	PROLIA.xml:S2:3670:3	O
been	PROLIA.xml:S2:3674:4	O
reported	PROLIA.xml:S2:3679:8	O
in	PROLIA.xml:S2:3688:2	O
patients	PROLIA.xml:S2:3691:8	O
receiving	PROLIA.xml:S2:3700:9	O
denosumab	PROLIA.xml:S2:3710:9	O
[	PROLIA.xml:S2:3720:1	O
see	PROLIA.xml:S2:3721:3	O
Adverse	PROLIA.xml:S2:3725:7	O
Reactions	PROLIA.xml:S2:3733:9	O
(	PROLIA.xml:S2:3743:1	O
6.1	PROLIA.xml:S2:3746:3	O
)]	PROLIA.xml:S2:3751:2	O
.	PROLIA.xml:S2:3753:1	O

A	PROLIA.xml:S2:3756:1	O
routine	PROLIA.xml:S2:3758:7	O
oral	PROLIA.xml:S2:3766:4	O
exam	PROLIA.xml:S2:3771:4	O
should	PROLIA.xml:S2:3776:6	O
be	PROLIA.xml:S2:3783:2	O
performed	PROLIA.xml:S2:3786:9	O
by	PROLIA.xml:S2:3796:2	O
the	PROLIA.xml:S2:3799:3	O
prescriber	PROLIA.xml:S2:3803:10	O
prior	PROLIA.xml:S2:3814:5	O
to	PROLIA.xml:S2:3820:2	O
initiation	PROLIA.xml:S2:3823:10	O
of	PROLIA.xml:S2:3834:2	O
Prolia	PROLIA.xml:S2:3837:6	O
treatment	PROLIA.xml:S2:3844:9	O
.	PROLIA.xml:S2:3853:1	O

A	PROLIA.xml:S2:3855:1	O
dental	PROLIA.xml:S2:3857:6	O
examination	PROLIA.xml:S2:3864:11	O
with	PROLIA.xml:S2:3876:4	O
appropriate	PROLIA.xml:S2:3881:11	O
preventive	PROLIA.xml:S2:3893:10	O
dentistry	PROLIA.xml:S2:3904:9	O
is	PROLIA.xml:S2:3914:2	O
recommended	PROLIA.xml:S2:3917:11	O
prior	PROLIA.xml:S2:3929:5	O
to	PROLIA.xml:S2:3935:2	O
treatment	PROLIA.xml:S2:3938:9	O
with	PROLIA.xml:S2:3948:4	O
Prolia	PROLIA.xml:S2:3953:6	O
in	PROLIA.xml:S2:3960:2	O
patients	PROLIA.xml:S2:3963:8	O
with	PROLIA.xml:S2:3972:4	O
risk	PROLIA.xml:S2:3977:4	O
factors	PROLIA.xml:S2:3982:7	O
for	PROLIA.xml:S2:3990:3	O
ONJ	PROLIA.xml:S2:3994:3	O
such	PROLIA.xml:S2:3998:4	O
as	PROLIA.xml:S2:4003:2	O
invasive	PROLIA.xml:S2:4006:8	O
dental	PROLIA.xml:S2:4015:6	O
procedures	PROLIA.xml:S2:4022:10	O
(	PROLIA.xml:S2:4033:1	O
e	PROLIA.xml:S2:4034:1	O
.	PROLIA.xml:S2:4035:1	O
g	PROLIA.xml:S2:4036:1	O
.	PROLIA.xml:S2:4037:1	O

tooth	PROLIA.xml:S2:4039:5	O
extraction	PROLIA.xml:S2:4045:10	O
,	PROLIA.xml:S2:4055:1	O
dental	PROLIA.xml:S2:4057:6	O
implants	PROLIA.xml:S2:4064:8	O
,	PROLIA.xml:S2:4072:1	O
oral	PROLIA.xml:S2:4074:4	O
surgery	PROLIA.xml:S2:4079:7	O
)	PROLIA.xml:S2:4086:1	O
,	PROLIA.xml:S2:4087:1	O
diagnosis	PROLIA.xml:S2:4089:9	O
of	PROLIA.xml:S2:4099:2	O
cancer	PROLIA.xml:S2:4102:6	O
,	PROLIA.xml:S2:4108:1	O
concomitant	PROLIA.xml:S2:4110:11	O
therapies	PROLIA.xml:S2:4122:9	O
(	PROLIA.xml:S2:4132:1	O
e	PROLIA.xml:S2:4133:1	O
.	PROLIA.xml:S2:4134:1	O
g	PROLIA.xml:S2:4135:1	O
.	PROLIA.xml:S2:4136:1	O

chemotherapy	PROLIA.xml:S2:4138:12	O
,	PROLIA.xml:S2:4150:1	O
corticosteroids	PROLIA.xml:S2:4152:15	O
,	PROLIA.xml:S2:4167:1	O
angiogenesis	PROLIA.xml:S2:4169:12	O
inhibitors	PROLIA.xml:S2:4182:10	O
)	PROLIA.xml:S2:4192:1	O
,	PROLIA.xml:S2:4193:1	O
poor	PROLIA.xml:S2:4195:4	O
oral	PROLIA.xml:S2:4200:4	O
hygiene	PROLIA.xml:S2:4205:7	O
,	PROLIA.xml:S2:4212:1	O
and	PROLIA.xml:S2:4214:3	O
co	PROLIA.xml:S2:4218:2	O
-	PROLIA.xml:S2:4220:1	O
morbid	PROLIA.xml:S2:4221:6	O
disorders	PROLIA.xml:S2:4228:9	O
(	PROLIA.xml:S2:4238:1	O
e	PROLIA.xml:S2:4239:1	O
.	PROLIA.xml:S2:4240:1	O
g	PROLIA.xml:S2:4241:1	O
.	PROLIA.xml:S2:4242:1	O

periodontal	PROLIA.xml:S2:4244:11	O
and	PROLIA.xml:S2:4256:3	O
or	PROLIA.xml:S2:4260:2	O
other	PROLIA.xml:S2:4263:5	O
pre	PROLIA.xml:S2:4269:3	O
-	PROLIA.xml:S2:4272:1	O
existing	PROLIA.xml:S2:4273:8	O
dental	PROLIA.xml:S2:4282:6	O
disease	PROLIA.xml:S2:4289:7	O
,	PROLIA.xml:S2:4296:1	O
anemia	PROLIA.xml:S2:4298:6	O
,	PROLIA.xml:S2:4304:1	O
coagulopathy	PROLIA.xml:S2:4306:12	O
,	PROLIA.xml:S2:4318:1	O
infection	PROLIA.xml:S2:4320:9	O
,	PROLIA.xml:S2:4329:1	O
ill	PROLIA.xml:S2:4331:3	O
-	PROLIA.xml:S2:4334:1	O
fitting	PROLIA.xml:S2:4335:7	O
dentures	PROLIA.xml:S2:4343:8	O
)	PROLIA.xml:S2:4351:1	O
.	PROLIA.xml:S2:4352:1	O

Good	PROLIA.xml:S2:4354:4	O
oral	PROLIA.xml:S2:4359:4	O
hygiene	PROLIA.xml:S2:4364:7	O
practices	PROLIA.xml:S2:4372:9	O
should	PROLIA.xml:S2:4382:6	O
be	PROLIA.xml:S2:4389:2	O
maintained	PROLIA.xml:S2:4392:10	O
during	PROLIA.xml:S2:4403:6	O
treatment	PROLIA.xml:S2:4410:9	O
with	PROLIA.xml:S2:4420:4	O
Prolia	PROLIA.xml:S2:4425:6	O
.	PROLIA.xml:S2:4431:1	O

Concomitant	PROLIA.xml:S2:4433:11	O
administration	PROLIA.xml:S2:4445:14	O
of	PROLIA.xml:S2:4460:2	O
drugs	PROLIA.xml:S2:4463:5	O
associated	PROLIA.xml:S2:4469:10	O
with	PROLIA.xml:S2:4480:4	O
ONJ	PROLIA.xml:S2:4485:3	O
may	PROLIA.xml:S2:4489:3	O
increase	PROLIA.xml:S2:4493:8	O
the	PROLIA.xml:S2:4502:3	O
risk	PROLIA.xml:S2:4506:4	O
of	PROLIA.xml:S2:4511:2	O
developing	PROLIA.xml:S2:4514:10	O
ONJ	PROLIA.xml:S2:4525:3	O
.	PROLIA.xml:S2:4528:1	O

For	PROLIA.xml:S2:4536:3	O
patients	PROLIA.xml:S2:4540:8	O
requiring	PROLIA.xml:S2:4549:9	O
invasive	PROLIA.xml:S2:4559:8	O
dental	PROLIA.xml:S2:4568:6	O
procedures	PROLIA.xml:S2:4575:10	O
,	PROLIA.xml:S2:4585:1	O
clinical	PROLIA.xml:S2:4587:8	O
judgment	PROLIA.xml:S2:4596:8	O
of	PROLIA.xml:S2:4605:2	O
the	PROLIA.xml:S2:4608:3	O
treating	PROLIA.xml:S2:4612:8	O
physician	PROLIA.xml:S2:4621:9	O
and	PROLIA.xml:S2:4631:3	O
or	PROLIA.xml:S2:4635:2	O
oral	PROLIA.xml:S2:4638:4	O
surgeon	PROLIA.xml:S2:4643:7	O
should	PROLIA.xml:S2:4651:6	O
guide	PROLIA.xml:S2:4658:5	O
the	PROLIA.xml:S2:4664:3	O
management	PROLIA.xml:S2:4668:10	O
plan	PROLIA.xml:S2:4679:4	O
of	PROLIA.xml:S2:4684:2	O
each	PROLIA.xml:S2:4687:4	O
patient	PROLIA.xml:S2:4692:7	O
based	PROLIA.xml:S2:4700:5	O
on	PROLIA.xml:S2:4706:2	O
individual	PROLIA.xml:S2:4709:10	O
benefit	PROLIA.xml:S2:4720:7	O
-	PROLIA.xml:S2:4727:1	O
risk	PROLIA.xml:S2:4728:4	O
assessment	PROLIA.xml:S2:4733:10	O
.	PROLIA.xml:S2:4743:1	O

Patients	PROLIA.xml:S2:4749:8	O
who	PROLIA.xml:S2:4758:3	O
are	PROLIA.xml:S2:4762:3	O
suspected	PROLIA.xml:S2:4766:9	O
of	PROLIA.xml:S2:4776:2	O
having	PROLIA.xml:S2:4779:6	O
or	PROLIA.xml:S2:4786:2	O
who	PROLIA.xml:S2:4789:3	O
develop	PROLIA.xml:S2:4793:7	O
ONJ	PROLIA.xml:S2:4801:3	O
while	PROLIA.xml:S2:4805:5	O
on	PROLIA.xml:S2:4811:2	O
Prolia	PROLIA.xml:S2:4814:6	O
should	PROLIA.xml:S2:4821:6	O
receive	PROLIA.xml:S2:4828:7	O
care	PROLIA.xml:S2:4836:4	O
by	PROLIA.xml:S2:4841:2	O
a	PROLIA.xml:S2:4844:1	O
dentist	PROLIA.xml:S2:4846:7	O
or	PROLIA.xml:S2:4854:2	O
an	PROLIA.xml:S2:4857:2	O
oral	PROLIA.xml:S2:4860:4	O
surgeon	PROLIA.xml:S2:4865:7	O
.	PROLIA.xml:S2:4872:1	O

In	PROLIA.xml:S2:4874:2	O
these	PROLIA.xml:S2:4877:5	O
patients	PROLIA.xml:S2:4883:8	O
,	PROLIA.xml:S2:4891:1	O
extensive	PROLIA.xml:S2:4893:9	O
dental	PROLIA.xml:S2:4903:6	O
surgery	PROLIA.xml:S2:4910:7	O
to	PROLIA.xml:S2:4918:2	O
treat	PROLIA.xml:S2:4921:5	O
ONJ	PROLIA.xml:S2:4927:3	O
may	PROLIA.xml:S2:4931:3	O
exacerbate	PROLIA.xml:S2:4935:10	O
the	PROLIA.xml:S2:4946:3	O
condition	PROLIA.xml:S2:4950:9	O
.	PROLIA.xml:S2:4959:1	O

Discontinuation	PROLIA.xml:S2:4961:15	O
of	PROLIA.xml:S2:4977:2	O
Prolia	PROLIA.xml:S2:4980:6	O
therapy	PROLIA.xml:S2:4987:7	O
should	PROLIA.xml:S2:4995:6	O
be	PROLIA.xml:S2:5002:2	O
considered	PROLIA.xml:S2:5005:10	O
based	PROLIA.xml:S2:5016:5	O
on	PROLIA.xml:S2:5022:2	O
individual	PROLIA.xml:S2:5025:10	O
benefit	PROLIA.xml:S2:5036:7	O
-	PROLIA.xml:S2:5043:1	O
risk	PROLIA.xml:S2:5044:4	O
assessment	PROLIA.xml:S2:5049:10	O
.	PROLIA.xml:S2:5059:1	O

5.5	PROLIA.xml:S2:5068:3	O
Atypical	PROLIA.xml:S2:5072:8	O
Subtrochanteric	PROLIA.xml:S2:5081:15	O
and	PROLIA.xml:S2:5097:3	O
Diaphyseal	PROLIA.xml:S2:5101:10	O
Femoral	PROLIA.xml:S2:5112:7	B-AdverseReaction
Fractures	PROLIA.xml:S2:5120:9	O

Atypical	PROLIA.xml:S2:5135:8	I-AdverseReaction
low	PROLIA.xml:S2:5144:3	O
-	PROLIA.xml:S2:5147:1	O
energy	PROLIA.xml:S2:5148:6	O
or	PROLIA.xml:S2:5155:2	O
low	PROLIA.xml:S2:5158:3	O
trauma	PROLIA.xml:S2:5162:6	O
fractures	PROLIA.xml:S2:5169:9	I-AdverseReaction
of	PROLIA.xml:S2:5179:2	I-AdverseReaction
the	PROLIA.xml:S2:5182:3	I-AdverseReaction
shaft	PROLIA.xml:S2:5186:5	I-AdverseReaction
have	PROLIA.xml:S2:5192:4	O
been	PROLIA.xml:S2:5197:4	O
reported	PROLIA.xml:S2:5202:8	O
in	PROLIA.xml:S2:5211:2	O
patients	PROLIA.xml:S2:5214:8	O
receiving	PROLIA.xml:S2:5223:9	O
Prolia	PROLIA.xml:S2:5233:6	O
[	PROLIA.xml:S2:5240:1	O
see	PROLIA.xml:S2:5241:3	O
Adverse	PROLIA.xml:S2:5245:7	O
Reactions	PROLIA.xml:S2:5253:9	O
(	PROLIA.xml:S2:5263:1	O
6.1	PROLIA.xml:S2:5266:3	O
)]	PROLIA.xml:S2:5271:2	O
.	PROLIA.xml:S2:5275:1	O

These	PROLIA.xml:S2:5277:5	O
fractures	PROLIA.xml:S2:5283:9	B-AdverseReaction
can	PROLIA.xml:S2:5293:3	O
occur	PROLIA.xml:S2:5297:5	O
anywhere	PROLIA.xml:S2:5303:8	O
in	PROLIA.xml:S2:5312:2	I-AdverseReaction
the	PROLIA.xml:S2:5315:3	I-AdverseReaction
femoral	PROLIA.xml:S2:5319:7	I-AdverseReaction
shaft	PROLIA.xml:S2:5327:5	I-AdverseReaction
from	PROLIA.xml:S2:5333:4	O
just	PROLIA.xml:S2:5338:4	O
below	PROLIA.xml:S2:5343:5	O
the	PROLIA.xml:S2:5349:3	O
lesser	PROLIA.xml:S2:5353:6	O
trochanter	PROLIA.xml:S2:5360:10	O
to	PROLIA.xml:S2:5371:2	O
above	PROLIA.xml:S2:5374:5	O
the	PROLIA.xml:S2:5380:3	O
supracondylar	PROLIA.xml:S2:5384:13	O
flare	PROLIA.xml:S2:5398:5	O
and	PROLIA.xml:S2:5404:3	O
are	PROLIA.xml:S2:5408:3	O
transverse	PROLIA.xml:S2:5412:10	O
or	PROLIA.xml:S2:5423:2	O
short	PROLIA.xml:S2:5426:5	O
oblique	PROLIA.xml:S2:5432:7	O
in	PROLIA.xml:S2:5440:2	O
orientation	PROLIA.xml:S2:5443:11	O
without	PROLIA.xml:S2:5455:7	O
evidence	PROLIA.xml:S2:5463:8	O
of	PROLIA.xml:S2:5472:2	O
comminution	PROLIA.xml:S2:5475:11	O
.	PROLIA.xml:S2:5486:1	O

Causality	PROLIA.xml:S2:5488:9	O
has	PROLIA.xml:S2:5498:3	O
not	PROLIA.xml:S2:5502:3	O
been	PROLIA.xml:S2:5506:4	O
established	PROLIA.xml:S2:5511:11	O
as	PROLIA.xml:S2:5523:2	O
these	PROLIA.xml:S2:5526:5	O
fractures	PROLIA.xml:S2:5532:9	O
also	PROLIA.xml:S2:5542:4	O
occur	PROLIA.xml:S2:5547:5	O
in	PROLIA.xml:S2:5553:2	O
osteoporotic	PROLIA.xml:S2:5556:12	O
patients	PROLIA.xml:S2:5569:8	O
who	PROLIA.xml:S2:5578:3	O
have	PROLIA.xml:S2:5582:4	O
not	PROLIA.xml:S2:5587:3	O
been	PROLIA.xml:S2:5591:4	O
treated	PROLIA.xml:S2:5596:7	O
with	PROLIA.xml:S2:5604:4	O
anti	PROLIA.xml:S2:5609:4	O
-	PROLIA.xml:S2:5613:1	O
resorptive	PROLIA.xml:S2:5614:10	O
agents	PROLIA.xml:S2:5625:6	O
.	PROLIA.xml:S2:5631:1	O

Atypical	PROLIA.xml:S2:5637:8	B-AdverseReaction
femoral	PROLIA.xml:S2:5646:7	I-AdverseReaction
fractures	PROLIA.xml:S2:5654:9	I-AdverseReaction
most	PROLIA.xml:S2:5664:4	O
commonly	PROLIA.xml:S2:5669:8	O
occur	PROLIA.xml:S2:5678:5	O
with	PROLIA.xml:S2:5684:4	O
minimal	PROLIA.xml:S2:5689:7	O
or	PROLIA.xml:S2:5697:2	O
no	PROLIA.xml:S2:5700:2	O
trauma	PROLIA.xml:S2:5703:6	O
to	PROLIA.xml:S2:5710:2	O
the	PROLIA.xml:S2:5713:3	O
affected	PROLIA.xml:S2:5717:8	O
area	PROLIA.xml:S2:5726:4	O
.	PROLIA.xml:S2:5730:1	O

They	PROLIA.xml:S2:5732:4	O
may	PROLIA.xml:S2:5737:3	O
be	PROLIA.xml:S2:5741:2	O
bilateral	PROLIA.xml:S2:5744:9	O
and	PROLIA.xml:S2:5754:3	O
many	PROLIA.xml:S2:5758:4	O
patients	PROLIA.xml:S2:5763:8	O
report	PROLIA.xml:S2:5772:6	O
prodromal	PROLIA.xml:S2:5779:9	O
pain	PROLIA.xml:S2:5789:4	O
in	PROLIA.xml:S2:5794:2	O
the	PROLIA.xml:S2:5797:3	O
affected	PROLIA.xml:S2:5801:8	O
area	PROLIA.xml:S2:5810:4	O
,	PROLIA.xml:S2:5814:1	O
usually	PROLIA.xml:S2:5816:7	O
presenting	PROLIA.xml:S2:5824:10	O
as	PROLIA.xml:S2:5835:2	O
dull	PROLIA.xml:S2:5838:4	O
,	PROLIA.xml:S2:5842:1	O
aching	PROLIA.xml:S2:5844:6	O
thigh	PROLIA.xml:S2:5851:5	B-AdverseReaction
pain	PROLIA.xml:S2:5857:4	I-AdverseReaction
,	PROLIA.xml:S2:5861:1	O
weeks	PROLIA.xml:S2:5863:5	O
to	PROLIA.xml:S2:5869:2	O
months	PROLIA.xml:S2:5872:6	O
before	PROLIA.xml:S2:5879:6	O
a	PROLIA.xml:S2:5886:1	O
complete	PROLIA.xml:S2:5888:8	O
fracture	PROLIA.xml:S2:5897:8	O
occurs	PROLIA.xml:S2:5906:6	O
.	PROLIA.xml:S2:5912:1	O

A	PROLIA.xml:S2:5915:1	O
number	PROLIA.xml:S2:5917:6	O
of	PROLIA.xml:S2:5924:2	O
reports	PROLIA.xml:S2:5927:7	O
note	PROLIA.xml:S2:5935:4	O
that	PROLIA.xml:S2:5940:4	O
patients	PROLIA.xml:S2:5945:8	O
were	PROLIA.xml:S2:5954:4	O
also	PROLIA.xml:S2:5959:4	O
receiving	PROLIA.xml:S2:5964:9	O
treatment	PROLIA.xml:S2:5974:9	O
with	PROLIA.xml:S2:5984:4	O
glucocorticoids	PROLIA.xml:S2:5989:15	O
(	PROLIA.xml:S2:6005:1	O
e	PROLIA.xml:S2:6006:1	O
.	PROLIA.xml:S2:6007:1	O
g	PROLIA.xml:S2:6008:1	O
.	PROLIA.xml:S2:6009:1	O

prednisone	PROLIA.xml:S2:6011:10	O
)	PROLIA.xml:S2:6021:1	O
at	PROLIA.xml:S2:6023:2	O
the	PROLIA.xml:S2:6026:3	O
time	PROLIA.xml:S2:6030:4	O
of	PROLIA.xml:S2:6035:2	O
fracture	PROLIA.xml:S2:6038:8	O
.	PROLIA.xml:S2:6046:1	O

During	PROLIA.xml:S2:6052:6	O
Prolia	PROLIA.xml:S2:6059:6	O
treatment	PROLIA.xml:S2:6066:9	O
,	PROLIA.xml:S2:6075:1	O
patients	PROLIA.xml:S2:6077:8	O
should	PROLIA.xml:S2:6086:6	O
be	PROLIA.xml:S2:6093:2	O
advised	PROLIA.xml:S2:6096:7	O
to	PROLIA.xml:S2:6104:2	O
report	PROLIA.xml:S2:6107:6	O
new	PROLIA.xml:S2:6114:3	O
or	PROLIA.xml:S2:6118:2	O
unusual	PROLIA.xml:S2:6121:7	O
thigh	PROLIA.xml:S2:6129:5	O
,	PROLIA.xml:S2:6134:1	O
hip	PROLIA.xml:S2:6136:3	O
,	PROLIA.xml:S2:6139:1	O
or	PROLIA.xml:S2:6141:2	O
groin	PROLIA.xml:S2:6144:5	O
pain	PROLIA.xml:S2:6150:4	O
.	PROLIA.xml:S2:6154:1	O

Any	PROLIA.xml:S2:6156:3	O
patient	PROLIA.xml:S2:6160:7	O
who	PROLIA.xml:S2:6168:3	O
presents	PROLIA.xml:S2:6172:8	O
with	PROLIA.xml:S2:6181:4	O
thigh	PROLIA.xml:S2:6186:5	O
or	PROLIA.xml:S2:6192:2	O
groin	PROLIA.xml:S2:6195:5	O
pain	PROLIA.xml:S2:6201:4	O
should	PROLIA.xml:S2:6206:6	O
be	PROLIA.xml:S2:6213:2	O
suspected	PROLIA.xml:S2:6216:9	O
of	PROLIA.xml:S2:6226:2	O
having	PROLIA.xml:S2:6229:6	O
an	PROLIA.xml:S2:6236:2	O
atypical	PROLIA.xml:S2:6239:8	O
fracture	PROLIA.xml:S2:6248:8	O
and	PROLIA.xml:S2:6257:3	O
should	PROLIA.xml:S2:6261:6	O
be	PROLIA.xml:S2:6268:2	O
evaluated	PROLIA.xml:S2:6271:9	O
to	PROLIA.xml:S2:6281:2	O
rule	PROLIA.xml:S2:6284:4	O
out	PROLIA.xml:S2:6289:3	O
an	PROLIA.xml:S2:6293:2	O
incomplete	PROLIA.xml:S2:6296:10	O
femur	PROLIA.xml:S2:6307:5	O
fracture	PROLIA.xml:S2:6313:8	O
.	PROLIA.xml:S2:6321:1	O

Patient	PROLIA.xml:S2:6323:7	O
presenting	PROLIA.xml:S2:6331:10	O
with	PROLIA.xml:S2:6342:4	O
an	PROLIA.xml:S2:6347:2	O
atypical	PROLIA.xml:S2:6350:8	O
femur	PROLIA.xml:S2:6359:5	O
fracture	PROLIA.xml:S2:6365:8	O
should	PROLIA.xml:S2:6374:6	O
also	PROLIA.xml:S2:6381:4	O
be	PROLIA.xml:S2:6386:2	O
assessed	PROLIA.xml:S2:6389:8	O
for	PROLIA.xml:S2:6398:3	O
symptoms	PROLIA.xml:S2:6402:8	O
and	PROLIA.xml:S2:6411:3	O
signs	PROLIA.xml:S2:6415:5	O
of	PROLIA.xml:S2:6421:2	O
fracture	PROLIA.xml:S2:6424:8	O
in	PROLIA.xml:S2:6433:2	O
the	PROLIA.xml:S2:6436:3	O
contralateral	PROLIA.xml:S2:6440:13	O
limb	PROLIA.xml:S2:6454:4	O
.	PROLIA.xml:S2:6458:1	O

Interruption	PROLIA.xml:S2:6460:12	O
of	PROLIA.xml:S2:6473:2	O
Prolia	PROLIA.xml:S2:6476:6	O
therapy	PROLIA.xml:S2:6483:7	O
should	PROLIA.xml:S2:6491:6	O
be	PROLIA.xml:S2:6498:2	O
considered	PROLIA.xml:S2:6501:10	O
,	PROLIA.xml:S2:6511:1	O
pending	PROLIA.xml:S2:6513:7	O
a	PROLIA.xml:S2:6521:1	O
risk	PROLIA.xml:S2:6523:4	O
benefit	PROLIA.xml:S2:6528:7	O
assessment	PROLIA.xml:S2:6536:10	O
,	PROLIA.xml:S2:6546:1	O
on	PROLIA.xml:S2:6548:2	O
an	PROLIA.xml:S2:6551:2	O
individual	PROLIA.xml:S2:6554:10	O
basis	PROLIA.xml:S2:6565:5	O
.	PROLIA.xml:S2:6570:1	O

5.6	PROLIA.xml:S2:6579:3	O
Serious	PROLIA.xml:S2:6583:7	O
Infections	PROLIA.xml:S2:6591:10	O

In	PROLIA.xml:S2:6607:2	O
a	PROLIA.xml:S2:6610:1	O
clinical	PROLIA.xml:S2:6612:8	O
trial	PROLIA.xml:S2:6621:5	O
of	PROLIA.xml:S2:6627:2	O
over	PROLIA.xml:S2:6630:4	O
7800	PROLIA.xml:S2:6635:4	O
women	PROLIA.xml:S2:6640:5	O
with	PROLIA.xml:S2:6646:4	O
postmenopausal	PROLIA.xml:S2:6651:14	O
osteoporosis	PROLIA.xml:S2:6666:12	O
,	PROLIA.xml:S2:6678:1	O
serious	PROLIA.xml:S2:6680:7	B-Severity
infections	PROLIA.xml:S2:6688:10	B-AdverseReaction
leading	PROLIA.xml:S2:6699:7	O
to	PROLIA.xml:S2:6707:2	O
hospitalization	PROLIA.xml:S2:6710:15	O
were	PROLIA.xml:S2:6726:4	O
reported	PROLIA.xml:S2:6731:8	O
more	PROLIA.xml:S2:6740:4	O
frequently	PROLIA.xml:S2:6745:10	O
in	PROLIA.xml:S2:6756:2	O
the	PROLIA.xml:S2:6759:3	O
Prolia	PROLIA.xml:S2:6763:6	O
group	PROLIA.xml:S2:6770:5	O
than	PROLIA.xml:S2:6776:4	O
in	PROLIA.xml:S2:6781:2	O
the	PROLIA.xml:S2:6784:3	O
placebo	PROLIA.xml:S2:6788:7	O
group	PROLIA.xml:S2:6796:5	O
[	PROLIA.xml:S2:6802:1	O
see	PROLIA.xml:S2:6803:3	O
Adverse	PROLIA.xml:S2:6807:7	O
Reactions	PROLIA.xml:S2:6815:9	O
(	PROLIA.xml:S2:6825:1	O
6.1	PROLIA.xml:S2:6828:3	O
)]	PROLIA.xml:S2:6833:2	O
.	PROLIA.xml:S2:6837:1	O

Serious	PROLIA.xml:S2:6839:7	B-Severity
skin	PROLIA.xml:S2:6847:4	B-AdverseReaction
infections	PROLIA.xml:S2:6852:10	I-AdverseReaction
,	PROLIA.xml:S2:6862:1	O
as	PROLIA.xml:S2:6864:2	O
well	PROLIA.xml:S2:6867:4	O
as	PROLIA.xml:S2:6872:2	O
infections	PROLIA.xml:S2:6875:10	B-AdverseReaction
of	PROLIA.xml:S2:6886:2	I-AdverseReaction
the	PROLIA.xml:S2:6889:3	I-AdverseReaction
abdomen	PROLIA.xml:S2:6893:7	I-AdverseReaction
,	PROLIA.xml:S2:6900:1	O
urinary	PROLIA.xml:S2:6902:7	I-AdverseReaction
tract	PROLIA.xml:S2:6910:5	I-AdverseReaction
,	PROLIA.xml:S2:6915:1	O
and	PROLIA.xml:S2:6917:3	O
ear	PROLIA.xml:S2:6921:3	I-AdverseReaction
,	PROLIA.xml:S2:6924:1	O
were	PROLIA.xml:S2:6926:4	O
more	PROLIA.xml:S2:6931:4	O
frequent	PROLIA.xml:S2:6936:8	O
in	PROLIA.xml:S2:6945:2	O
patients	PROLIA.xml:S2:6948:8	O
treated	PROLIA.xml:S2:6957:7	O
with	PROLIA.xml:S2:6965:4	O
Prolia	PROLIA.xml:S2:6970:6	O
.	PROLIA.xml:S2:6976:1	O

Endocarditis	PROLIA.xml:S2:6978:12	B-AdverseReaction
was	PROLIA.xml:S2:6991:3	O
also	PROLIA.xml:S2:6995:4	O
reported	PROLIA.xml:S2:7000:8	O
more	PROLIA.xml:S2:7009:4	O
frequently	PROLIA.xml:S2:7014:10	O
in	PROLIA.xml:S2:7025:2	O
Prolia	PROLIA.xml:S2:7028:6	O
-	PROLIA.xml:S2:7034:1	O
treated	PROLIA.xml:S2:7035:7	O
patients	PROLIA.xml:S2:7043:8	O
.	PROLIA.xml:S2:7051:1	O

The	PROLIA.xml:S2:7053:3	O
incidence	PROLIA.xml:S2:7057:9	O
of	PROLIA.xml:S2:7067:2	O
opportunistic	PROLIA.xml:S2:7070:13	B-AdverseReaction
infections	PROLIA.xml:S2:7084:10	I-AdverseReaction
was	PROLIA.xml:S2:7095:3	O
similar	PROLIA.xml:S2:7099:7	O
between	PROLIA.xml:S2:7107:7	O
placebo	PROLIA.xml:S2:7115:7	O
and	PROLIA.xml:S2:7123:3	O
Prolia	PROLIA.xml:S2:7127:6	O
groups	PROLIA.xml:S2:7134:6	O
,	PROLIA.xml:S2:7140:1	O
and	PROLIA.xml:S2:7142:3	O
the	PROLIA.xml:S2:7146:3	O
overall	PROLIA.xml:S2:7150:7	O
incidence	PROLIA.xml:S2:7158:9	O
of	PROLIA.xml:S2:7168:2	O
infections	PROLIA.xml:S2:7171:10	B-AdverseReaction
was	PROLIA.xml:S2:7182:3	O
similar	PROLIA.xml:S2:7186:7	O
between	PROLIA.xml:S2:7194:7	O
the	PROLIA.xml:S2:7202:3	O
treatment	PROLIA.xml:S2:7206:9	O
groups	PROLIA.xml:S2:7216:6	O
.	PROLIA.xml:S2:7222:1	O

Advise	PROLIA.xml:S2:7224:6	O
patients	PROLIA.xml:S2:7231:8	O
to	PROLIA.xml:S2:7240:2	O
seek	PROLIA.xml:S2:7243:4	O
prompt	PROLIA.xml:S2:7248:6	O
medical	PROLIA.xml:S2:7255:7	O
attention	PROLIA.xml:S2:7263:9	O
if	PROLIA.xml:S2:7273:2	O
they	PROLIA.xml:S2:7276:4	O
develop	PROLIA.xml:S2:7281:7	O
signs	PROLIA.xml:S2:7289:5	O
or	PROLIA.xml:S2:7295:2	O
symptoms	PROLIA.xml:S2:7298:8	O
of	PROLIA.xml:S2:7307:2	O
severe	PROLIA.xml:S2:7310:6	O
infection	PROLIA.xml:S2:7317:9	O
,	PROLIA.xml:S2:7326:1	O
including	PROLIA.xml:S2:7328:9	O
cellulitis	PROLIA.xml:S2:7338:10	O
.	PROLIA.xml:S2:7348:1	O

Patients	PROLIA.xml:S2:7355:8	O
on	PROLIA.xml:S2:7364:2	O
concomitant	PROLIA.xml:S2:7367:11	O
immunosuppressant	PROLIA.xml:S2:7379:17	O
agents	PROLIA.xml:S2:7397:6	O
or	PROLIA.xml:S2:7404:2	O
with	PROLIA.xml:S2:7407:4	O
impaired	PROLIA.xml:S2:7412:8	O
immune	PROLIA.xml:S2:7421:6	O
systems	PROLIA.xml:S2:7428:7	O
may	PROLIA.xml:S2:7436:3	B-Factor
be	PROLIA.xml:S2:7440:2	O
at	PROLIA.xml:S2:7443:2	O
increased	PROLIA.xml:S2:7446:9	O
risk	PROLIA.xml:S2:7456:4	O
for	PROLIA.xml:S2:7461:3	O
serious	PROLIA.xml:S2:7465:7	B-Severity
infections	PROLIA.xml:S2:7473:10	B-AdverseReaction
.	PROLIA.xml:S2:7483:1	O

Consider	PROLIA.xml:S2:7485:8	O
the	PROLIA.xml:S2:7494:3	O
benefit	PROLIA.xml:S2:7498:7	O
-	PROLIA.xml:S2:7505:1	O
risk	PROLIA.xml:S2:7506:4	O
profile	PROLIA.xml:S2:7511:7	O
in	PROLIA.xml:S2:7519:2	O
such	PROLIA.xml:S2:7522:4	O
patients	PROLIA.xml:S2:7527:8	O
before	PROLIA.xml:S2:7536:6	O
treating	PROLIA.xml:S2:7543:8	O
with	PROLIA.xml:S2:7552:4	O
Prolia	PROLIA.xml:S2:7557:6	O
.	PROLIA.xml:S2:7563:1	O

In	PROLIA.xml:S2:7565:2	O
patients	PROLIA.xml:S2:7568:8	O
who	PROLIA.xml:S2:7577:3	O
develop	PROLIA.xml:S2:7581:7	O
serious	PROLIA.xml:S2:7589:7	O
infections	PROLIA.xml:S2:7597:10	O
while	PROLIA.xml:S2:7608:5	O
on	PROLIA.xml:S2:7614:2	O
Prolia	PROLIA.xml:S2:7617:6	O
,	PROLIA.xml:S2:7623:1	O
prescribers	PROLIA.xml:S2:7625:11	O
should	PROLIA.xml:S2:7637:6	O
assess	PROLIA.xml:S2:7644:6	O
the	PROLIA.xml:S2:7651:3	O
need	PROLIA.xml:S2:7655:4	O
for	PROLIA.xml:S2:7660:3	O
continued	PROLIA.xml:S2:7664:9	O
Prolia	PROLIA.xml:S2:7674:6	O
therapy	PROLIA.xml:S2:7681:7	O
.	PROLIA.xml:S2:7688:1	O

5.7	PROLIA.xml:S2:7697:3	O
Dermatologic	PROLIA.xml:S2:7701:12	O
Adverse	PROLIA.xml:S2:7714:7	O
Reactions	PROLIA.xml:S2:7722:9	O

In	PROLIA.xml:S2:7737:2	O
a	PROLIA.xml:S2:7740:1	O
large	PROLIA.xml:S2:7742:5	O
clinical	PROLIA.xml:S2:7748:8	O
trial	PROLIA.xml:S2:7757:5	O
of	PROLIA.xml:S2:7763:2	O
over	PROLIA.xml:S2:7766:4	O
7800	PROLIA.xml:S2:7771:4	O
women	PROLIA.xml:S2:7776:5	O
with	PROLIA.xml:S2:7782:4	O
postmenopausal	PROLIA.xml:S2:7787:14	O
osteoporosis	PROLIA.xml:S2:7802:12	O
,	PROLIA.xml:S2:7814:1	O
epidermal	PROLIA.xml:S2:7816:9	B-AdverseReaction
and	PROLIA.xml:S2:7826:3	O
dermal	PROLIA.xml:S2:7830:6	B-AdverseReaction
adverse	PROLIA.xml:S2:7837:7	I-AdverseReaction
events	PROLIA.xml:S2:7845:6	I-AdverseReaction
such	PROLIA.xml:S2:7852:4	O
as	PROLIA.xml:S2:7857:2	O
dermatitis	PROLIA.xml:S2:7860:10	B-AdverseReaction
,	PROLIA.xml:S2:7870:1	O
eczema	PROLIA.xml:S2:7872:6	B-AdverseReaction
,	PROLIA.xml:S2:7878:1	O
and	PROLIA.xml:S2:7880:3	O
rashes	PROLIA.xml:S2:7884:6	B-AdverseReaction
occurred	PROLIA.xml:S2:7891:8	O
at	PROLIA.xml:S2:7900:2	O
a	PROLIA.xml:S2:7903:1	O
significantly	PROLIA.xml:S2:7905:13	O
higher	PROLIA.xml:S2:7919:6	O
rate	PROLIA.xml:S2:7926:4	O
in	PROLIA.xml:S2:7931:2	O
the	PROLIA.xml:S2:7934:3	O
Prolia	PROLIA.xml:S2:7938:6	O
group	PROLIA.xml:S2:7945:5	O
compared	PROLIA.xml:S2:7951:8	O
to	PROLIA.xml:S2:7960:2	O
the	PROLIA.xml:S2:7963:3	O
placebo	PROLIA.xml:S2:7967:7	O
group	PROLIA.xml:S2:7975:5	O
.	PROLIA.xml:S2:7980:1	O

Most	PROLIA.xml:S2:7982:4	O
of	PROLIA.xml:S2:7987:2	O
these	PROLIA.xml:S2:7990:5	O
events	PROLIA.xml:S2:7996:6	O
were	PROLIA.xml:S2:8003:4	O
not	PROLIA.xml:S2:8008:3	O
specific	PROLIA.xml:S2:8012:8	O
to	PROLIA.xml:S2:8021:2	O
the	PROLIA.xml:S2:8024:3	O
injection	PROLIA.xml:S2:8028:9	O
site	PROLIA.xml:S2:8038:4	O
[	PROLIA.xml:S2:8043:1	O
see	PROLIA.xml:S2:8044:3	O
Adverse	PROLIA.xml:S2:8048:7	O
Reactions	PROLIA.xml:S2:8056:9	O
(	PROLIA.xml:S2:8066:1	O
6.1	PROLIA.xml:S2:8069:3	O
)]	PROLIA.xml:S2:8074:2	O
.	PROLIA.xml:S2:8078:1	O

Consider	PROLIA.xml:S2:8080:8	O
discontinuing	PROLIA.xml:S2:8089:13	O
Prolia	PROLIA.xml:S2:8103:6	O
if	PROLIA.xml:S2:8110:2	O
severe	PROLIA.xml:S2:8113:6	O
symptoms	PROLIA.xml:S2:8120:8	O
develop	PROLIA.xml:S2:8129:7	O
.	PROLIA.xml:S2:8136:1	O

5.8	PROLIA.xml:S2:8145:3	O
Musculoskeletal	PROLIA.xml:S2:8149:15	O
Pain	PROLIA.xml:S2:8165:4	O

In	PROLIA.xml:S2:8176:2	O
post	PROLIA.xml:S2:8179:4	O
-	PROLIA.xml:S2:8183:1	O
marketing	PROLIA.xml:S2:8184:9	O
experience	PROLIA.xml:S2:8194:10	O
,	PROLIA.xml:S2:8204:1	O
severe	PROLIA.xml:S2:8206:6	B-Severity
and	PROLIA.xml:S2:8213:3	O
occasionally	PROLIA.xml:S2:8217:12	O
incapacitating	PROLIA.xml:S2:8230:14	B-Severity
bone	PROLIA.xml:S2:8245:4	B-AdverseReaction
,	PROLIA.xml:S2:8249:1	O
joint	PROLIA.xml:S2:8251:5	B-AdverseReaction
,	PROLIA.xml:S2:8256:1	O
and	PROLIA.xml:S2:8258:3	O
or	PROLIA.xml:S2:8262:2	O
muscle	PROLIA.xml:S2:8265:6	B-AdverseReaction
pain	PROLIA.xml:S2:8272:4	I-AdverseReaction
has	PROLIA.xml:S2:8277:3	O
been	PROLIA.xml:S2:8281:4	O
reported	PROLIA.xml:S2:8286:8	O
in	PROLIA.xml:S2:8295:2	O
patients	PROLIA.xml:S2:8298:8	O
taking	PROLIA.xml:S2:8307:6	O
Prolia	PROLIA.xml:S2:8314:6	O
[	PROLIA.xml:S2:8321:1	O
see	PROLIA.xml:S2:8322:3	O
Adverse	PROLIA.xml:S2:8326:7	O
Reactions	PROLIA.xml:S2:8334:9	O
(	PROLIA.xml:S2:8344:1	O
6.2	PROLIA.xml:S2:8347:3	O
)]	PROLIA.xml:S2:8352:2	O
.	PROLIA.xml:S2:8356:1	O

The	PROLIA.xml:S2:8358:3	O
time	PROLIA.xml:S2:8362:4	O
to	PROLIA.xml:S2:8367:2	O
onset	PROLIA.xml:S2:8370:5	O
of	PROLIA.xml:S2:8376:2	O
symptoms	PROLIA.xml:S2:8379:8	O
varied	PROLIA.xml:S2:8388:6	O
from	PROLIA.xml:S2:8395:4	O
one	PROLIA.xml:S2:8400:3	O
day	PROLIA.xml:S2:8404:3	O
to	PROLIA.xml:S2:8408:2	O
several	PROLIA.xml:S2:8411:7	O
months	PROLIA.xml:S2:8419:6	O
after	PROLIA.xml:S2:8426:5	O
starting	PROLIA.xml:S2:8432:8	O
Prolia	PROLIA.xml:S2:8441:6	O
.	PROLIA.xml:S2:8447:1	O

Consider	PROLIA.xml:S2:8449:8	O
discontinuing	PROLIA.xml:S2:8458:13	O
use	PROLIA.xml:S2:8472:3	O
if	PROLIA.xml:S2:8476:2	O
severe	PROLIA.xml:S2:8479:6	O
symptoms	PROLIA.xml:S2:8486:8	O
develop	PROLIA.xml:S2:8495:7	O
[	PROLIA.xml:S2:8503:1	O
see	PROLIA.xml:S2:8504:3	O
Patient	PROLIA.xml:S2:8508:7	O
Counseling	PROLIA.xml:S2:8516:10	O
Information	PROLIA.xml:S2:8527:11	O
(	PROLIA.xml:S2:8539:1	O
17.8	PROLIA.xml:S2:8542:4	O
)]	PROLIA.xml:S2:8548:2	O
.	PROLIA.xml:S2:8552:1	O

5.9	PROLIA.xml:S2:8563:3	O
Suppression	PROLIA.xml:S2:8567:11	O
of	PROLIA.xml:S2:8579:2	O
Bone	PROLIA.xml:S2:8582:4	O
Turnover	PROLIA.xml:S2:8587:8	O

In	PROLIA.xml:S2:8601:2	O
clinical	PROLIA.xml:S2:8604:8	O
trials	PROLIA.xml:S2:8613:6	O
in	PROLIA.xml:S2:8620:2	O
women	PROLIA.xml:S2:8623:5	O
with	PROLIA.xml:S2:8629:4	O
postmenopausal	PROLIA.xml:S2:8634:14	O
osteoporosis	PROLIA.xml:S2:8649:12	O
,	PROLIA.xml:S2:8661:1	O
treatment	PROLIA.xml:S2:8663:9	O
with	PROLIA.xml:S2:8673:4	O
Prolia	PROLIA.xml:S2:8678:6	O
resulted	PROLIA.xml:S2:8685:8	O
in	PROLIA.xml:S2:8694:2	O
significant	PROLIA.xml:S2:8697:11	O
suppression	PROLIA.xml:S2:8709:11	B-AdverseReaction
of	PROLIA.xml:S2:8721:2	I-AdverseReaction
bone	PROLIA.xml:S2:8724:4	I-AdverseReaction
remodeling	PROLIA.xml:S2:8729:10	I-AdverseReaction
as	PROLIA.xml:S2:8740:2	O
evidenced	PROLIA.xml:S2:8743:9	O
by	PROLIA.xml:S2:8753:2	O
markers	PROLIA.xml:S2:8756:7	O
of	PROLIA.xml:S2:8764:2	O
bone	PROLIA.xml:S2:8767:4	O
turnover	PROLIA.xml:S2:8772:8	O
and	PROLIA.xml:S2:8781:3	O
bone	PROLIA.xml:S2:8785:4	O
histomorphometry	PROLIA.xml:S2:8790:16	O
[	PROLIA.xml:S2:8807:1	O
see	PROLIA.xml:S2:8808:3	O
Clinical	PROLIA.xml:S2:8812:8	O
Pharmacology	PROLIA.xml:S2:8821:12	O
(	PROLIA.xml:S2:8834:1	O
12.2	PROLIA.xml:S2:8837:4	O
)	PROLIA.xml:S2:8843:1	O
and	PROLIA.xml:S2:8845:3	O
Clinical	PROLIA.xml:S2:8849:8	O
Studies	PROLIA.xml:S2:8858:7	O
(	PROLIA.xml:S2:8866:1	O
14.1	PROLIA.xml:S2:8869:4	O
)]	PROLIA.xml:S2:8875:2	O
.	PROLIA.xml:S2:8879:1	O

The	PROLIA.xml:S2:8881:3	O
significance	PROLIA.xml:S2:8885:12	O
of	PROLIA.xml:S2:8898:2	O
these	PROLIA.xml:S2:8901:5	O
findings	PROLIA.xml:S2:8907:8	O
and	PROLIA.xml:S2:8916:3	O
the	PROLIA.xml:S2:8920:3	O
effect	PROLIA.xml:S2:8924:6	O
of	PROLIA.xml:S2:8931:2	O
long	PROLIA.xml:S2:8934:4	O
-	PROLIA.xml:S2:8938:1	O
term	PROLIA.xml:S2:8939:4	O
treatment	PROLIA.xml:S2:8944:9	O
with	PROLIA.xml:S2:8954:4	O
Prolia	PROLIA.xml:S2:8959:6	O
are	PROLIA.xml:S2:8966:3	O
unknown	PROLIA.xml:S2:8970:7	O
.	PROLIA.xml:S2:8977:1	O

The	PROLIA.xml:S2:8979:3	O
long	PROLIA.xml:S2:8983:4	O
-	PROLIA.xml:S2:8987:1	O
term	PROLIA.xml:S2:8988:4	O
consequences	PROLIA.xml:S2:8993:12	O
of	PROLIA.xml:S2:9006:2	O
the	PROLIA.xml:S2:9009:3	O
degree	PROLIA.xml:S2:9013:6	O
of	PROLIA.xml:S2:9020:2	O
suppression	PROLIA.xml:S2:9023:11	B-AdverseReaction
of	PROLIA.xml:S2:9035:2	I-AdverseReaction
bone	PROLIA.xml:S2:9038:4	I-AdverseReaction
remodeling	PROLIA.xml:S2:9043:10	I-AdverseReaction
observed	PROLIA.xml:S2:9054:8	O
with	PROLIA.xml:S2:9063:4	O
Prolia	PROLIA.xml:S2:9068:6	O
may	PROLIA.xml:S2:9075:3	B-Factor
contribute	PROLIA.xml:S2:9079:10	O
to	PROLIA.xml:S2:9090:2	O
adverse	PROLIA.xml:S2:9093:7	O
outcomes	PROLIA.xml:S2:9101:8	O
such	PROLIA.xml:S2:9110:4	O
as	PROLIA.xml:S2:9115:2	O
osteonecrosis	PROLIA.xml:S2:9118:13	B-AdverseReaction
of	PROLIA.xml:S2:9132:2	I-AdverseReaction
the	PROLIA.xml:S2:9135:3	I-AdverseReaction
jaw	PROLIA.xml:S2:9139:3	I-AdverseReaction
,	PROLIA.xml:S2:9142:1	O
atypical	PROLIA.xml:S2:9144:8	B-AdverseReaction
fractures	PROLIA.xml:S2:9153:9	I-AdverseReaction
,	PROLIA.xml:S2:9162:1	O
and	PROLIA.xml:S2:9164:3	O
delayed	PROLIA.xml:S2:9168:7	B-AdverseReaction
fracture	PROLIA.xml:S2:9176:8	I-AdverseReaction
healing	PROLIA.xml:S2:9185:7	I-AdverseReaction
.	PROLIA.xml:S2:9192:1	O

Monitor	PROLIA.xml:S2:9194:7	O
patients	PROLIA.xml:S2:9202:8	O
for	PROLIA.xml:S2:9211:3	O
these	PROLIA.xml:S2:9215:5	O
consequences	PROLIA.xml:S2:9221:12	O
.	PROLIA.xml:S2:9233:1	O
